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Abstract: Does airway pathology in severe preschool wheezers predict 
childhood asthma? 
 
Although one third of all preschool children wheeze, only half of these will have 
persistent symptoms and go on to have asthma at school age. Pathological changes 
characteristic of asthma, including eosinophilic inflammation and increased reticular 
basement membrane thickness, were evident in endobronchial biopsies from severe 
recurrent wheezers aged 2-3 years when compared with age matched controls. 
However, at the time of endobronchial biopsy it was not known which children would 
persistently wheeze and develop asthma at school age.  
 
The work of this thesis follows up this group of children, both preschool wheezers 
(n=47) and non-wheezing controls (n=21), aged between 6-11 years and establishes 
the presence or absence of school age asthma, relating this to pre-school airway 
pathology. Children (n=51) were followed up at school age, and those who attended 
for the research visit (n=39) were characterised in terms of atopic status, lung 
function (spirometry, lung clearance index) and airway inflammation (exhaled nitric 
oxide) at school age. Forty percent (15/37) of preschool wheezers had developed 
asthma at school age. Although increased airway smooth muscle is an established 
pathological feature of asthma in school age children, nothing is known about airway 
smooth muscle in preschool wheezers, hence airway smooth muscle, smooth 
muscle mast cells and reticular basement membrane tenascin-C were measured in 
the endobronchial biopsies taken at preschool age. Next, airway remodelling 
(increased airway smooth muscle and increased reticular basement membrane 
thickness) and airway inflammation at preschool age were related to the presence or 
absence of asthma at school age. 
 
Sixty two percent (42/68) of children had one or more evaluable biopsies for airway 
smooth muscle assessment. Although reticular basement membrane thickness and 
submucosal eosinophils were significantly higher in preschool wheezers compared 
with controls, they did not discriminate the children who developed asthma by school 
age, suggesting these airway pathological features may be associated with current 
symptoms rather than future asthma risk. In contrast preschool airway smooth 
muscle was increased in those severe preschool wheezers who went on to develop 
8 
 
school age asthma (n=8, median age 8.2 [6-10.4] years, median ASM 0.12 [0.08-
0.16]) when compared with those who did not develop asthma (n=24, median age 
7.3 [5.9-11] years, median ASM 0.07 [0.02-0.23]), p=0.007. These data suggest that 
future studies investigating the mechanisms underlying the persistence of preschool 
wheeze and its development to asthma should have a primary focus on airway 
smooth muscle.  
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Chapter 1 
Preschool Wheeze 
1.1 Introduction 
Wheeze is a polyphonic, musical, whistling sound produced in the airways during 
breathing. Around 1 in 3 children will have at least one episode of wheeze prior to 
their third birthday(1) and by age 7 years 40% of children report at least 1 episode of 
wheezing(2). It is estimated that children aged 1–5 years with wheeze cost the United 
Kingdom (UK) health service a total of £53 million with the greatest expenditure 
being £34 million in primary care(3).  
 
Wheeze in preschool children is often associated with respiratory viral infection and 
children may be completely asymptomatic between infections(4). Although most 
cases of persistent asthma begin in early life, spontaneous resolution of wheezing 
will occur in many young children(5). Only half of children with wheeze in preschool 
age will go on to have asthma at school age(6). Those children who remain 
symptomatic and develop asthma are the focus of this thesis. The diagnosis of 
asthma is a clinical one and there are no standardised diagnostic criteria(7). Most 
definitions include symptoms of wheeze, breathlessness, chest tightness or cough 
coupled with physiological evidence of variable airflow obstruction. More recent 
descriptions of asthma in children and in adults have included components of airway 
hyper-responsiveness and airway inflammation. In particular the Global Initiative for 
Asthma (GINA) guidelines define asthma as ‘a common chronic disorder of the 
airways that is complex and characterised by variable and recurring symptoms, 
airflow obstruction, bronchial hyperresponsiveness, and an underlying 
inflammation’(8). However, how airway inflammation and airway hyper-
responsiveness (AHR) relate to each other and how they contribute to the clinical 
manifestations of asthma is unclear. In many cases, neither will actually be 
measured, and the evidence implicating eosinophilic inflammation in wheezing in 
infancy is scanty. 
 
The work described in this thesis is the follow up at school age of a previously 
studied cohort of severe preschool wheezers (‘preschool’ is defined in this thesis as 
aged between 3 months and 5 years)(9). The aim was to determine if airway 
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pathology, including airway inflammation and remodelling at preschool age can 
predict school age asthma. There is no current treatment that is disease modifying, 
namely which prevents the progression of preschool wheeze to asthma, but 
determining which wheezers will have school age asthma may be the first step in 
helping to identify which children to target for further investigation of the mechanisms 
leading to the development of asthma. This chapter will focus on the early preschool 
years, specifically in relation to the difficulties associated with correctly identifying 
true wheeze, wheeze phenotypes and the usefulness of currently proposed clinical 
asthma predictive indexes. Airway pathology that is characteristic of asthma will also 
be reviewed.  
 
1.2 Difficulties in assessing wheeze prevalence 
There is considerable overlap between different preschool wheeze phenotypes. One 
of the difficulties in untangling the different preschool wheeze phenotypes is the 
reliance in longitudinal epidemiological studies on a parental report of wheeze to 
assess prevalence, table 1.1(1;10-15). This is dependent on parental understanding of 
the term “wheeze”, but parental and physician perception of wheeze is often very 
different. One factor responsible for the poor prediction of which preschool children 
with wheeze develop future asthma is the use of the word “wheeze” to describe 
many disparate sounds. 
 
At least 30% of parents use other words for wheeze and 30% of parents have 
labelled other sounds as "wheeze" in research studies using video questionnaires as 
the ‘gold standard’(16;17). In particular, incorrect labeling of upper airway noises such 
as stertor, stridor or snoring as wheeze in young children may lead to an 
overestimate of both prevalence and frequency of wheeze at preschool age(16;17). In 
a large questionnaire based study of over 4000 children aged 6-10 years, only 30% 
of families exclusively used the word “whistling” to describe wheezing, with a large 
proportion of parents descibing other sounds as wheeze, most commonly rattly 
breathing (43.1%), followed by wet cough (20%) and noises from the nose or throat 
(20%) and least commonly snoring (3.2%)(17). Frequent attacks of reported wheeze, 
maternal history of asthma and maternal education were significantly associated with 
a correct identification of wheeze as a whistling / squeaking sound, while incorrect 
identification was commoner in families of South Asian ethnicity, parents whose first 
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language was not English and families living in areas of social deprivation(17). 
Interestingly, “whistling” was only mentioned by 11% of 200 parents of children with 
‘asthma’, when asked what they understood by wheeze, although it features in most 
wheeze epidemiology questionnaires(16). Video questionnaires of upper and lower 
respiratory noises in parents of children with asthma or other respiratory conditions 
show that the correct labelling of wheeze was 59% and 47% for other sounds such 
as stridor, snoring, stertor(18). Conversely, the prevalence of wheeze may also be 
underestimated, in one study 19% of children labelled as cough by parents were 
diagnosed with wheeze on auscultation by physicians(19). Physicians were able to 
reliably judge the presence and severity of wheeze, when compared with wheeze 
analysed by acoustic techniques, whereas nurses and parents were much less 
reliable(20). 
 
The prevalence of preschool wheeze varies internationally between 17-50%, table 
1.1. There were different definitions of ‘preschool’, which may contribute to some of 
the variability in reported prevalence. Importantly, children with parentally reported, 
but unconfirmed wheeze, have no difference in pulmonary function when compared 
to those who never wheezed, whereas children with physician confirmed wheeze 
have significantly poorer lung function(21). Table 1.1 summarises the main cohort 
studies that report both preschool wheeze and school age asthma prevalence.   
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Table 1.1: Birth cohort studies from different regions report different prevalence’s of wheeze at preschool age and 
subsequent school-age asthma 
 (* = % of asthma in whole cohort at school age, # = % of preschool wheezers with asthma at school age)
Author Birth Cohort Country Year of 
publication 
Number
of 
children 
Subject 
Retention 
Preschool wheeze 
prevalence 
Wheeze Prevalence of 
school age 
asthma 
Caudri et al
(10)
 PIAMA Rotterdam, 
Netherlands 
2009 3963 88% Age 1-4 years 55% Parental 
report 
Age 7 years 11%*
 
 
 
Henderson et al
(11)
 
 
 
Jackson et al
(22)
 
 
 
Bisgaard et al
(23)
 
ALSPAC 
 
 
COAST 
 
 
COPSAC 
 
Avon, UK 
 
 
Wisconsin 
USA 
 
Denmark 
2008 
 
 
2008 
 
 
2007 
6265 
 
 
289 
 
 
411 
54% 
 
 
89% 
 
 
79% 
Age 1-5 years 40% 
 
 
Age 1-3 years (20-50%) 
 
 
Not assessed 
Parental 
report 
 
Doctor 
diagnosed 
 
Doctor 
diagnosed 
 
Age 7 years 50%*
 
 
 
Age 6 years 28%*
 
 
 
Age 5 years 14%* 
Lodrup Carlsen et al
(14)
 
 
Environment and 
Childhood Asthma 
(ECA)  
 
Oslo, 
Norway 
2006 803 77% Age 0-3 years 21.4% Parental 
report 
Age 10 years- 11%
* 
Age10 years -61%
# 
Kurukulaaratchy et al
(12)
 Isle of Wight Isle of Wight  2003 1456 71% Age 1-4 years 33% Parental 
report 
 
Wheeze over past 
year 
Age 10 years 37%* 
 
Lau et al
(24)
 
 
 
 
German MAS 
 
 
Berlin  
Germany 
 
 
2003 
 
 
 
1314 
 
 
 
71.5% 
 
Age 1-7 years 17.4% 
 
Parental 
report 
 
 
Age 7 years  
-10% current 
wheezing
# 
-6.1% DD asthma
# 
 
Oddy et al
(15)
 Perth Perth. 
Australia 
 
1999 2187 91% Age 1-6 years 22.5% Parental 
report 
Age 6 years DD 
asthma 30.9%* 
Martinez et al
(1)
 Tucson  Tucson, 
Arizona, USA 
1995 1246 66% Age 0-3 years 48.5% Parental 
report 
Age 6 years 40%
# 
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1.3.1 Preschool wheezing – classification of phenotypes 
The roots of most cases of asthma are in early childhood and it is likely some 
children are predisposed to asthma even before birth(5). Longitudinal cohort studies 
from birth to adulthood have provided insight into the natural history of asthma and 
have described several different wheeze phenotypes at preschool age. A phenotype 
is defined in this thesis as a cluster of clinical or pathological features which tend to 
be associated, and which are useful in some way, such as in managing the child or 
understanding the mechanisms of a disease(25). Approaches to describing 
phenotypes may be subjective, whereby children are divided into subsets based on a 
hypothesis by a clinician (for example, induced sputum patterns of cellularity), or can 
be objective, where phenotypes are mathematically derived in an unbiased manner 
(for example, latent class analysis and systems biology approaches). The latter 
avoids the constraints of investigator imposed classifications which are vulnerable to 
bias. Latent class analysis is a form of cluster analysis in which subjects are grouped 
according to similarities of response levels to a number of measured categorical 
variables. However, it should be noted that so-called ‘objective’ methods of analysis 
are also vulnerable to bias, in that the investigator has to determine which datasets 
are actually included in the analysis. 
 
Epidemiological studies using unselected or selected high risk populations have 
demonstrated that different early wheeze patterns in terms of age of onset, 
frequency, severity and triggers (viral or bacterial) have different natural histories. 
Clinical phenotypes have also been described based on temporal wheeze patterns 
(episodic viral and multiple trigger wheeze). However, there is overlap between 
some of these described phenotypes. These can likely only be resolved by a large 
multicentre, long-term study with antenatal recruitment and repeated objective 
assessments using biomarkers (for example, exhaled nitric oxide (FeNO), exhaled 
breath condensate or induced sputum) as proxy measurements of inflammation to 
identify clinically useful phenotypes and early predictors of disease progression. 
Systems biology is one such innovative research technique which looks at biology as 
a group of connected pathways, using genetic, molecular, histopathology and 
physiological data to create a mathematical or computational model using principal 
component analysis that can then be used to define asthma phenotypes. The U-
BIOPred consortium is currently undertaking a large international study in asthma 
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using this approach(26). The next section of this thesis describes the main cohort 
studies in which children were recruited either before or shortly after birth. 
 
1.3.2 The Tucson Children’s Respiratory Study (TCRS) 
TCRS was a landmark longitudinal epidemiological study which began in 1980 to 
investigate potential risk factors during the first 3 years of life for the future 
development of asthma(1). It was one of the first cohort studies to recruit unselected 
infants at or shortly after birth. Its strengths include the large number of infants 
(n=1246), measurements made in cord blood before the onset of any respiratory 
illness and a long period of follow up with good retention of subjects. The TCRS has 
made a large contribution to our knowledge of preschool wheezing, describing three 
distinct wheezing phenotypes (transient infant wheezers, late onset wheezers and 
persistent wheezers)(1). It was also the first longitudinal cohort study to develop an 
asthma predictive index in preschool wheezers(27), discussed in section 1.6. 
 
Tucson Children’s Respiratory Study - wheezing phenotypes  
Transient wheezers 
Transient wheezers were children who wheezed only during the first three years of 
life and who had stopped by age 6 years. Lung function as measured by maximal 
flow at functional residual capacity (Vmax FRC) was lower in transient wheezers than 
their non wheezing peers(1) shortly after birth and at age 6 years and they continued 
to have lower levels of forced expiratory flows at age 11 and 16 years(6), figure 1.1. 
Their diminished lung function shortly after birth, before any postnatal respiratory 
insult, suggests the need to focus on antenatal factors which may predispose these 
children to wheezing. As the airways grow children are less likely to wheeze with 
respiratory viral infections. Risk factors for transient wheezing include prematurity, 
maternal smoking, maternal atopy, maternal hypertension and younger maternal 
age(1;28-30). 
 
Persistent Wheezers  
Persistent wheezers referred to children who continued to wheeze throughout the 
first 6 years of life. Persistent wheezers had higher total serum immunoglobulin E 
(IgE) than non-wheezers at 9 months, despite no association between cord blood 
IgE and persistent wheezing at 6 years suggesting IgE mediated sensitisation may at 
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least start to develop during the first year of life. Almost all the persistent wheezers 
were sensitised to at least one aeroallergen by age 6 years. VmaxFRC in infancy in 
persistent wheezers is similar to those children who subsequently never wheezed, 
but by 6 years of age, these children had reduced pulmonary function which 
subsequently tracks with time(1). Children with persistent wheezing were more likely 
to have more severe symptoms, eczema, rhinitis apart from colds and a maternal 
history of asthma. 
 
Late onset wheezers 
Late onset wheezers are those who wheeze at age 6 years but do not wheeze in the 
first 3 years of life. Although late onset wheezers were as likely to remain 
symptomatic to 16 years as persistent wheezers they had no significant deficits in 
lung function. Children in the late onset wheezing group were more likely to be atopic 
than those children that had never wheezed, but atopy was less prevalent in this 
group than the persistent wheezers. Lung function tracks for all 3 phenotypes from 
the preschool years to adolescence at least, figure 1.1. This suggests that lung 
function deficits in children with asthma are already present by 6 years of age and 
remain stable (or at least do not improve) throughout adolescence. While the Tucson 
study has added greatly to our knowledge of the evolution of preschool wheeze, 
epidemiological classifications can only be applied retrospectively and do not 
contribute to the clinical management of the individual child. Furthermore, these 
phenotypes are largely self-fulfilling as children were only assessed at 3 fixed time 
points, and so could only have those 3 wheeze phenotypes.  
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Figure 1.1: Cross-sectional z scores of height-adjusted maximal expiratory 
flows at ages 2.4 months and 6, 11, and 16 years for the preschool wheeze 
phenotypes(6) Changes in pulmonary function are established by 6 years of age, 
and track through to late adolescence 
 
 
1.3.3 British Avon Longitudinal Study of Parents and Children (ALSPAC birth 
cohort) 
Although the wheeze patterns as defined by the TCRS(1) group were self-fulfilling, 
the findings were largely confirmed by the British Avon Longitudinal Study of Parents 
and Children (ALSPAC) birth cohort(6;11). This was a longitudinal birth cohort study in 
which data on wheezing were available at 7 time points from birth to 7 years of age 
in 6,265 (45%) of the 14,062 unselected children(11). Wheeze phenotypes were 
determined using latent class analysis (which allows phenotypes to emerge from the 
data, rather than be imposed on it as in the TCRS) and largely confirmed the 
temporal wheezing patterns and associated risk factors of the TCRS(1). Two other 
phenotypes were also described; “prolonged early wheeze” characterised by 
wheezing in non atopic children from 6 to 54 months with low prevalence from age 
69 months onwards and “intermediate onset wheeze” with onset between ages 18 
and 42 months. These wheezing phenotypes were later confirmed in the Prevalence 
and Incidence of Asthma and /Mite Allergy (PIAMA) Dutch birth cohort (also using 
latent class analysis) adding further evidence to the existence of an intermediate-
onset phenotype with onset of wheeze after 2 years of age(31). Unlike in the Tucson 
children(1) the intermediate phenotype had a stronger association with atopy than the 
 30 
persistent or late onset wheezers. Childhood wheeze phenotypes most associated 
with atopy and airway hyperresponsiveness (AHR) in this study had onset after 18 
months. This cohort study suggests all wheezy phenotypes including the late onset 
wheezers are associated with impaired lung function by school age(11). 
 
1.3.4 German Multicentre Allergy study (MAS) 
The German MAS was a birth cohort (n=1314) of healthy term infants (⅓ had 2 
parents with atopy and increased cord blood IgE, and ⅔ had 1 parent with atopy) 
recruited in 1990 and were followed up until 13 years of age. The purpose of the 
study was to investigate the role of allergic sensitisation and allergen exposure in 
early life in the development of asthma. Children were followed annually including 
both clinical and lung function (body plethysmography) assessment, and also 
measurement of specific IgE to food and aeroallergens. The study showed that 
children with persistent or late onset wheeze have impaired pulmonary function at 7 
years(13), similar to the findings of the Tucson study. In children with wheeze, lung 
function tracked along values found at age 7, until age 10 and 13 years. However, 
the course of lung function differed significantly between 7-13 years in atopic and 
non atopic wheezers with impairment in all lung function indices only seen in atopic 
wheezers. The MAS cohort was the only study which measured childhood lung 
function at 10 and 13 years after bronchodilator treatment. This still showed reduced 
lung function in wheezing children, but the differences were less(32). 
 
In contrast to the TCRS study 90% of children with early wheeze, but no atopy, lost 
their symptoms at school age and had normal lung function by puberty(32). This group 
may represent children who wheezed with viral infections at preschool age. 
Importantly, sensitisation to perennial allergens such as house dust mite, cat and 
dog hair that developed in the first 3 years of life was associated with a loss of lung 
function at school age. A positive family history of atopy, or early IgE sensitisation to 
aeroallergens were the strongest factors predicting whether children wheezing early 
in life will continue wheezing until puberty(32).  
 
1.3.5 British Manchester Asthma and Allergy (MAAS) cohort study 
The Manchester Asthma and Allergy Study (MAAS) is an unselected, population-
based study which recruited 1186 children antenatally(33). Children were followed 
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prospectively, and attended review clinics at ages 1, 3, 5 and 8 years where skin 
prick tests were performed to aero- and food allergens. Lung function was measured 
using whole body plethsmography at age 3 (49%) and 5 (67%) years and showed 
reduced lung function in children with a history of transient and persistent wheeze 
similar to the TCRS and ALSPAC studies, and similar to the TCRS showed no 
difference in lung function between children who never wheezed and late-onset 
wheezers at age 5(34).  
 
Table 1.2:Comparison of preschool wheeze phenotypes and associated lung 
function in the Tucson Children’s Respiratory Study (TCRS), Avon 
Longitudinal Study of Parents and Children (ALSPAC) and Manchester Asthma 
and Allergy Study (MAAS) 
 TCRS ALSPAC MAAS  
 Birth Age 6 yrs Age 8-9 yrs Age 3 yrs Age 5 yrs 
Never Wheezed 
Transient wheeze 
 
Prolonged early wheeze 
Intermediate Onset wheeze 
Late onset Wheeze 
Persistent Wheeze 
N 
↓ 
 
- 
- 
N 
N 
N 
↓ 
(some catch up ) 
- 
- 
N 
↓↓ 
N 
↓ 
 
↓↓ 
↓↓ 
↓ 
↓↓ 
N 
↓* 
 
- 
- 
N 
↓↓ 
N 
↓ 
 
- 
- 
N 
↓↓ 
 
TCRS: Lung function was measured by Vmax FRC at infancy and age 6 years
(1)
 
ALSPAC: Lung function was not assessed at birth and FEV1 was measured at 8-9 years. All wheeze 
phenotypes were associated with decrements of FEV1 when compared with the never wheezed 
group
(11)
. The greatest decrements were associated with prolonged early, intermediate onset and 
persistent wheezing
(11)
.  
MAAS: Lung function measured by specific airways resistance at 3 and 5 years. *Children with 
transient wheeze had reduced lung function at 3 years when compared to non-wheezers but it was 
not statistically significant
(34)
 
 
Similar to the German MAS the MAAS study also showed that early sensitisation to 
allergens (house dust mite, cat, dog, grasses, milk, egg) was associated with a 
decrement in lung function. Children who had never wheezed in the first 3 years of 
life had significantly higher specific airways resistance if they were atopic, or were at 
high risk of atopy (i.e., if both parents were atopic)(33). The MAAS also adopted a 
machine based learning approach for latent classes of sensitisation analysis which 
suggested that IgE antibody responses do not reflect a single phenotype of atopy, 
but rather multiple different atopic vulnerabilities(35). In particular children with 
multiple early atopic vulnerability were more likely to persistently wheeze(35). This 
study may in part explain the global variations in asthma and atopy, as atopic 
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vulnerabilities may differ in each location consequent to differences in genetic 
predisposition and environmental exposures(35). The importance of early 
environmental influences is highlighted by a study of asthma in South East Asian 
women living in Leicester(36). Asthma prevalence in South East Asia is much lower 
than in the UK(37). Women were born in South East Asia and immigrated to the UK in 
the first 4 years of life acquired the asthma risk of the UK, whereas women 
immigrating to the UK older than 5 years retained the South East Asian asthma 
prevalence(36).  
 
1.3.6 Perth study 
The Western Australian pregnancy cohort study is a prospective birth cohort initially 
established (1989-92) which recruited 253 healthy full term infants(38). The rapid 
thoracoabdominal compression technique was used to determine VmaxFRC and AHR 
in infancy (n=253) at 1 month, 6 months and 12 months of age. At 11 years of age 
study participants (n=176) attended an assessment that included measurement of 
spirometry, AHR to histamine and skin prick reactivity(39). However, contrary to the 
TCRS study, the Perth study suggested that persistent wheezers had abnormal lung 
function (VmaxFRC) at birth which did not deteriorate with time suggesting that 
impaired lung function preceded the development of persistent wheezy disorders 
and may predispose children to asthma(40). The question of whether decreased lung 
function is a cause or consequence of asthma remains unresolved. The Perth study 
also reported that children who transiently wheeze have reduced VmaxFRC at 4 
weeks (similar to TCRS group), and reduced forced expiratory volume in one second 
(FEV1) at 6 years, but normal FEV1 by 11 years
(41).  
 
In contrast TCRS transient wheezers have some lung function catch up with time but 
remain impaired when compared with non-wheezers, figure 1.1. However, given the 
much larger numbers in the TCRS study its results are more likely to be correct. 
Secondly, spirometry is a crude measure of lung function in asthma(42) and other 
assessments of lung function may have detected some decrements. The Perth study 
also showed that children with house dust mite specific IgE titres of greater than 0.20 
kU/L by age 2 years have a 12.7% risk of persistent wheeze, increasing 
progressively to an 87.2% risk with increasing numbers of severe lower respiratory 
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tract illnesses experienced(43). The role of AHR and the future development of 
asthma will be discussed in section 1.4. 
 
1.3.7 Environment and Childhood Asthma (ECA)  
In 1992 3754 unselected infants (with a birth weight greater than 2kg) born in Oslo, 
Norway were enrolled at birth into the Environment and Childhood Asthma (ECA) 
study. Information on the child’s health and environmental exposures was collected 
from parents by questionnaires at birth and when the child was age 0.5, 1, 1.5, 2, 4, 
and 10 years(14;44). Lung function was assessed shortly after birth (aged 2-3 days) in 
802 infants while awake using tidal breathing techniques(45). Similar to the Perth 
findings, infants with abnormal tidal breathing patterns (the fraction of expiratory time 
to peak tidal expiratory flow to total expiratory time [tPTEF/tE]) were more likely to 
have asthma at 10 years of age (77% follow-up)(45). The 10-year follow-up of the 
Oslo birth cohort also showed that doctor diagnosed asthma before the age of 10 
years was positively associated with early life respiratory infections including croup, 
the common cold and otitis media as reported by parents at the 6 month and 12 
month questionnaires(46).  
 
1.3.8 Copenhagen Study on Asthma in Childhood (COPSAC) 
The Copenhagen Prospective Study on Asthma in Childhood (COPSAC) is a single-
center, birth cohort study of children (n=411) born to asthmatic mothers between 
1998 and 2001. Infants had lung function measured using the raised volume 
thoracoabdominal compression technique, assessment of AHR using metacholine 
and FeNO measured at 1 month of age. Children were reviewed at 6 monthly 
intervals and followed up with a long-term diary card based on wheezy symptoms for 
the first 6 years of life (76% follow up)(47). FeNO levels (measured in 62% of the 
cohort) were increased in 1-month-old symptom-free babies who developed transient 
early wheeze but not persistent wheeze, but was unrelated to neonatal lung 
function(47). This suggests an early disease process unrelated to airway calibre 
contributing to the transient wheeze phenotype(47).  
 
Perhaps a more interesting finding was that infants colonised in the hypopharyngeal 
region with S. pneumoniae, H. influenzae, or M. catarrhalis, or with a combination of 
these organisms, at 1 month of age were at two fold increased risk for recurrent 
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wheeze and asthma early in life(23). Blood eosinophil counts and total IgE at 4 years 
of age were significantly increased in children who were colonised as neonates(23). 
Children in this study continued to have hypopharyngeal aspirates and 
nasopharyngeal aspirates taken every 6 months at routine follow up visits and also 
for any wheezy episode that lasted for 3 days or more(48). Wheezy episodes were 
significantly associated with H influenzae, M catarrhalis, and S pneumonia, similar to 
but independent of the association with virus infections(48), figure 1.2. It is unknown 
whether the bacterial colonisation acts an environmental trigger in genetically 
predisposed children, or there is a subtle immunodeficiency in children who develop 
asthma leading to mucosal bacterial colonisation.  
 
However, it is worth noting in this context that recent work has highlighted the 
importance of airway bacteria in normal and abnormal immunological 
development(49). Once thought to be sterile, it is now clear that there is a rich 
bacterial flora in the human lower airway(50), although not all groups have reproduced 
this finding(51). From animal work, it is clear that absence of the normal lower airway 
flora leads to more pronounced TH2 inflammation
(52) and that the airway microbiome 
may modulate the response to inflammation(53;54). Human data are more indirect. A 
recent manuscript linked increased environmental bacterial and fungal diversity to a 
reduced risk of asthma and atopic disease in children from farming and non-farming 
environments(49). Furthermore, babies delivered by caesarean section are at 
increased risk of atopic disease(55), and this has been linked to altered intestinal 
flora(56). Infants of atopic parents who had a home but not hospital normal vaginal 
delivery had reduced risk of asthma and eczema at the same age(57). The area of the 
interactions between the microbiomes of the intestine and the airway, and the 
development of disease, is rapidly evolving. 
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Figure 1.2: Risk of recurrent wheeze. COPSAC showed a strong association 
between colonisation of the airways with common pathogenic bacteria and 
development of recurrent wheeze and asthma(58).  
 
 
 
1.3.9 Childhood Origins of Asthma birth cohort study (COAST) 
The Childhood Origins of Asthma (COAST) birth cohort study followed 289 children 
at high risk of asthma from birth, focusing on viral infections in the first year of life. At 
least 1 parent was required to have one or more positive skin prick tests to 
aeroallergens or a history of doctor diagnosed asthma. Nasopharyngeal specimens 
were taken during wheezy exacerbations during the first 3 years of life. The COAST 
study confirmed that 50% of children wheeze with respiratory syncytial virus (RSV) 
and 25% of children will wheeze with rhinovirus(59). Rhinovirus wheezing in early life 
(0-3 years) was a better independent indicator of asthma risk at 6 years than RSV 
associated wheezing or aero-allergen sensitisation(22). Nearly 90% of children 
wheezing with rhinovirus at age 3 subsequently developed asthma regardless of the 
presence or absence of aeroallergen sensitisation(22;59). Interestingly, allergic 
sensitisation during early life predisposes children to more severe viral respiratory 
illnesses and wheezing, particularly with rhinovirus, but that wheezing respiratory 
illnesses do not increase the risk for the subsequent development of allergic 
sensitisation(60).  
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1.3.10. Clinical wheeze phenotypes:- European Respiratory Society 
classification of preschool wheeze 
A major limitation of epidemiological wheeze phenotypes is that they can only be 
applied retrospectively. Secondly, there is considerable overlap between phenotypes 
that have been described. Patterns of temporal wheeze in preschool children as 
described by the European Respiratory Society (ERS) Taskforce are multiple-trigger 
and episodic (viral) wheeze(61). This classification of wheeze phenotypes is clinical 
and can be applied by the physician prospectively at preschool age. 
Episodic (viral) wheezers are children who wheeze during discrete time 
periods usually with a cold or other clinically diagnosed viral respiratory tract 
infection but who do not wheeze between episodes.  
Multiple-trigger wheezers are children who wheeze both during 
exacerbations and between episodes. This group of children are often, but not 
always, also atopic. 
 
Multiple-trigger wheezers have been shown to have pulmonary function 
abnormalities as measured by increased ventilation inhomogeneity, particularly of 
the conducting airways independent of atopic and current wheeze status and 
evidence of airway pathology changes similar to asthma when compared to episodic 
(viral) wheezers(62;63). Pulmonary function in episodic viral wheezers did not differ 
significantly from control subjects(62). Multiple trigger wheezers also had increased 
exhaled nitric oxide levels when compared to viral or episodic wheezers(62). 
However, these wheeze phenotypes are not fixed and children can move from one to 
the other. For example, episodic viral wheeze may evolve into a multiple-trigger 
pattern, and multiple trigger wheeze may become episodic over time or with 
treatment with inhaled corticosteroids. Multiple trigger and episodic wheeze 
phenotype stability was assessed every 3 months over a 1 year period and only 
remained stable in 50% of preschool children in a West Australian intervention 
study(64). However, frequent monitoring may have changed our view of natural 
history of wheeze in these children. It is possible that increased inhomogeneity of the 
conducting airways in the multiple-trigger preschool wheezers may reflect increased 
disease severity in a subgroup of preschool children who in response to viruses and 
environmental stimuli have more prolonged periods of persistent airflow obstruction 
or alternatively that multiple-trigger wheeze represent a different disease phenotype. 
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1.4 Early airway hyperresponsiveness 
It is not clear whether increased premorbid AHR predisposes children to develop 
asthma or whether AHR develops as part of the pathophysiology of asthma. Three 
cohorts from London, Perth and Copenhagen have reported studies of AHR in early 
infancy, before the onset of symptoms and prior to the establishment of allergic 
airway inflammation(39;65-67).  
 
The London cohort measured AHR to histamine (expressed as the provocative 
concentration (PC) of histamine that induced a 30% (PC30) decrease in VmaxFRC) in 
healthy term infants (n=73) with at least 1 atopic parent by using the rapid 
thoracoabdominal compression technique(65). AHR in female infants but not in male 
infants predicted subsequent wheezing in the first year of life. Children were followed 
up age 10 years with 89% follow up for wheezing history and 50% follow up with 
spirometry and methacholine challenge. An association was reported between 
neonatal AHR and transient early wheeze but not persistent wheeze at 10 years(66). 
Neonatal AHR also significantly predicted subsequent FEV1 at 10 years but there 
was no correlation with subsequent AHR (PC20 the concentration of methacholine 
causing a 20% drop in FEV1)
(66).  
 
The Perth cohort measured AHR to histamine (concentration provoking a 40% 
reduction in VmaxFRC (PC40)) on 3 occasions at 1 month, 6 months and 12 months in 
202 unselected infants using the rapid thoracoabdominal technique(68). Children were 
followed up with assessments of lung function, AHR and asthma at age 6 and 11 
years(39). AHR in late infancy at 1 year but not at 1 or 6 months (when reduced 
VmaxFRC was present) was associated with wheeze persistence at 11 years
(39). 
Unlike with the London cohort although AHR at 1 month was associated with asthma 
at 6 years, it was not at 11 years(39). Conversely, reduced airway function (VmaxFRC) 
present in early infancy is also associated with persistence of wheeze at 11 years of 
age, independent of the effect of increased AHR and atopy in childhood(40). Neither 
the Perth nor the London cohort showed association between AHR in infancy and at 
school age(39;66). However, the absence of increased AHR in both infancy and 
childhood was associated with a zero incidence of asthma and wheeze age 10-11 
years in both studies. 
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The COPSAC birth cohort also studied AHR (PC20 FEV0.5) to methacholine in 402 
neonates(67). The 17q21 gene variants (ORMDL3) were associated with increased 
AHR in infancy and at 4 years of age but not at 6 years of age, suggesting a genetic 
determinant of neonatal AHR(67). There was no associated risk of eczema, rhinitis, or 
allergic sensitization with the 17q21 gene variant.  
 
The London and Perth cohort studies suggest that different factors drive AHR in 
infancy and later in life. Genetic factors such as β- adrenoceptor polymorphisms may 
influence AHR in the neonatal period(66), but other factors including early viral and 
bacterial infections or development of atopy may predominate after this. It should 
also be noted that measurements of AHR are very challenging in infants and 
increased AHR may not have been detected in some. On the other hand AHR may 
be detected in adults without respiratory symptoms. There is also a close link 
between upper and lower airways with 30% of adults with moderate-severe allergic 
rhinitis (perceiving only nasal symptoms) demonstrating AHR on methacholine 
challenge(69).  
 
The 3 studies assessing AHR in infants used direct methods of assessing AHR with 
pharmacological stimuli such as histamine or metacholine causing constriction of the 
airway smooth muscle, leading to airway narrowing and airflow limitation. Indirect 
stimuli (allergens, cold air, exercise) act through one or more intermediate pathways, 
many (but not all) of which involve release of mediators from inflammatory cells. 
Bronchoconstriction from both direct and indirect airway challenges is reported to 
induce airway remodelling in patients with asthma(70).  
 
1.5. Lung function and asthma : school age to adulthood 
Both the TCRS and German MAS studies have shown deficits in lung function in 
those with persistent wheeze are present by 6 years and track through to 
adolescence(6;32). The longest running cohort studies, Melbourne(71) and Dunedin(72), 
have tracked deficits in lung function from time of recruitment at school age to 
adulthood in asthmatics.  
 
The Melbourne asthma study was the first longitudinal asthma cohort study which 
followed randomly selected 7 year old school children at 7 year intervals until age 50 
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years between 1964 and 2007(71;73). The term wheezy bronchitis was used in the 
1960s to refer to wheezing in association with a respiratory tract infection (which 
would now be termed ‘episodic viral wheeze’). This cohort study is particularly 
interesting as children were recruited in 1967 before the routine use of inhaled 
steroids, β-agonists or sodium cromoglycate and helps to clarify the natural evolution 
of early childhood wheezing to adult asthma without modern interventions. At 42 
years only 5% of the original wheezy bronchitis group had persistent asthma but 
70% of the asthma group and 90% of the severe asthma group were still 
symptomatic. Most of the children with severe asthma had either a barrel chest 
deformity or reduction in FEV1 at recruitment, rarely seen now in clinical practice. 
Furthermore, children with severe asthma had more than 30 times the risk of 
developing adult chronic obstructive lung disease (COPD) as adults compared to 
children without asthma(73). 
 
Children from Dunedin (n=1139) were recruited shortly after the children from the 
Melbourne cohort study. The Dunedin cohort were born between 1972-1973 and 
followed from 9 years at 2 or 3 yearly intervals until age 26 years(72). Subject 
retention was 59%. Persistence of wheeze was associated with smoking at 21 years 
(odds ratio (OR)=1.71), AHR (OR=3), female sex (OR=1.71) and sensitisation to 
house dust mite (OR=2.41) at 13 years. However, history of early childhood 
wheezing was retrospectively recalled when the children were 9 years old, which 
may have predisposed the study to maternal recall bias.  
 
1.6.1 Asthma Prediction Indices  
Many preschool children with wheeze do not have asthma characterised by 
eosinophilic inflammation and are unlikely to respond to asthma treatment. At 
present there is no treatment able to prevent the development of school age asthma 
in preschool children with wheeze. Studies have shown that neither intermittent(74) 
nor continuous(75;76) inhaled corticosteroids (ICS) prevent the development of asthma 
in episodic wheezers. Intermittent ICS therapy in the first 3 years of life had no effect 
on the progression from episodic to persistent wheezing and no short-term benefit 
during episodes of wheezing(74). Children at high risk of future asthma were enrolled 
in the Prevention of Early Asthma in Kids study (PEAK)(77) to assess if chronic early 
therapy with ICS initiated in children aged 2 to 3 years of age at high risk of asthma 
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can prevent the development of persistent asthma at 4 to 6 years of age. This 
hypothesis was subsequently disproven in this group of high risk children(76). 
Similarly, a subsequent study confirmed the early use of ICS in wheezy preschool 
children 1-2 years had no effect on the natural history of asthma, and nor did 
treatment prevent lung function decline or reduce airway reactivity by age 5 years(75). 
Other approaches to prevent the development of asthma have used anti-histamine 
treatment in high risk children with atopic dermatitis. The Early Treatment of the 
Atopic Child (ETAC) trial randomised infants aged 1-2 years to cetirizine or placebo 
for 18 months(78). There was no difference in wheeze prevalence for the group as a 
whole at the three-year follow-up (18 months after randomization was complete) but 
asthma was delayed in a subgroup of infants with atopic dermatitis sensitized to 
grass pollen and house dust mite(78). A second study, using L-cetirizine, was 
completely negative (Warner JO, personal communication). 
 
Since loss of lung function takes place before 6 years of age, the preschool years 
represent a potential window for intervention to modify the natural history of asthma. 
Despite the body of literature regarding asthma and risk factors for its development, 
surprisingly few studies give ‘predictive indices’ for the development of asthma in 
young children with wheeze. Improved ability to predict which preschool wheezers 
are at high risk of persistent wheeze and school age asthma would be useful firstly to 
study mechanisms of conversion of episodic viral wheeze to asthma; and secondly 
as a tool to define high risk groups to allow the appropriate selection of children for 
future prevention strategies. 
 
Cohort studies have been used to try to develop prediction indexes of the likelihood 
of later asthma in children with wheeze at preschool age. There are four main 
asthma predictive indices to date. The ‘Castro-Rodriguez’(27),‘Isle of Wight’(12), and 
PIAMA birth cohort(10) indices are based on cohort studies with greater than 1000 
patients and use asthma risk factors identified in epidemiological studies including 
parental history of asthma and atopy, and presence of other atopic conditions such 
as allergic rhinitis and eczema to develop a predictive index. The Oslo case control 
study(79) is smaller and used a simple score based on frequency, persistence and 
severity of wheeze to predict later asthma.  
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1.6.2 ‘Castro-Rodriguez’ Asthma Predictive Index 
As part of the Tucson longitudinal birth cohort study parents with children who 
wheezed had reported their severity on a scale (1-5, from 1= ‘very rarely’ to 5= ‘on 
most days’) at the year 2 and 3 surveys. Children with a score of greater than 3 were 
defined as frequent wheezers. To classify children at risk of asthma two indices, a 
‘stringent index’ and a ‘loose index’ for the prediction of asthma were designed. For 
the stringent index the child had to be an early frequent wheezer during the first 3 
years of life and meet one major or 2 minor criteria. For the loose index the children 
had to have wheeze at any time during the first 3 years and meet one major or 2 
minor criteria, table 1.3. The ‘stringent index’ had good negative predictive value 
(NPV) (86%) and very poor positive predictive value (PPV) (42%) for diagnosis of 
asthma by 11 years. Conversely, a more 'loose index' which only required infrequent 
wheezing episodes plus the same combination of other risk factors still had high 
NPV (87%) but even lower PPV (27%). Sensitivity decreased with increasing age to 
13 years, but specificity remained constant. The PEAK trial modified the published 
‘Castro-Rodriguez’ asthma predictive index(27) to include children age 2 years and 
markers of allergic sensitisation to improve future asthma prediction, table 1.3.  
 
Table 1.3: Original and modified ‘Castro-Rodriguez’ asthma predictive index 
Differences between the original and modified asthma predictive index are shown in 
italics 
 
The child must have a history of 4 or more wheezing episodes with at least 1 confirmed by a 
physician plus 
 
Major criteria  
Parental history of asthma   
Physician-diagnosed atopic dermatitis 
Allergic sensitisation to ≥ 1 aeroallergen   
 
Minor criteria  
Wheezing unrelated to colds  
Blood eosinophils ≤4%  
Doctor Diagnosed Allergic Rhinitis  
Allergic sensitisation to milk, egg  or peanuts  
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1.6.3 ‘Isle of Wight’ Asthma Predictive Index  
A randomly selected birth cohort was established on the Isle of Wight in 1989 to 
prospectively study the natural history of childhood asthma(12). Enrolment was at 
birth and information on family history of allergy (parental or siblings), household 
pets, smoking habit, social class, birth weight was recorded and cord blood IgE 
measured. Children were followed up at 1, 2, 4 and 10 years. Skin prick testing was 
performed on most children seen at 4 years (n=981). Follow up was 71% (n=1034) in 
children with information available from the 4 visits over the 10 year period. Risk 
factors including family history of asthma, atopy as measured by skin prick tests at 4 
years, recurrent chest infections and recurrent nasal symptoms (which were shown 
to have a protective effect) were used to create a cumulative risk score (0-4) for 
wheeze persistence. A maximum risk score of ‘4’ was associated with prevalence for 
wheezing persistence of 83% at age 10 years while a ‘0’ score was associated with 
prevalence for transient wheezing of 80%. A limitation of this index is that scores at 
either extreme were only present in a few children. A score of 3 had a PPV of 68% 
and a NPV of 74%. The likelihood ratio, which refers to sensitivity/(1-specificity) and 
provides a direct estimate of how much the asthma predictive index will change the 
odds of having a disease, was 3 for an asthma predictive score of 3.  
 
1.6.4 ‘PIAMA’ Asthma Predictive index 
The PIAMA birth cohort followed 3,963 children for 8 years in the Netherlands. 
Between 0 and 4 years of age, 2,171 (55%) children reported ‘‘wheezing,’’ ‘‘coughing 
at night without a cold,’’ or both(10). In these children possible predictors for later 
asthma were assessed at the age respiratory symptoms were first reported. Eight 
clinical parameters independently predicted asthma at 7 to 8 years of age: male sex, 
post-term delivery, parental education less than third level, any parental inhaled 
asthma medication use, wheezing frequency, wheeze / dyspnoea apart from colds, 
respiratory infections, and eczema. A clinical risk score was developed (range, 0-55 
points) based on these 8 clinical parameters at the time preschool children first 
reported asthma. Eleven percent of children with symptoms at 0-4 years of age had 
asthma at 7-8 years of age. The area under the receiver operating characteristic 
curve (AUC) for this score is 0.74. The predictive power of this rule is not easily 
comparable with that of other studies because of differences in study design. As with 
all such studies, there was no second validation cohort. Symptomatic children with a 
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score of less than 10 points had a 3% risk of asthma, whereas children with a score 
of 30 points or greater had a 42% risk of asthma.  
 
1.6.5 ‘Oslo’ Asthma Predictive Index 
The ‘Oslo’ asthma predictive index was derived from a nested case control study 
within the ECA study(14), comprising 233 2-year-old subjects with recurrent (>2 
episodes) bronchial obstruction and 216 subjects without bronchial obstruction(79). A 
severity score (0-12 points) at 2 years was calculated by frequency and persistence 
of bronchial obstruction and hospital admissions because of recurrent wheeze. 
Wheeze sufficiently severe to require hospitalisation had been shown to be a risk 
factor for the development of asthma(79). A severity score of greater than 5 is 
predictive of asthma, PPV (44-51%) and NPV (78-87%). This score had a linear 
increase with an increase in OR of 1.35 for each point increase in the severity score. 
The OR for persistent wheeze increased from 3.7 to 9.8 as the severity score 
increased from 1-12. However, there were very wide confidence intervals at both 
extremes of the scale. 
 
1.6.6 General Practice based Asthma Predictive Indices 
Two general practice based studies also developed very simple asthma predictive 
indices using postal questionnaires to diagnose asthma at school age(80;81). In a 
British study of children aged 0-4 years, only wheeze after exercise and history of 
eczema or hay fever at preschool age were predictive of wheezing 6 years after 
follow up(80). Absence of these two factors reduced the likelihood of asthma at age 6 
years by a factor of 5(80). Limitations of this study include the small numbers with 
recurrent preschool wheeze (<150), poor subject retention and the lack of any 
objective confirmation of wheeze. The general practices were situated on a housing 
estate in Manchester with evidence of socioeconomic deprivation, which may limit 
generalisability. 
 
Eyesink et al(81), measured IgE in 654 children aged 1-4 years with persistent 
coughing for greater than 5 days who presented to primary care in the Netherlands. 
All children with a raised IgE (27%, n=96) but only a random sample of children 
(n=96) with a negative IgE were followed up until age 6. In contrast to the German 
MAS study(32), addition of specific IgE (for house dust mite, cat and dog dander) to a 
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prediction model based on age, wheeze and family history of pollen allergy had little 
effect on the asthma predictive values. This study had several limitations including 
loss of 25% of the atopic children to follow up, history of wheezing which was 
retrospectively obtained from patient notes, and inclusion of children with isolated 
recurrent cough, a very non-specific symptom of asthma.   
 
Summary 
Current asthma predictive indices have better negative predictive values than 
positive predictive values. This suggests that the API models are better at excluding 
asthma rather than identifying the children who will develop asthma at school age. 
The PPVs for asthma predictive indices range from (27-68)% which is little better 
than flipping a coin in predicting which preschool wheezers will persistently wheeze 
and have asthma at school age. The four most clinically significant asthma predictive 
indexes are summarised in table 1.4.  
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Table 1.4: Asthma Predictive indexes for children with recurrent wheeze at preschool age have good negative but poor positive predictive values 
DD=doctor diagnosed;  PPV=positive predictive value;  NPV= negative predictive value 
 
 
Study 
 
 
Number of children  
 
Asthma Predictive Index 
 
Predictive value for asthma at age 10 
 
Castro Rodriguez JA, 2000
(27) 
(* asthma measured at age 11 
years) 
 
 
 
 
 
 
 
 
1,246 
 
Major Criteria 
Parental DD asthma 
DD eczema 
Minor Criteria 
DD allergic rhinitis 
Wheezing apart from colds 
Peripheral blood eosinophilia 
 
Stringent Index 
Frequent wheeze plus 
One major or two minor criteria 
Loose index 
Any wheeze plus 
One major or two minor criteria 
 
‘stringent index’ 
PPV (42%), NPV (86%) 
Specificity (97%) 
Sensitivity (16%) 
OR= 4.3-9.8 
‘loose index’ 
PPV (27%) NPV (87%) 
Sensitivity (40%) 
Specificity (80%) 
OR 2.6-5.5 
 
Sensitivity decreased with increasing age, but specificity remained constant. The 
negative predictive values were high for all ages. If a ‘loose index’ is used a high 
proportion of children will not go on to have asthma.  
 
Kurululaaratchy RJ, 2003
(12) 
  
 
 
1,456 
 
Score 0-4 
Recurrent chest infections at 2 years 
Family history of asthma 
Atopic skin prick tests at 4 years 
Absence of nasal symptoms at 1 year 
 
 
Score of ≥ 3 increases likelihood of asthma by 3 
PPV (68%), NPV (74%) 
Sensitivity (52%) 
Specificity (84%) 
Likelihood ratio=3.4 
Very few children with scores of either 0 or 4 
Devulappalli CS, 2008
(79) 
  
 
449 Score 0-12 
Frequency persistence of wheeze 
Persistence of wheeze 
Number of hospital admissions 
Scores >5 are indicative of asthma 
PPV (43.9-51%), NPV (78-87%)  
Sensitivity (2-51%)  
Specificity (88-99%)  
2 point score rise increased the OR by 1.82 (CI 1.57-2.11) 
 
Caudri D, 2009
(10)
 
 
3963 
 
Score 0-55 
Wheezing frequency 
Serious infections 
DD eczema 
Use of inhaled medications 
 
Score ≥ 30  
PPV 42%, NPV 91% 
Sensitivity 19% 
Specificity 97% 
 46 
1.7 Airway pathology and asthma 
Epidemiological studies have failed to provide us with a predictive index for 
preschool wheeze which has a good positive predictive value for asthma at school 
age. The pathology of asthma is characteristic and very different from the normal 
airway; hence pathological indices may be better positive predictors of asthma 
progression. The next section reviews what is known about the pathology of 
paediatric preschool wheeze and asthma. 
 
1.7.1 Safety of endobronchial biopsies for assessing airway pathology 
Early evidence for airway changes associated with asthma came from post mortem 
studies, often in adults who had died from fatal asthma exacerbations(82;83). More 
recently routine use of bronchoscopy and endobronchial biopsy (EB) for purely 
research purposes in adults has advanced our understanding of the pathology of 
asthma, allowing the comparison of endobronchial tissue between asthmatic adults 
with normal healthy individuals(84). There are guidelines on the most appropriate 
research methods to perform, process and analyse endobronchial biopsies, with 
specific guidelines for paediatric EB incorporated(85). The safety of EB has now been 
reported for school aged and preschool children(86-90). In children, bronchoscopy can 
only be performed if there is a clinical indication. However, it adds just 5 minutes to 
the bronchoscopy procedure to obtain three endobronchial biopsies in children(91). 
The taking of additional samples for research at the time of such a procedure can be 
justified if the ethics committee approves, the carers consent, and the child gives age 
appropriate assent. 
 
1.7.2 Airway pathology features typical of asthma 
Typical pathological abnormalities seen in EB from asthmatic adults and older 
children include; airway inflammation (particularly eosinophils and T lymphocytes) 
and airway remodelling (defined as structural changes in the airway wall including 
increased reticular basement membrane (RBM) thickness, increased airway smooth 
muscle (ASM), epithelial shedding, angiogenesis and goblet cell hyperplasia, figure 
1.3 & 1.4(92-95). However, the role of airway remodelling and inflammation in disease 
persistence and progression is not clear. Furthermore, the onset and course of 
airway inflammatory changes and remodelling in children with asthma are not yet 
fully characterised. One aim of this thesis is to further characterise airway pathology 
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in severe recurrent preschool wheezers and its relationship to future school age 
asthma. 
 
1.7.3 Airway inflammation in asthma 
Airway inflammation in asthma involves multiple cells, particularly CD4+ T 
lymphocyte cells, eosinophils and mast cells. Stimulation of these cells leads to 
release of proinflammatory mediators and cytokines, which in turn cause vascular 
leakage, smooth muscle contraction, inflammatory cell infiltration, mucus 
hypersecretion and airway hyperresponsiveness.  
 
T lymphocytes 
T lymphocytes are particularly important in driving inflammation. When CD4+ T-
helper cells are activated, they differentiate depending on the local cytokine milieu 
into distinct lineages of effector cells, called T helper (TH) cell types including TH1, 
TH2, TH9, TH17 and TH22, or regulatory T cells (Tregs). TH1 cells contribute to 
protection against viruses and bacteria, and TH2 cells protect against parasites and 
helminths. Children and adults with asthma typically show a predominant TH2 
immune inflammatory profile which develops after exposure to an inhaled 
aeroallergen, characterised by cytokines such as interleukin (IL)-4, IL-5 and Il-13(96). 
However, asthma has several subphenotypes and this is perhaps an oversimplified 
approach. TH17 cells are reported to be mainly involved in neutrophilic asthma 
phenotypes(97). At birth, there is a presumed fetal TH2 predominance, thought to be 
necessary to prevent immune rejection of the fetus by the mother, but as exposure to 
bacteria and viruses in infancy and early childhood drives a switch to a TH1 
phenotype, characterized by the release of cytokines such as interferon-γ(96;98). The 
TH1/TH2 balance may not be fully developed in infant and preschool wheezers. 
Delayed maturation of TH1 responses in the neonate may contribute to the 
development of atopy(99). Treg cells constitute 5–10% of the total CD4+ T cells and 
control TH1 and TH2 immune responses. It is likely that primary functions of Treg cells 
in the airways is to limit the inflammatory consequences of infection and to maintain 
tolerance to harmless, inhaled aeroallergens(96). Steroid naive wheezy children aged 
8-20 months at a high risk of developing asthma (using the Castro-Rodriguez 
predictive index) had a significantly lower absolute number of Treg cells and lower 
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expression of IFN-γ following in vitro stimulation with house dust mite compared with 
those at a low risk of future asthma(100). 
 
Eosinophilic inflammation  
Eosinophils are the prominent cell type in many asthmatics(101) and increased 
eosinophils have been found in blood(102), sputum(103), bronchoalveolar lavage 
(BAL)(104)  and endobronchial biopsy tissue(105). Although not all children with asthma 
show eosinophilic inflammation, adults and children with asthma who have tissue 
eosinophilia have worse airway remodelling and more acute exacerbations(93;106;107).  
 
1.7.4 Airway remodelling in asthma 
Airway remodelling is a key pathological feature of asthma and is defined as the 
presence of persistent changes to the normal airway wall structure involving changes 
in the composition, organisation and function of structural cells including enhanced 
turnover of extracellular matrix components(108). Remodelling can occur both during 
normal lung growth and development and in response to injury and inflammation(109). 
In asthma, it is uncertain whether airway remodelling occurs as a result of tissue 
injury and repair or whether it is driven by (as yet undetermined) specific factor(s). 
Features of airway remodelling, such as increased RBM thickness and increased 
ASM mass in adult asthmatics are associated with persistent airflow limitation, 
reduced lung function and AHR(110;111). However, it is unclear which individual 
components of remodelling contribute to the clinical manifestations of asthma and in 
fact whether all remodelling is detrimental in asthma or whether some aspects may 
be protective. This thesis will focus primarily on the two most well-described aspects 
of remodelling which have been consistently associated with lung function 
abnormalities, increased RBM thickness(112) and increased ASM(110).  
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Figure 1.3: A paediatric endobronchial biopsy showing epithelium, reticular 
basement membrane (RBM), submucosa and airway smooth muscle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reticular basement membrane 
The RBM is visible as an acellular layer directly beneath the epithelium, figure 1.3. 
The RBM is not present in healthy airways of all species and its function and the 
reason for its presence in healthy humans remain unclear. Recently the natural 
history of RBM development has been described in humans(113). The RBM in 
children is visible 30 weeks post conceptional age and increases in thickness with 
age until birth, and subsequently increases rapidly until about 6 years of age(113). 
RBM thickness continues to increase after age 6 years, but at a slower rate, until 
about 17 years(113). However, there is considerable variability in RBM thickness 
measurements in healthy school age children and adults(113). 
 
Increased RBM thickness is the hallmark of established asthma in adults(114), and is 
seen by school-age (6-16 years) in severe(115;116) and mild-moderate(93;117) 
asthmatics. The abnormal thickening of the RBM begins early in childhood(9;116), and 
is already maximally thickened in children aged 6–16 years with severe 
asthma(116;118;119).  
 
 
RBM 
     Smooth muscle 
 
 
 
 
 
 
Submucosa 
Epithelium 
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Airway smooth muscle 
Increased ASM mass is thought to account for most of the functional contribution of 
airway remodelling to the pathophysiology of AHR(109;120). Increased smooth muscle 
mass in the airway wall of asthmatic children and adults is due to both hypertrophy 
and hyperplasia of smooth muscle cells(110;121;122) and has been linked to both 
disease severity and duration(110;123). In particular, alterations in ASM are most 
consistently associated with abnormalities in lung function. ASM hypertrophy and 
hyperplasia in school aged children and adults with asthma have been significantly 
related to bronchodilator responsiveness(110;121). Furthermore, the proportion of ASM 
increases as airflow limitation worsens(124;125).  
 
Epithelium and Epithelial Mesenchymal Trophic Unit 
The bronchial epithelium acts as a barrier separating the external environment and 
the lung parenchyma. The epithelium is emerging as an area of interest as new 
research shows interactions between the epithelium and the immune system are 
crucial in driving asthma(126). Genetic studies also suggest that the epithelium plays a 
significant role in the allergic response. The protocadherin-1 gene on chromosome 
5q31-q33, which is significantly associated with AHR, encodes an adhesion 
molecule expressed in airway epithelium, which at least suggests that a structural 
defect affecting the integrity of the airway epithelium contributes to the development 
of AHR(127). Epithelial cells from children with mild asthma are intrinsically different 
both biochemically and functionally compared with epithelial cells from children 
without asthma(128). Asthmatic epithelial cells from children with asthma also 
spontaneously produced significantly greater amounts of IL-6, prostaglandin E2, and 
epidermal growth factor, and equivalent amounts of IL-1β and soluble intracellular 
adhesion molecule-1, but significantly lower amounts of transforming growth factor 
(TGF) β1(128).  
 
Early adult asthmatic endobronchial biopsy studies showed epithelial 
desquamation(129), but the implication of this is controversial as some evidence 
suggests that epithelial damage may be due to tissue processing(130). The presence 
of epithelial shedding in children is unclear. Children with mild-moderate asthma 
(aged 2-15 years) had evidence of epithelial shedding on EB(94). However, no 
differences in epithelial shedding was seen between atopic and non-atopic children 
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with mild-moderate asthma(107). In contrast, school age children (aged 5-16 years) 
had similar epithelial shedding on EB when compared to nonasthmatic controls(119), 
but atopic children with severe asthma had more epithelial shedding than non-atopic 
children with severe asthma(119). It is possible that there is an increased influence of 
atopy on epithelial shedding as asthma severity increases.  
 
The bronchial epithelium and underlying RBM have a close spatial and functional 
inter-relationship and are considered an epithelial-mesenchymal trophic unit (EMTU). 
Many types of challenges to the epithelium, including pathogens, allergens, 
environmental pollutants, cigarette smoke, and even mechanical forces, can elicit 
production of mediators by the epithelium, which can be translated into remodelling 
responses by the mesenchyme(131). Damage to epithelial cells is thought to stimulate 
fibroblasts which lie directly underneath the epithelium to differentiate into 
myofibroblasts that secrete extracellular matrix (ECM) proteins as well as 
proinflammatory mediators(131). In asthma, it has been suggested that abnormal 
mechanical susceptibility to injury and aberrant repair responses result in persistent 
activation of the EMTU leading to tissue remodelling and altered airway function(131)  
 
Angiogenesis 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is 
recognised in both mild and severe asthma(132). Morphological analysis of the 
vascular bed in biopsies from adults with asthma report an increase in both total 
number of vessels and vascular area(132). Children with mild-moderate asthma and 
atopic children without asthma had an increase in lamina propria vessels when 
compared to normal non-atopic control children(94).  
 
Goblet cell hyperplasia 
Goblet cell hyperplasia has been established as a pathologic characteristic of mild, 
moderate(133), and severe asthma in adults(134). Hypersecretion of mucus into the 
airway lumen in asthmatic patients appears to be caused by both submucosal gland 
hypertrophy and goblet cell hyperplasia(133;134). Abnormalities in goblet cell number 
are accompanied by changes in stored and secreted mucin(133). Mild adult 
asthmatics have increased stored mucin in the airway epithelium, whereas adults 
with moderate asthma have both increased stored and secreted mucin(133). An 
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important factor causing the increased mucus production may be persistent allergen 
inhalation. Neonatal mouse pups had evidence of goblet cell hyperplasia after 3 
weeks of inhaled allergen challenge, however evidence of goblet cell hyperplasia 
was no longer present 4 weeks after stopping allergen challenge(135). Goblet cell 
hyperplasia, epithelial shedding or angiogenesis in EB from preschool children are 
not discussed further in this thesis. In particular the epithelium was not intact in EB 
from both preschool wheezers and controls, the subjects of this thesis, and thought 
to be related to biopsy processing(130). 
 
Figure 1.4: Interactions between the environment, airway remodelling and 
inflammation are involved in the pathogenesis of asthma (Reproduced with 
permission Llyod et al, Nature Medicine 2010)(126) 
 
 
 
1.7.5 Pathogenesis of asthma  
Several models of the onset of asthma pathophysiology have been proposed(136). 
The initial assumption was that persistent chronic inflammation or recurrent episodes 
of acute inflammation result in the development of chronic airway remodelling over 
many years, and in a minority of patients resulting in irreversible airway obstruction. 
This suggests that airway inflammation is an early event and remodelling late in the 
pathogenesis of asthma. Recent findings challenge the hypothesis that inflammation 
is the primary driver of pathological change in asthmatic airways. 
Bronchoconstriction itself in adult asthmatics without additional inflammation has 
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been shown to induce airway remodelling(70). A more likely hypothesis is that airway 
inflammation and airway remodelling occur in parallel driven by some ‘asthma 
factor’(136). This is confirmed by animal data; neonatal mice exposed to inhaled 
house dust mite developed eosinophilic inflammation, airway remodelling, and AHR 
in parallel between 2-3 weeks of age(135).  
 
It has also been suggested that in asthma a structurally and functionally defective 
lower airways epithelium underlies abnormal responses to the inhaled environment 
leading to enhanced signalling between the EMTU and immune cells(137). This in turn 
promotes a microenvironment that facilitates allergic sensitisation, supports different 
types of inflammation and predisposes the airways to exacerbations leading to 
persistence of asthma during childhood(137).  
 
1.8 What is known about airway remodelling and inflammation in preschool 
children? 
The natural history of the airway pathology associated with preschool wheeze is not 
completely understood. School age children with mild asthma aged 4-12 years 
already had evidence of both airway eosinophilia and increased RBM thickness, 
suggesting that airway remodelling and inflammation began before age 4 years(93). 
Infants aged 1 year recruited from Helsinki, Finland despite having severe wheeze 
and reversible airflow obstruction, did not have features of either increased 
subepithelial inflammation or increased RBM thickening in EB(138). However, 
preschool children recruited from the Royal Brompton Hospital (RBH) London aged 
2-3 years with confirmed severe, recurrent wheezing did have evidence of increased 
subepithelial eosinophilic inflammation and RBM thickening in EB when compared to 
age matched non-wheezing controls(9). Allowing for the limitations (these were two 
separate cross sectional studies with different definitions of preschool wheeze), 
these two studies suggest that there may be a window between the onset of 
symptoms, and two years of age, during which features of airway remodelling and 
inflammation consistent with asthma develops. This suggests that pathological 
abnormalities characteristic of asthma become evident around 2 years of age, very 
similar to the timing of onset of abnormal lung function in the TCRS persistent 
wheezers and likely future asthmatics(6).  
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Importantly, non-atopic children (median age 5 years, range 2-15 years) with 
multiple-trigger wheezing and bronchodilator reversibility had evidence of increased 
RBM thickness, suggesting non-atopic wheezing in children is also associated with 
this characteristic pathological features of asthma(107). In support of this, children who 
had EB at RBH (median age 2 years) were compared by multiple-trigger and 
episodic wheeze phenotypes at 4 years. Multiple-trigger wheezers had increased 
RBM thickness and eosinophils when compared with episodic wheezers(63). 
However, RBM thickness is not as great in the severe preschool school wheezers 
when compared school age children with difficult-to-treat asthma, suggesting that 
disease process may not be fully established at age 2-3 years, figure 1.5.  
 
Figure 1.5: Reticular basement membrane (RBM) thickness in preschool 
confirmed wheezers (CW) is increased when compared to non wheezing 
control subjects (Ctrl), but is significantly less than school-aged children with 
difficult asthma(9) 
 
 
 
There are few data available on the school age respiratory outcomes for children 
who had EB for wheezing at preschool age. Follow up of the wheezy 1 year old 
infants from Helsinki at 3 years of age showed that individual values of RBM 
thickness at 1 year of age correlated with higher respiratory morbidity and more 
frequent purchase of ICS at 3 years, but follow up data at school age has not been 
reported(139). EB were performed in Czech children (n=27) aged 1-12 years without a 
diagnosis of asthma for recurrent or chronic respiratory symptoms and were followed 
up at variable time periods after EB (22–80 months) to determine whether or not they 
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had subsequently developed asthma(140). Although, this study has several limitations 
children who developed asthma following EB had increased eosinophilia and RBM 
thickness suggesting pathological changes preceded the diagnosis of asthma(140).   
 
Follow up of the severe, recurrent wheezers recruited from the RBH aged 4-5 years 
showed that RBM thickness and subepithelial eosinophils correlated with FeNO but 
not lung function(63). However, neither at this time (aged 4-5 years) nor at the time 
the time of the original study, was it known which of the severe, recurrent preschool 
wheezers recruited from the RBH would have developed asthma by school age. 
Exploring the pathophysiology of severe recurrent wheeze in preschool children 
further may help establish at what age different components of airway remodelling 
appear and their relationship to future asthma. This is the first step in identifying the 
remodelling components that could be potential targets for any future interventional 
studies and at what point in the natural history treatment should be initiated to 
achieve the best results. It is likely that early diagnosis and prevention of airway 
remodelling has the potential to decrease disease severity and prevent disease 
expression. Some aspects of airway remodelling are beneficial, for example tissue 
repair following injury, so any future therapies will need to differentiate harmful and 
beneficial remodelling. This thesis will explore airway pathology associated with 
preschool wheeze further, and relate airway remodelling and inflammation at 
preschool age to the presence or absence of asthma at school age. 
 
1.9 Airway pathology not previously explored in severe recurrent preschool 
wheezers 
Airway pathology in children with severe recurrent wheeze is incompletely 
understood. Nothing is known about the role of ASM, mast cells or tenascin-C a 
component of the RBM in severe recurrent wheezers or their relationship to future 
asthma at school age. 
 
Tenascin -C 
RBM thickness detects a group rather than individual difference between wheezers 
and controls suggesting RBM thickness alone may not be a good marker of future 
asthma in the individual child(9), figure 1.5. Tenascin-C (TN-C) is an extracellular 
matrix glycoprotein component of the RBM and is almost absent in normal adult 
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tissues, but expression is increased during organogenesis and fibrotic, neoplastic 
and inflammatory conditions. TN-C is expressed in both acute and chronic 
inflammatory conditions(141) including increased expression in the RBM in asthma(142-
144). However, this has not previously been explored in the RBM of severe recurrent 
preschool wheezers and may be more specific in detecting individual children who 
will wheeze persistently and develop asthma. This will be discussed in detail in 
chapter 4. 
 
Airway Smooth Muscle 
It has previously been shown that moderate to severe asthmatic children as young 
as 8 years have increased ASM when compared to age matched controls(121). 
Reversibility of bronchial obstruction in school age children with asthma has also 
been associated with increased smooth muscle mass(121). However, although there 
is increased RBM thickness in 2-3 year old severe recurrent wheezers nothing is 
known concerning airway smooth muscle at pre-school age. Chapter 5 will discuss 
ASM in preschool wheezers. 
 
Mast cells  
Mast cells are one of the cell types critical in mediating the acute response in 
asthma. Amongst other mediators, mast cells secrete histamine, prostaglandin D2, 
and leukotriene C4, which are capable of inducing bronchoconstriction, mucus 
secretion, and mucosal oedema, all features of asthma(145). Increased mast cells 
have been found in the epithelium(146), submucosa(147), and ASM(148-150) in EB from 
adult asthmatics. In particular, mast cell infiltration of ASM distinguishes asthma from 
eosinophilic bronchitis in adults and correlates with airway hyperresponsiveness(148-
150). Mast cells are found adjacent to the blood vessels in the lamina propria in 
normal human airways but migrate to the ASM in adult asthmatics(148). Smooth 
muscle mast cells have been associated with increased IL-4 and IL-13 positive cells 
within smooth muscle(151). Activation of mast cell β-tryptase in the ASM bundle 
promotes airway smooth muscle cell differentiation into a more contractile phenotype 
possibly by the autocrine release of TGF-β(152).  
 
Studies which reviewed the role of mast cells in children are limited. Children 
(median age 12 years) with severe therapy resistant asthma had no associated mast 
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cell myositis(119). Furthermore, children (aged 4-12 years) with mild-moderate asthma 
had no difference in submucosal mast cells when compared with atopic children 
without asthma and children with no atopy or asthma(93). Infants with reversible 
airflow obstruction (median age 1 year) from Helsinki had no increase in submucosal 
mast cells(138). The role of mast cells (both submucosal and smooth muscle) in 
children with severe recurrent preschool wheeze is unknown. Chapter 6 will discuss 
submucosal airway inflammation including both submucosal and airway smooth 
muscle mast cells. 
 
1.10 Hypotheses, Aims & Objectives 
In summary, a limitation of the previous study investigating the pathology of 
preschool wheeze(9) is that at the time of biopsy it was not known which wheezers 
would go on to develop asthma by school-age. The purpose of this thesis is to study 
these children who are now at school age (6-11) years, establish current asthma 
status and relate this to early pathological findings. Other features of airway 
remodelling (increased ASM and RBM TN-C) and inflammation (mast cells) that 
have not previously been explored in children with preschool wheeze will also be 
investigated. In particular increased airway smooth muscle is a feature of established 
asthma in adults and children as young as 7 years, but nothing is known about ASM 
in preschool wheezers. 
 
Hypotheses 
1. School-aged children with asthma have evidence of airway remodelling 
(increased reticular basement membrane thickness and ASM) and 
eosinophilic airway inflammation in endobronchial biopsies taken while 
symptomatic at preschool age, when compared to school-aged children 
without asthma. 
 
2. A combination of clinical and airway pathological characteristics at 
preschool age may be used to predict asthma at school age, better than 
clinical features alone. 
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Aims 
1. To establish whether the preschool children (both wheezers and non-
wheezing controls) who had a bronchoscopy and endobronchial biopsy 
between October 2002 and February 2005 (study number 02-061), and 
are currently aged 6-11 years have asthma.  
 
2. To extend the previously made observations on airway wall changes in 
pre-school wheeze by quantifying tenascin-C, ASM and mast cells in 
endobronchial biopsies 
 
3. To determine whether any or all of pulmonary function, exhaled nitric 
oxide, and airway hyperresponsiveness at school age relates to the airway 
pathology in the preschool years.  
 
4. To determine the relationships between combinations of clinical 
characteristics and pathological markers on endobronchial biopsy at 
preschool age and a diagnosis of asthma at school age. 
 
Specific Objectives 
 
1. To collect information from the children now aged 6-11 years who had an 
endobronchial biopsy between 2002 and 2005 (study number 02-061) on 
current symptoms (history and examination), atopic status (skin prick 
tests), airway inflammation (exhaled nitric oxide, induced sputum 
cytology), lung function (spirometry, multiple breath washout, and 
hypertonic saline challenge). 
 
2. To establish the most discriminative and repeatable method of measuring 
tenascin-C expression within the reticular basement membrane 
(comparing stereology and use of computer aided image analysis) in 
endobronchial biopsies archived in paraffin. 
 
3. To quantify both RBM thickness and RBM tenascin-C in preschool 
endobronchial biopsies and relate the findings to any subsequent asthma 
diagnosis 
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4. To quantify the proportion of ASM in the preschool endobronchial biopsies 
and relate this to the presence or absence of asthma at school age 
 
5. To measure submucosal eosinophil volume density by stereology, and 
mast cell infiltration within the submucosa and ASM by total cell counts in 
pre-school bronchial mucosal biopsies, and relate the findings to any 
subsequent asthma diagnosis 
 
6. To generate an asthma predictive index for school age asthma, based on 
a combination of clinical and pathological features in the pre-school years 
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Chapter 2 
Clinical Research visit 
Subjects, Methods and Results 
 
2.1 Summary of study design 
This was a second cross-sectional study of children who are now at school age who 
were originally prospectively recruited from the RBH between 2002 and 2005(9). The 
group comprises preschool controls (children without lower respiratory symptoms) 
and children who had severe, recurrent wheeze aged 3 months to 5 years and had 
undergone bronchoscopy, EB and assessment of atopy at preschool age as part of 
their clinical investigation. These children were followed up at age 6-11 years to 
establish whether they had developed asthma. The children who agreed to return for 
a research visit at school age underwent assessment of lung function, airway 
inflammation and atopy (study number 6243). The investigator (RO’R) was blind to 
the biopsy pathology results during the clinical visits and to all clinical data during the 
airway pathology measurements. 
 
2.2 Study details at preschool age 
 
2.2.1 Patient characteristics of the preschool ‘wheezers’ group 
These data have been reported before(9). In brief, all of the children (n=47) included 
in the original study as wheezers had at least 3 severe episodes of wheeze (each 
episode with symptoms for more than 3 days) in the previous 6 months(9). They had 
all been referred to the RBH for specialist advice regarding management of their 
respiratory symptoms. The majority of the children had at least 1 admission to 
hospital. Almost all of the children had also undergone a trial of inhaled 
corticosteroids (ICS) and had persistent symptoms despite use of prescribed 
medications including inhaled β-agonists.  
 
Children were characterised into wheeze phenotypes, namely episodic (symptoms 
with viral colds, otherwise asymptomatic) and multi-trigger (acute exacerbations with 
viral colds and interval symptoms between colds). The following exclusion criteria 
had been applied at preschool age by Dr Sejal Saglani (SS) to ensure that those 
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included were not more likely to have a diagnosis other than asthma as an 
explanation for their wheeze; 
i) children with isolated cough without associated noisy breathing 
ii) children whose main problem was recurrent lower respiratory tract infection 
iii) children who were on long term oxygen therapy 
iv) children with chronic lung disease of prematurity. 
 
2.2.2 Patient characteristics of the preschool ‘Controls’ group 
Controls (n=21) for the original study were obtained in one of two ways(9). The 
majority were recruited from patients referred for further assessment of troublesome 
stridor or to assess airway compression from a vascular ring. The remainder were 
recruited from patients undergoing a clinically indicated right sided diagnostic cardiac 
catheterisation and whose carers consented to a research bronchoscopy and EB 
before the cardiac angiogram. None of the controls had a history of wheezing. The 
ideal controls would have been truly normal children, but this would obviously not 
have been ethical.  
 
2.2.3 Use of video questionnaire to identify wheeze in the preschool group 
Parent and physician perception of wheeze may be different making it difficult to 
assess prevalence of asthma accurately(16-19;153;154). It has been shown that there 
may be as little as 50% agreement between parents and clinicians’ findings of 
wheeze(18). Therefore, all parents were shown a validated video questionnaire 
containing 4 clips each lasting 1 minute of pre-school children making different 
respiratory noises(18;153). The first showed an example of wheeze (male, 6 years), the 
second stridor (male aged 6 months) and the other two clips showed different upper 
respiratory noises (both female aged 10 and 24 months). The first upper respiratory 
noise sounded like a child snoring, although she was awake and the second sound 
resembled that of loud mouth breathing. Parents were asked “Which if any of the 
noises in this video does your child make?” They were free to choose none, one or 
more video clips.  
Children were then classified as  
 Confirmed Wheeze (CW) (n=27) 
- Children whose parents reported wheeze as their child’s main symptom and 
also identified wheeze from the video questionnaire 
 62 
 Reported Wheeze (RW) (n=20) 
- Children whose parents reported wheeze as their child’s main symptom but did 
not recognise it on video questionnaire. 
 Controls (n=21) 
-Children whose parents reported stridor or no symptoms from video 
questionnaire. 
 
2.2.4 Preschool atopic status 
All children had atopic status assessed by measuring total IgE and 
radioallergosorbent tests (RAST) to three food (milk, egg, peanut) and five aero-
allergens (grass and tree pollen, house dust mite, cat and dog). The sample of blood 
was taken while the children were anesthetised for bronchoscopy. Eczema was 
defined as a positive parental report of doctor diagnosed eczema at preschool age. 
Atopic status was defined at preschool age as the presence of either or both of 
eczema and at least one positive RAST to food or aero-allergens.  
 
2.2.5 Fibreoptic bronchoscopy and endobronchial biopsy 
Fibreoptic bronchoscopy and EB was performed under general anaesthetic at 
preschool age by one of four respiratory paediatric consultants. A size 2.8mm 
bronchoscope was used for children aged 3 months to 2 years, and a 3.6mm 
bronchoscope was used for older children. After evaluation of the airway up to 4 
endobronchial biopsies were taken from the sub-carinae of the 3rd and 4th generation 
bronchi of the right lower lobe using rat tooth forceps (1mm, Olympus, Keymed, UK 
serial number FB-56D-1) from all children. 
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Table 2.1: Demographic details of all subjects and controls recruited at 
preschool age. (The children with confirmed wheeze were significantly older and 
heavier than the other groups.) 
 
 
 
Confirmed 
wheeze 
n=27 
Reported 
Wheeze 
n=20 
Controls 
 
n=21 
p 
Male / Female 17 / 10 12 / 8 16 / 5  
 
Age (months) 
Range (months) 
 
29  
(6-57) 
 
15.5  
(6-58) 
 
15 
(3-42) 
 
0.005ⱡ 
     
Weight (median kg) 
Range (kg) 
14 
(7.04-26.4) 
9.37  
(6.16-19.6) 
11.2  
(5.45-18.7) 
0.009ⱡ ⱡ 
 
Atopic* 
 
Eczema 
 
16 (60%) 
 
13 
 
11 (55%) 
 
6 
 
7 (33%) 
 
5 
 
 
IgE (IU/ml) 
Range (IU/ml) 
 
Birth weight (median kg) 
Range 
 
39.5 
(1-2605) 
 
3.43 
(1.87-4.45) 
 
14 
(1-195) 
 
3.5 
(1.6-4.6) 
 
13.5 
(1-292) 
 
3.26 
(1.95-2.99) 
 
0.22 
 
 
0.66 
 
Gestation (median weeks) 
Range (weeks) 
 
39 
(30-42) 
 
40 
(32-42) 
 
39 
(28-41) 
 
 
0.58 
Main reported symptom 
Wheeze 
Wheeze and cough (equal) 
Cough more than wheeze 
Barking cough 
Stridor 
Shortness of breath 
None 
 
16 
7 
7 
0 
0 
0 
0 
 
11 
7 
1 
0 
0 
1 
0 
 
0 
0 
0 
2 
14 
1 
  4** 
 
 
Family history of asthma 
Maternal history of asthma 
Paternal history of asthma 
 
 
3 
6 
 
 
4 
2 
 
 
5 
1 
 
     
Day care (< 1year) 
Pets (Cat/ Dog) 
 
Smoking 
Maternal smoking 
Paternal smoking 
Maternal smoking during 
pregnancy 
 
Treated with ICS  
Dose of ICS  
(mcg beclomethasone)*** 
Range (mcg) 
5 
4 
 
 
7 
12 
11 
 
 
14 
 
800 
(200-2000) 
1 
6 
 
 
6 
3 
5 
 
 
10 
 
400 
(100-1000) 
2 
5 
 
 
3 
5 
1 
 
 
3 
 
500 
(200-500) 
 
*eczema and / or one or more positive RASTs to aero or food allergens 
**n=2 had cardiac angiogram, n=2 had bronchoscopy to assess severity of vascular ring 
***Or beclomethasone equivalent 
Significant difference between ⱡCW and controls, ⱡⱡCW and controls & CW and RW
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2.3 Aims of current study 
The aims and objectives of this part of the study were to  
1. To establish whether the preschool children (both wheezers (confirmed and 
reported, n=48) and non-wheezing controls (n=21)) who had bronchoscopy and 
EB between October 2002 and February 2005 and at the time of re-recruitment 
were aged 6-11 years had a diagnosis of asthma. 
2. To characterise the preschool cohort at school age in terms of lung function, 
airway inflammation and atopy by collecting information on  
- current symptoms (history and examination) 
- atopic status (skin prick tests) 
- lung function (spirometry, multiple breath washout (SF6), hypertonic saline 
challenge) 
- airway inflammation (exhaled nitric oxide, induced sputum cytology). 
 
2.4 Difficulties in diagnosing asthma 
One of the most difficult aspects of this thesis and a challenge in all asthma research 
is the absence of a gold standard diagnostic test for the disease. Reported asthma 
prevalence varies both with time and area partly due to the different criteria used to 
define asthma, table 2.2(10;12;27;79;155). Criteria most often used to define asthma 
include one or more of the following, wheeze, doctor’s diagnosis of asthma, asthma 
medication use and positive bronchial challenge. Asthma prevalence rates vary 
widely depending on the definition used for diagnosis. Prevalence rates of asthma 
within a cohort of children can vary from 15% using a diagnosis of doctor diagnosed 
asthma ever and wheeze in the last 12 months, to 50% using a definition of AHR and 
symptoms and/or use of medication in the last 12 months(156). 
 
The term asthma, as used today, is likely more inclusive compared with previous 
physicians’ diagnoses, including many more children with milder symptoms who 
might not have been diagnosed with asthma in the past. Increased awareness of 
asthma as a disease both among parents and physicians is also likely to have 
increased reporting. Doctor diagnosed asthma is often used in epidemiological 
studies to qualify the diagnosis, but often there is little consensus on asthma 
diagnosis between physicians. Studies have shown that up to 30% of adults with a 
history of doctor diagnosed asthma did not have asthma after objective assessment 
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of lung function and AHR(157). In many, but not all, countries there is avoidance of the 
term asthma until school age. Even the definition of the start of school age is 
variable, being defined as anything between 4 and 8 years.  
 
It is widely accepted that parental and physician perception of wheeze is often 
different and in many cases parents may label other upper respiratory noises as 
wheeze (section 1.2). Furthermore, lower prevalence rates have been found based 
on written medical reports rather than the diagnosis of asthma based on parental 
report of wheeze in the last 12 months on the International Study of Asthma and 
Allergy in children (ISAAC) questionnaire(156;158). This may have been for several 
reasons including incompleteness of records, errors in parental recall or often 
physicians using asthma as an all embracing diagnosis for recurrent cough or 
general respiratory symptoms without confirming the diagnosis. 
 
Definition of current asthma in this study 
There is no consensus as to what definition of asthma at school age should be used. 
In the present study a diagnosis of asthma based on symptoms alone was made at 
school age. Current ‘asthma’ at school age was defined for the purpose of this 
research as a parental report of wheeze in the last 12 months and a parental report 
of doctor diagnosed asthma ever. This information was available for all children 
recruited at school age. Measures of lung function and lung inflammation were only 
available in the subgroup who attended for a research visit. All references to school 
age asthma in this thesis have used this definition.  
 
The use of asthma medication was not part of the diagnostic criteria in this study. 
ICS and inhaled salbutamol are often prescribed to children for the treatment of 
general respiratory symptoms. Cough is a common complaint in childhood with 10% 
of preschool and early school aged children having chronic cough without wheeze at 
some time(159). Although persistent cough in children without wheeze is much less 
likely to be asthma(160), children may often be prescribed ICS. Indeed, three of the 
original group of controls were treated with ICS at preschool age for stridor and / or a 
barking cough, although there is no evidence for efficacy in this group. Children with 
chronic wet cough may have bronchiectasis or persistent bacterial bronchitis but may 
also be prescribed inhaled corticosteroids(161).  
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Table 2.2: Different criteria used for diagnosing asthma 
 
Study  
 
 
Age 
(years) 
 
       Criteria for diagnosing asthma 
 
Castro-Rodriguez Index 
AJRCCM 2000
(27)
 
 
6-13 
 
 asthma diagnosed by a physician with plus ≥ 1 episode of asthma during the previous year  
or  
 had >3 episodes of wheezing during the previous year regardless of asthma diagnosis 
 
lsle of Wight 
Eur J Resp 2003
(12)
 
 
10 
 
 "Current wheeze" was recorded as having occurred in the prior 12 months. 
 
 
 
Eysink et al 
BPGP 2005
(81)
 
 
6 
 
 combination of both symptoms and/or use of asthma medication and impaired lung function. 
 Symptoms were defined as current complaints or complaints during the previous 12 months of 
wheezing and/or shortness of breath and/or recurrent coughing.  
 Use of asthma medication was defined as use of ß2 agonists or inhaled corticosteroids currently or 
during the previous 12 months.  
 Impaired lung function was defined as a positive histamine test, (PC20 <8mg/ml).  
 Children with no wheeze in the last 12 months were not considered to have asthma. 
 
Oslo severity score 
Thorax 2007
(79)
 
 
10 
 
 Two of the following three criteria  
(1) Dyspnoea, chest tightness and/or wheezing from 0 to 3 years and/or from 4 to 10 years of age 
(2) Doctor diagnosed asthma 
(3) Used asthma medication (inhaled corticosteroids, β2 agonists, sodium cromoglycate, leucotriene antagonists  
      and/or aminophylline) at 0–3 years and/or 4–10 years 
 
 Current asthma was defined as asthma (see above) plus at least one of the following criteria 
positive: 
(1) Dyspnoea, chest tightness and/or wheezing during the past 12 months 
(2) Use of asthma medication during the past 12 months 
(3) Positive exercise test 
 
 
Frank et al 
BMJ 2008
(162)
 
 
8 
 
 wheeze reported in the ISAAC survey
(158)
 at age 8 
 
 
Caudri et al  
JACI 2009
(10)
 
 
8 
 
 Positive asthma diagnosis if children had ≥1 positive items at 7 years and ≥1 positive items at 8 
years.  
 
(1) at least 1 episode of wheezing 
(2) inhaled steroids prescribed by a medical doctor 
(3) a doctor’s diagnosis of asthma (a parental report of a doctor’s diagnosis of asthma at any time and a parental  
report of asthma during the past 12 months).  
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2.5 Rationale for choosing assessment methods  
Non-invasive, age appropriate methods were used to assess atopy (skin prick tests) 
airway inflammation (FeNO and sputum eosinophilis), exposure to tobacco smoke, 
lung function (spirometry and multiple breath washout (MBW)), and AHR. The 
reasons for selecting these techniques are as follows: 
 Skin prick tests are an easy and acceptable method of establishing the atopic 
status of a preschool child(163). Ideally atopy would have been measured using 
both RAST and skin prick tests at school age as concordance for individual 
allergens is poor(164). However, it was deemed not ethically appropriate to do a 
further blood test at school age for research purposes alone. Furthermore, 
inclusion of a blood test in the research protocol would certainly have 
decreased the number of children recruited to the study. 
 FeNO is increasingly used as a biomarker of eosinophilic airway inflammation 
in children and adults with asthma. FeNO is derived from endogenous nitric 
oxide (NO) production by inducible NO synthase in airway epithelium and 
inflammatory cells. FeNO can reliably be measured at 50ml/s in preschool and 
school age children (section 2.8.7). In children with asthma, FeNO shows 
some correlation with eosinophils in induced sputum(165) and with increased 
submucosal eosinophils in EB tissue(63;166) particularly in steroid-naïve 
children. However, raised FeNO is also associated with atopy in children 
irrespective of whether they have asthma(167). Secondly, attempts to treat 
asthma using FeNO levels to guide anti-inflammatory treatment have had 
limited success(168). The use of FeNO as an inflammatory marker does not 
reflect other inflammatory phenotypes in asthma such as neutrophilic airway 
inflammation which is why sputum induction was attempted.  
 Exposure to passive smoking was assessed objectively as this is known to be 
associated with increased symptoms and decreased lung function in school 
children(169). This was done by measuring salivary cotinine the principal 
metabolite of nicotine(170). 
 Lung function was measured using both spirometry and MBW. Spirometry 
although routinely performed to monitor children with asthma, is unlikely to 
detect subtle decrements in lung function(42). MBW has been shown to be a 
more sensitive test in detecting ventilation heterogeneity in children with 
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asthma than spirometry(171;172). MBW has the advantage that unlike spirometry 
measurements normal values outside the first year of life are for practical 
purposes independent of age, gender and height(173;174). This will be 
discussed in more detail in section 2.8.3. 
 Hypertonic saline was chosen to perform an indirect airway 
hyperresponsiveness challenge as it is acceptable to parents and in principal 
a combined sputum induction could be performed at the same time(175). The 
advantage in using an indirect challenge, over a direct challenge (e.g. 
histamine, metacholine) is that it is more physiological as most asthma stimuli 
in real life are indirect (exercise, allergen, cold air). A significant positive 
response suggests that inflammatory cells and their mediators are present in 
the airways in sufficient numbers and concentration to suggest that asthma is 
active at the time of testing(176). The corollary to this is that there can be a 
negative test in children with known asthma suggesting good control or mild 
disease(176). Induced sputum can be used to assess the inflammatory profile 
of the airways in children with asthma. In particular sputum cytology is used 
as a marker of airway inflammation in asthmatics(177).  
 
2.6 Ethical approval for the present study (the work of this thesis)  
Ethical approval was obtained from the Brompton, Harefield and NHLI NHS 
Research Ethics Committee (08/H0708/93). The original ethics submission was 
prepared by SS (the principal investigator). Ethical approval was given on 
23/10/2008. The protocol was changed to include multiple breath washout as part of 
the assessment of lung function which was approved as a substantial amendment on 
23/01/09 prior to beginning recruitment. 
 
2.7 Recruitment for the present study 
Between 2009 and 2010 children who had participated in the original study were 
identified and recruited for follow up. A study invitation letter and parent and child 
information leaflets were mailed to each family, appendix 1-3. The letters were 
followed after 10-14 days by a telephone call. The study was discussed at length on 
the telephone and parents were given the opportunity to ask questions. If parents 
had any concerns, no appointment was made and a second telephone call was 
made 2-3 months later. Those interested in participation were then given an 
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appointment for a clinical research visit. Written confirmation of the appointment time 
and advice to withhold ICS and long acting ß-agonists for 24 hours and short acting 
ß-agonists for 12 hours prior to the appointment was sent. Children with severe 
asthma on regular oral corticosteroids or immunomodulating steroid sparing agents 
(such as cyclosporin, azathioprine or methotrexate) were advised not to withhold 
treatment. Parents were advised not to withhold medication if their child was unwell. 
The family was telephoned 1-2 days prior to the research visit to remind them of the 
appointment time and that they needed to withhold ICS and ß-agonists as above. If 
parents felt the child was unwell at time of telephone consultation the test was 
deferred for at least 2 weeks. For those families that could not be traced from 
hospital records, the general practitioner was approached for up to date contact 
details. If this failed, the local referring paediatrician was also contacted for further 
information. In all families contacted who did not wish to attend for a research visit a 
telephone questionnaire was administered where possible.  
 
2.8 Research visit  
The research visit lasted 2.5-3 hours. The procedures were done in the order listed 
below, and are discussed in more detail in subsequent sections.  
I. Study consent 
II. Height and weight 
III. Lung clearance index 
IV. Video questionnaire 
V. Study questionnaire 
VI. Salivary cotinine 
VII. Exhaled nitric oxide (single expiratory flow rate 50ml/sec) 
VIII. Spirometry  
IX. Skin prick testing for common aero and food allergens  
           (cat, dog, grass, tree, house dust mite, aspergillus, egg, milk, peanut) 
X. Combined AHR and sputum induction using nebulised hypertonic saline 
(4.5%)(175).  
 
2.8.1 (I). Study consent 
All test procedures were explained and parents were asked to read and sign a 
consent form, appendix 4. The child’s general practitioner was also informed of the 
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child’s participation in the study, appendix 5. Informed consent was given to use the 
photographs in this chapter for illustration purposes. 
 
2.8.2 (II). Height and weight 
The child’s height without shoes was measured in centimetres to one decimal place 
by a calibrated wall-mounted Harpenden stadiometer. Weight was measured in 
kilograms to one decimal place with calibrated electronic scales, with the child 
wearing minimal clothing. 
 
2.8.3 (III). Multiple breath washout (MBW)  
Multiple breath washout (MBW) is a test of distal airway gas mixing efficiency which 
requires only passive co-operation, making it very attractive as a test in young 
children. It requires the subject to breathe tidally an inert tracer gas such as nitrogen 
(N2), helium (He), sulphur hexafluoride (SF6) or argon in a low concentration until 
equilibrium is reached. The child is disconnected from the tracer gas during 
expiration, and the tracer gas is then ‘washed out’ by continued tidal breathing of 
room air(174;178;179). The longer the wash-out time, the more inefficient is distal airway 
gas mixing. The use of this technique in children was first described in cystic fibrosis 
in 1985(180). Prospective longitudinal studies in children with cystic fibrosis have 
established that it is more sensitive to early lung disease than spirometry(181;182). 
MBW has also been shown to be a sensitive indicator of pulmonary function 
abnormalities in preschool wheezers and school age asthmatics(62;171). 
 
MBW was measured in this study using the modified Innocor flow meter and side 
stream gas analyser (Innovision, Denmark) and pneumotachograph (Hans Rudolph, 
USA). This has been previously validated for use in adults and children as young as 
five years(173). The gas analysis unit is calibrated once per year by an Innovision 
engineer in line with manufacturer instructions. A calibration of the flowmeter and the 
flow-gas delay was performed once a day. Further calibrations were also performed 
if the gas sample line or the flowmeter screen was replaced. The flowmeter was 
calibrated before each study visit using a 3 litre syringe at low, medium and fast flow 
rates. The flow-gas delay was measured by assessing the carbon dioxide rise time 
by initially making slow expirations followed by very fast inspirations until the Innocor 
confirms measurement of the flow-gas delay. The inspirations have to be fast in 
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order to get a precise determination of the flow-gas delay. If one or two breaths failed 
the software automatically filtered these results. The flow-gas delay did not vary 
more than 20-40 ms from day to day in line with manufacturer instructions. 
 
Children were seated with a nose clip and breathed 0.2% SF6 in medical air, 
supplied from a compressed gas cylinder (BOC, Hertford, UK) via a mouthpiece and 
flow past (bias flow) system until an alveolar plateau had been reached, figure 2.1. 
The gas supply was then detached in expiration and patients breathed room air until 
the measured end-tidal SF6 concentration was 1/40th of the starting concentration 
(0.005%), figure 2.2. Tidal breathing was used throughout the test, each taking 5–10 
min to complete. Washouts were repeated three times at each stage to obtain mean 
values(183). Washouts were excluded if the measured functional residual capacity 
(FRC) differed by more than 10% from both other repeat washouts(183). 
 
Figure 2.1: Wash-in phase of multiple breath washout (Child seated with a nose 
clip breathing 0.2% sulphur hexafluoride (SF6) in medical air).  
 
 
 
 
 
 
 Bias flow 
  SF6  
   
 
    Innocor 
pneumotachograph 
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Figure 2.2: Multiple breath washout (SF6) The black trace represents flow and the 
green trace SF6 concentration) 
A - Gas wash-in until lung equilibrium reached (SF6 concentration 0.2%) 
B - Gas supply disconnected in expiration 
C - SF6 concentration falls with each expired breath 
Gas wash-out is complete when the concentration of expired inert gas falls to 1/40 
the original value, i.e. 0.005% 
 
Many indices have been used to describe the wash-out curve, of which the most 
commonly reported is lung clearance index, for which functional residual capacity 
also needs to be determined(184). However, wash-out curves do not provide 
information on the sites of ventilation inhomogeneity, but this can be calculated from 
the MBW if the phase III slope (SIII) is calculated for each breath(185;186). The slope of 
phase 3 for each breath can then be used to calculate ventilation inhomogeneity 
measured by convection in the conducting airways (Scond) and by diffusion-
convection in the acinar airways (Sacin).  
 
The following measures from MBW are reported in this study: 
• Lung Clearance Index (LCI) 
• Functional Residual Capacity (FRC) 
• Acinar Airways Inhomogeneity (Sacin) 
• Conducting Airways Inhomogeneity (Scond) 
 
Lung Clearance Index (LCI) 
LCI is defined as the total cumulative expired volume (CEV) required to washout the 
tracer gas to 1/40th of the starting value, divided by the measured FRC (CEV/FRC).  
 
A              B 
 
 
C 
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Functional Residual capacity (FRC) 
Functional residual capacity (FRC) was calculated from the total volume of expired 
tracer gas (SF6) divided by the end-tidal SF6 concentration at completion of 
washout(187). Washouts were excluded if there was a greater than 10% difference in 
FRC from the other 2 washouts. LCI, FRC, Scond and Sacin are all calculated as the 
mean of at least two reproducible measurements out of three washouts(171).  
 
Calculation of phase III slope 
The calculation of the SnIII compares the concentration differences between lung 
units to the mean lung unit value. As the washout progresses this difference between 
lung units initially increases, but then remains constant as the concentration gradient 
between inspired gas and the resident gas in the two units falls. The progression of 
SnIII through the washout allows the observed ventilation inhomogeneity to be 
attributed to two separate mechanisms, convection dependent inhomogeneity and 
diffusion-convection dependant inhomogeneity, figure 2.3. Scond represents 
convection dependent inhomogeneity in the conducting airways and is predicted to 
increase linearly throughout the MBW test(186). Sacin represents diffusion–convection 
related ventilation inhomogeneity generated in the acinar airways and only increases 
for the first 5 breaths or 1.5 lung turnovers(186). After the first 1.5 lung turnovers the 
increase in SnIII is diffusion independent and represents convection dependent 
inhomogeneity. 
 
In this study each breath of the SF6 concentration was plotted as a function of 
expired volume. A least-square fit of the slope of the alveolar phase (phase III slope, 
SnIII) was done. The margins of the regressed portion were manually adjusted to 
avoid phase II or phase IV elements, the influence of cardiogenic oscillations or 
signal noise obviously distorting the slopes. The SIII was then normalised by the 
mean tracer gas concentration over the phase III interval of interest, to account for 
dilution, giving the normalised phase III slope (SnIII) for SF6
(173).  
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Figure 2.3: The contribution of convection dependant inhomogeneity cdi 
(Scond) and diffusion-convection dependant inhomogeneity dcdi (Sacin) to 
overall ventilation inhomogeneity(174)(Adapted by Dr Sonnappa) 
Conduction dependant inhomogeneity (CDI) has a linear relationship with expired 
volume when expressed as lung turnover (TO) Diffusion convection dependant 
inhomogeneity (DCDI) rises for the first 5 breaths, or 1.5 turnovers, and then is 
unchanged. The Scond index is calculated as the slope of the SnIII versus turnover 
CDI relationship. Sacin is the DCDI component of the first breath SnIII, calculated by 
subtracting the CDI component (see inset equation). 
 
 
Calculation of Scond and Sacin 
Sacin and Scond were calculated by the method described by Verbanck et al
(185;188). 
The SnIII for each breath was plotted as a function of lung turnover. Scond and Sacin 
are derived from the normalised slope curves. Scond is the normalised difference per 
unit lung turnover which is derived from lung turnovers 1.5-6 where only conductive 
airways are known to contribute to the rate of rise of normalised slope, figure 2.4. 
Sacin is derived from the normalised slope of the first breath which is predominantly 
generated by the diffusion convection dependant ventilation inhomogeneity within 
peripheral acinar lung units, figure 2.4. Sacin is determined by subtracting the slope of 
the first breath against lung turnover.  
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Figure 2.4: Normalised alveolar slopes (SnIII) generated from a child with a 
normal multiple breath washout test represented as a function of lung turnover 
(TO) (Sacin is derived from the first breath and Scond from lung turnovers 1.5-6) 
 
 
                                  Sacin                                          Scond 
 
SnIII was not reported from any breaths that were not clearly visible, either because 
of inadequate breath volume or signal noise. If the first breath from a run could not 
be reported, or if more than one third of breaths over the Scond regression interval 
could not be reported, then that MBW was excluded from analysis. Scond and Sacin 
are only reported if results from two or more MBW runs were available. Tidal volume 
was not restricted in the patients. Normalised phase III slope values were corrected 
by multiplying by the breath volume before calculating Scond and Sacin to allow 
comparison of the data with published work in adults who were limited to breaths of 1 
litre(174;183). In using this protocol, negative Scond values may be seen in both healthy 
volunteers and those with very mild disease. Although biologically this is impossible, 
negative values are seen in practice owing to variation in tidal volume throughout the 
washout and lack of progression of the normalised phase III slope(171;174).  
 
2.8.4 (IV). Video Questionnaire 
Parents were shown a modified video questionnaire with 4 clips; 1) wheeze (male 6 
years), 2) nasal upper respiratory noises (female aged 10 months); 3) wet cough 
(male 7 years); 4) stridor (male age 4 years). Video clips 1&2 were shown at 
preschool and school age. The third and fourth video clips were changed from those 
used at preschool age which showed children age 6 and 10 months to a more age 
appropriate examples of stridor and wet cough. All video clips had been previously 
          TO 
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validated(18). Parents were again asked ‘Which if any of these noises does your child 
make?‘. They were also asked ‘Has your child made any of these noises in the 
past?’. They were free to choose one or more video clips.  
 
2.8.5 (V). Study Questionnaire 
The study questionnaire used was a modified ISAAC core questionnaire for asthma 
age 6-7 years, and the ISAAC core questionnaires for eczema and allergic rhinitis 
age 6-7 years(158). A second questionnaire recorded medication history including oral 
and inhaled corticosteroid use, total number of hospital admissions with wheeze, 
household pets, length of time spent in nursery and parental smoking. Parents were 
also asked if their child’s symptoms were mainly associated with colds or with allergy 
or if they were triggered by multiple stimuli. Although information such as family 
history of asthma, birth details and parental smoking during pregnancy had 
previously been recorded the answers were re-checked. Both questionnaires were 
interviewer directed and the answers were recorded by the interviewer. The same 
questionnaire was used for both the controls and wheezers, appendix 6. 
 
2.8.6 (VI). Salivary Cotinine 
Exposure to exhaled tobacco smoke is measured using the biomarker cotinine. 
Cotinine is a metabolite of nicotine that can be measured in urine, serum, saliva, and 
hair. Saliva was chosen as a non-invasive measurement of exposure to cigarette 
smoking and collected using plain (non citric acid) cotton salivettes. The child was 
asked to chew or suck the cotton salivette until it was saturated. Salivary cotinine 
analysis was performed using a salivary cotinine quantitative enzyme immunoassay 
analysis kit (Salimetrics®, USA). A salivary cotinine greater than 1.2ng/ml was 
defined as evidence of passive cigarette smoke exposure(170). 
 
2.8.7 (VII). Exhaled Nitric Oxide (FeNO) (single expiratory flow rate 50ml/s) 
NO is formed in both the upper and lower respiratory tracts and diffuses into the 
lumen by gaseous diffusion down a concentration gradient(189). Exhaled NO 
concentrations from the lower respiratory tract are significantly flow dependent, with 
a marked increase in exhaled FeNO concentration at low flows. This flow 
dependence is characteristic of a diffusion based process for NO transfer from 
airway wall to lumen and is explained by faster flows minimising the transit time of 
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alveolar gas in the airway, thereby reducing the amount of airway NO transferred(190). 
The use of a constant expiratory flow of 50ml/s (FeNO50) is recommended to obtain 
reproducible FeNO results which are comparable between groups(189). Multiple 
exhalation flow FeNO has been previously used to calculate bronchial and alveolar 
nitric oxide production in older school age children with a median age of 14 (8-18) 
years(190). FeNO measurements at multiple exhalation flow rates was not done as 
most of the children (median age 7 years) were unable to perform the manoeuvres at 
higher flow values(190).  
 
FeNO was measured using NiOX (Aerocrine AB, Solna Sweden). A constant 
temperature of 22°C was maintained in the room in which the analyser was stored to 
ensure optimal operating conditions. The ambient NO was recorded prior to each 
reading and was always <300ppb in accordance with the manufacturer’s 
recommendations. Calibration of the analyser was performed every 14 days 
according to the manufacturer’s instructions. External gases required for calibration 
were NO-free air and a calibration gas mixture of 1-200 ppb NO in N2 connected to 
the instrument rear panel. Calibration was automatically carried out by pressing a 
button on the keypad (one-button-calibration). In order to assure reliability of its 
results the analyser has an integrated calibration module for zero level and the NO 
reference gas. The flow head was calibrated daily prior to measurements using a 
100ml calibration syringe. The equipment has an on-line display of flow control that 
allows the selection of good exhalations and the rejection of suboptimal exhalations. 
FeNO was always measured before forced expiratory manoeuvres such as 
spirometry because these may cause a decrease in FeNO levels(191). 
 
The procedure was explained and demonstrated to the child before beginning the 
test. All measurements were made with the child sitting holding the instrument held 
in front of them. A nose clip was not used. Children had several practise runs to 
optimise technique before proceeding to an actual measurement. An online method 
was used to measure FeNO where the expirate is continuously sampled by the 
analyzer, and the resultant NO profile versus time or exhaled volume, together with 
other exhalation variables (e.g., airway flow rate), is captured and displayed in real 
time(189). For the measurement, NO-free air (generated by the NiOX module 
internally from ambient air) was inhaled to near total lung capacity over a period of 2 
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to 3 seconds through the mouth-piece of the instrument. Then the child was asked to 
exhale slowly, being encouraged to maintain a constant flow by a visual display on a 
screen (blowing a little girl in a balloon between 2 cliffs), figure 2.5. There was 
automatic control of exhaled flow rate to a constant 50ml/s, making it easier for the 
child to comply. The NiOX analyser only accepts measurements as valid if the 
expiratory flow is between 37.5 and 62.5 ml/s at every instant. If the flow was not 
steady or decreased below 50ml/s the test was repeated. The exhaled NO value is 
the mean NO level during a 3 second NO plateau. Three acceptable readings 
(defined as agreement to within 10%) were performed with at least 30 second 
intervals between manoeuvres. FeNO50 was calculated as the mean of the plateaus 
from three technically satisfactory exhalations.  
 
Figure 2.5: Exhaled nitric oxide measurement with visual feedback incentive  
.  
 
2.8.8 (VIII). Spirometry performance and quality control 
Spirometry was performed using the Vitalograph Compact (Vitalograph, 
Buckingham, UK). The spirometer was calibrated on the day of the study visit with a 
one litre syringe. As for many of the children it was the first attempt at spirometry a 
period of training was necessary. The child was familiarised with the equipment and 
a demonstration was given. The child was observed closely to ensure that there was 
no leak and that the manoeuvre was performed optimally. Manoeuvres were rejected 
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if the subject was thought to use sub-optimal effort, if a full inspiratory breath was not 
taken, if there was coughing during the first second, if a plateau was not reached on 
the volume-time curve, or if the blow was terminated prior to full expiration. The 
highest sum of forced vital capacity (FVC) and FEV1 of the 3 manoeuvres was 
recorded as per American Thoracic Society (ATS) / ERS guidelines(192). If the child 
had difficulty performing the manoeuvre then interactive computerised incentive 
spirometry was used (Vitalograph Pneumotrac, Spirotrac® IV software). As this 
machine was situated in another room and was often in use for busy outpatient 
clinics it was not possible to use it routinely. All spirometry results were compared to 
appropriate recent reference ranges(193). 
 
2.8.9 (IX). Skin-prick testing for common aero and food allergens 
SPT were performed for three common food allergens (egg, cow’s milk and peanut) 
and six common aero-allergens (cat & dog dander, grass & tree pollens, Aspergillus 
fumigatus and Dermatophagoides pteronyssinus) (Soluprick SQ, Alk Abello, 
Denmark)(163). A small drop of allergen extract was placed on the volar surface of the 
arm and the skin was pierced with a 1mm lancet (ALK, Denmark) in the centre of the 
droplet, ensuring a small amount of allergen penetrated into the skin, figure 2.6. A 
positive (histamine) and a negative control were always performed at the same time. 
The outer contour of the wheal reaction was outlined using a fine felt-tip pen, and the 
result expressed as the mean of the lengths of the longest diameter and the 
perpendicular line through its centre. The results were read 15 minutes after 
application. SPT was regarded as positive if the wheal size was at least 3mm greater 
than the negative control. The test was considered void if there was no reaction to 
the positive control. If a child was uncomfortable or had large wheals, after the test 
was read topical mepyramine maleate (Anthisan) was applied.  
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Figure 2.6: Skin prick tests (A droplet from allergen and from positive and negative 
controls were placed on the skin) 
 
 
 
2.8.10 (X). Combined bronchial hyper-responsiveness and sputum induction 
A combined airway hyperresponsiveness and sputum induction test was 
performed(175). Children were asked to rinse their mouth and blow their nose to 
reduce squamous cell contamination before sputum induction was started. The 
children were instructed how to cough and clear the throat in order to obtain the best 
sample. The baseline FEV1 was recorded as the highest of the 3 manoeuvres from 
satisfactory spirometric curves (above). Children were seated comfortably and asked 
to inhale hypertonic (4.5%) saline for periods of increasing duration (0.5, 1, 2, 3 x 4 
minute) using an ultrasonic nebuliser (De Vilbliss 2000, Somerset) as per the ISAAC 
protocol(163). FEV1 was measured after each inhalation period and the higher of 2 
readings were selected.  
 
The initial 3 nebulisation periods of 30 seconds, 1 minute and 2 minutes were 
performed without encouraging sputum production, figure 2.7. After each of the three 
4 minute nebulisation periods children were encouraged to cough and expectorate 
sputum into the falcon tube. If the FEV1 remained within 15% of the baseline value, 
nebulisation was repeated. If, after two repetitions, the FEV1 was less than 15% 
 81 
below the baseline value, the duration of the inhalation period was doubled again 
according to the protocol. Clinical symptoms such as cough or wheeze were 
recorded at each stage.  
 
The bronchial challenge was stopped if either the FEV1 had fallen by 15% from 
baseline or the total inhalation period of 15.5 min had been reached. The saline 
canister was weighed on an electronic balance (Ohaus Scout pro, Switzerland) 
before the first and after the last inhalation period in order to measure the aerosol 
dose delivered. Children whose FEV1 had decreased by more than 15% were given 
salbutamol (1000µg) through a large volume spacer and spirometry was repeated 10 
minutes later to ensure return to baseline values before discharge. In children with a 
baseline FEV1 of 75% of the predicted value, no bronchial challenge was performed. 
 
Figure 2.7: Child inhaling 4.5% saline nebulised using an ultrasonic nebuliser 
(De Vilbliss 2000)  
 
 
Different statistical approaches have been proposed for the analysis of stepwise 
provocation data such as a hypertonic saline challenge. AHR can be measured in 
terms of provocation time causing a decrease in FEV1 (PT15). Insufficient numbers of 
children in this study had a positive bronchial challenge and a PT15 slope could not 
be calculated. In this study BHR was defined as a dichotomous variable (yes/no) 
4.5% Saline 
Ultrasonic 
nebuliser 
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where a fall in FEV1 ≥ 15% was considered positive and < 15% fall in FEV1 was 
considered negative.  
 
Sputum processing 
Sputum samples were stored on ice until ready for processing. All samples were 
processed within 2 hours. The sample was poured into a petri dish, mucoid plugs 
selected and removed with a forceps. A selected rather than whole sample 
processing method was used to reduce salivary contamination(194) because this 
improves intra-observer repeatability of differential cell counts. The selected sputum 
was returned to a clean preweighed tube and weighed using a microbalance. One 
percent stock Dithiothreitol (DTT) (0.1%) was then added to the sputum in the ratio 
of 4 ml DTT to 1g sputum. The mixture was gently aspirated with a 3 ml disposable 
wide bore plastic pipette and then gently agitated on a rolling mixer (Denley Spiramix 
5, Denley Instruments, Colchester, UK) for 15 minutes. The sample was filtered 
using a 48m pore nylon mesh filter. Phosphate buffered saline (PBS) (in the ratio of 
4 ml PBS to 1g original sputum weight) was used to wash out the tube and added to 
the filtrate (through the filter). The filtrate was centrifuged (Sorvall RT6000D, Thermo 
Fisher Scientific Inc, Massachusetts, USA) at 4C for 10 minutes at 400g (1500rpm).  
 
The remaining pellet was resuspended in 1ml PBS and mixed by gentle vortexing 
(Vortex mixer, Vorsicht, Germany). 20µl of sputum cell suspension was added to 
20µl trypan blue (1 in 2 dilution factor). 10µl of the mixture was placed under the light 
microscope (Leitz, Wetzlar, Germany) using a haemocytometer (improved 
Neubauer, BDH, Leicestershire, UK). All leukocytes (viable stained yellow and dead 
stained blue) and squamous cells were counted in the bottom left middle and top 
right quadrants of the haemocytometer grid. The total leukocyte count per ml was 
calculated using the following formula: 
Total leukocyte count = 
mean number of viable and dead leukocytes X trypan blue dilution factor X104 
After calculation of the total leukocyte count the sputum cell suspension was 
adjusted to 200,000 cells/ml by diluting with PBS. Using 100 l of cell suspension per 
slide, the mixture was centrifuged (Shandon Cytospin Preparation System, Thermo 
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Shandon, Cheshire, UK) at 450rpm for 3 min. If the total leukocyte count was less 
than 2 x 105 /ml aliquots of 200µl or 400µl of sputum cell suspension were loaded. 
The 4 slides were left to air dry for 30 minutes and then fixed with methanol. The 
slides were then stained with a modified Wright Giemsa stain Reastain® Quick-Diff 
staining kit (Reagena Ltd. Toivala, Finland). 
 
2.9 Completion of research visit 
The children and parents were thanked for their time and participation. Study results 
were detailed and subsequently mailed to all participants in the clinical research visit. 
Travel expenses incurred in attending the RBH were reimbursed to the families.  
 
2.10 School age atopy 
Atopy was defined as either a parental report of eczema or allergic rhinitis in the 
ISAAC core questionnaires(158) or the presence of 1 or more positive skin prick tests 
at school age. This definition has been used throughout this thesis. Current eczema 
was defined as yes to both of the questions ‘Has your child ever had an itchy rash 
which was coming and going for at least 6 months?’ and ‘Has your child had this 
itchy rash at any time in the last 12 months?’ Current allergic rhinitis was defined as 
a positive response to ‘In the past 12 months, has your child had a problem with 
sneezing, or a runny, or a blocked nose when he/she did not have a cold or the flu?’ 
 
2.11 Statistical analysis 
The Mann Whitney U test was used to detect differences between 2 groups. Where 
more than 2 groups were present Kruskal-Wallis test was used, followed by Dunn’s 
post test to detect differences between groups. Categorical data was analysed using 
Chi-squared or Fisher’s exact test as appropriate. Spearman rank correlation was 
used to assess the relationship between numerical variables. Cohen's kappa 
coefficient was used to measure the reliability or inter-rater agreement for qualitative 
items. Coefficient of variation (CoV) was used to measure repeatability between 
repeats of the same test on different occasions. Bland-Altman plots were used to 
assess agreement between two investigators. Sample size was opportunistic, 
determined by recruitment to the previous study and success of follow up at school 
age; in any case, there are no data to inform a power calculation. Analyses were 
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performed using MedCalc v12.1.0, GraphPad Prism version 5.02(OR) and 
SPSSv17. 
 
2.12 Current Study:- Recruitment 
2.12.1 Children followed up at school age 
Thirty nine children attended for a research visit, figure 2.8. Twelve families were 
either unable or did not wish to attend for a research visit but all subsequently 
agreed to answer a telephone questionnaire (see appendix). Total recruitment for 
either a full research visit or a telephone questionnaire was 51/68 (75%). Preschool 
and school age clinical characteristics for children followed up at school age are 
shown in table 2.3. 
 
2.12.2 Co-morbid pathology at school age 
Of the preschool CW group (n=21), two children had bronchiectasis at school age. 
One of the children with bronchiectasis attended for a research visit and the family of 
the second child answered a telephone questionnaire only, but the child’s clinical 
notes were obtained from the local hospital with permission from her parents. One 
child who completed the telephone interview had been removed from the care of his 
mother age 4 because of fabricated and induced illness. His father who had been his 
primary carer since then stated during telephone interview that he had never 
wheezed in his care. Two children were being treated for severe asthma in the Royal 
Brompton Hospital and were enrolled in a difficult asthma assessment during the 
study recruitment period(195) and a third child had been treated with cyclosporin for 
severe refractory asthma for several years in another hospital prior to assessment.  
 
In the RW group (n=16) one girl was noted to have digital clubbing at the research 
visit, was referred for follow up and subsequently diagnosed with bronchiectasis. A 
boy from the RW group had a low FEV1 at the research visit and was subsequently 
found to have evidence of air trapping and atelectasis in both lower lobes on high 
resolution computerised tomography (CT) of the chest. One girl had motor and 
learning difficulties and one boy had Carpenter’s syndrome and autistic spectrum 
disorder at school age making it difficult for them to participate in many of the lung 
function tests. Another boy was diagnosed in 2009 with cor triatriatum having had a 
long history of being breathless on exertion. One girl had scimitar syndrome with an 
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associated congenitally small right lung. One child from the original RW group was 
enrolled during the study period to our difficult asthma protocol(195). 
 
Of the original group of preschool controls (n=14), 3 children had repaired complex 
congenital heart disease in early childhood and were very well. A fourth child had a 
Trisomy 14 mosaicism and a repaired Tetralogy of Fallot but was unable to attend for 
assessment. A fifth child in the control group had congestive cardiac failure 
secondary to a large ventricular septal defect at time of study recruitment; this was 
subsequently repaired in 2010. One boy had mild tracheal compression secondary to 
a right sided aortic arch. A girl who had a bronchoscopy at preschool age for 
investigation of cyanotic episodes was subsequently diagnosed with ulcerative colitis 
at age five, figure 2.8. 
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Figure 2.8: Study recruitment and alternative or co-morbid diagnosis at school age other than asthma 
 
 
 
 
Figure 3.1: Study recruitment and alternative or co-morbid diagnosis at school age other than asthma ------------------------------------------------Recruited at school age-------------------------------------------------------------
-- 
-------------Children with alternative or co-morbid diagnosis (other than asthma) at school age--------------------------- 
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Table 2.3: Characteristics of children followed up at school age from 
2009-2010 (Children with school age asthma had higher preschool IgE, and 
school age eczema and allergic rhinitis when compared to those without 
asthma at school age.) 
 Asthma 
16 
No asthma 
35 
p 
 
Male / Female 
Birth weight (kg) 
Gestation (weeks) 
 
11 / 5 
3.41 (1.87-4.21) 
39 (30-42) 
 
21 / 14 
3.38 (1.6-4.41) 
40 (34-42) 
 
0.54 
0.57 
0.51 
Age at FOB (months) 
Weight at FOB (kg) 
28 (3-57) 
13.35 (5.6-25) 
17 (3-55) 
11 (5.45-26.4) 
0.01 
0.043 
Preschool IgE (IU/ml) 
Preschool ≥1 positive RAST, n (%) 
Age at first episode of wheeze (months) 
70 (1-635) 
6 (37.5) 
14 (1.5-24) 
9 (1-432)† 
10 (31.3)† 
6.5 (0.5-66) 
0.04 
0.75 
0.21 
 
Wheeze at preschool age 
Confirmed wheezers 
Reported wheezers 
No wheeze 
 
16 
11 
4 
1 
 
22 
10 
12 
13 
 
 
 
 
Parental history doctor diagnosed asthma‡ 
Paternal history doctor diagnosed asthma 
Maternal history doctor diagnosed asthma 
 
13 
5 
5 
 
17‡ 
1 
7 
 
0.04 
0.01 
0.28 
 
Age at follow up (years) 
Reported wheeze in last 12 months 
Wheeze pattern 
Episodic (with colds) 
Multiple trigger  
Frequency of wheeze 
None 
1-3 attacks of wheezing 
4-12 attacks of wheezing 
>12 attacks of wheezing 
 
8.2 (6-10.4) 
16 
 
3 
13 
 
0 
4 
8 
4 
 
7.3 (5.9-11) 
7 
 
5 
2 
 
28 
4 
2 
1 
 
0.1 
 
 
Exercise induced wheeze 
Dry cough at night§ 
 
Number of hospital admissions with wheeze 
ever 
 
Use of ICS at school age 
Dose of ICS (mcg beclomethasone) ll 
 
Eczema 
13 
14 
 
 
17 (0-160) 
 
13 
400 (200-1200)ll 
 
12 
2 
7 
 
 
3 (0-20) 
 
4 
300 (200-400) 
 
4 
 
 
 
 
0.005 
 
 
 
 
0.0001 
Allergic rhinitis 
 
7 
 
9 
 
0.001 
 
*Data is reported as median and range.  
†Results not available on 3 children  
‡Family history was unknown in 2 children, as were both adopted at birth (previously in control group) 
§Dry cough at night apart from a cough associated with a cold or chest infection 
llOr beclomethasone equivalent (2 parents did not know the prescribed ICS dose) 
 
 88 
2.12.3 Children lost to follow up at school age 
Seventeen children were lost to follow up. I was unable to contact 16/17 
children despite contacting both the referring paediatrician and their General 
Practitioner at preschool age. One child who had a Trisomy 21 and complex 
congenital heart disease died shortly after recruitment to the preschool study 
at age 11 months from left ventricular infarction. There was no difference 
between children who participated in the study and those lost to follow up in 
terms of sex (p=0.77), or age at bronchoscopy and endobronchial biopsy 
(p=0.77) or preschool IgE (0.99), table 2.4. 
 
Table 2.4: No difference in clinical characteristics of preschool children 
followed up at school age and those lost to follow up 
 Followed up 
n=51 
Lost to follow up 
n=17 
p 
Age at biopsy* 19 (3-57) 15 (7-58) 0.77 
Male/ Female 32/19 12/5 0.77 
Wheezers/ Controls 37/14 10/7 0.36 
Preschool IgE (IU/ml) 21 (1-635)† 18 (1-2605) 0.99 
*Data is reported as median and range.  
†Results not available on 5 children  
 
2.13. Clinical characteristics of children followed up at school age 
2.13.1 Family history of asthma 
Parents were asked if there was a history of maternal or paternal doctor 
diagnosed asthma. Two children had been adopted shortly after birth and their 
birth family history was unknown. Both of these children were in the ‘control’ 
preschool group. 
 
Children with school age asthma were more likely to have a first degree family 
member with asthma (13/16 versus 17/33, Fishers exact test, p=0.043). 
Children with wheeze at preschool age (either reported or confirmed) and 
school age asthma were also more likely to have either a maternal or paternal 
(parental) history of asthma (Fischer’s exact test, p=0.038). Although a 
paternal history of doctor diagnosed asthma increased the likelihood of school 
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age asthma (p=0.01), a maternal history of doctor diagnosed asthma 
specifically did not (p=0.49), table 2.5. 
 
Table 2.5: Contingency table of all children recruited comparing (i) 
parental history of asthma; (ii) doctor diagnosed maternal history of 
asthma; (iii) doctor diagnosed paternal history of asthma with school 
age asthma status (Children with asthma at school age were more likely to 
have a paternal history of asthma.) 
(i)  School age 
asthma 
Total  yes no 
Family history 
asthma 
yes 
no 
13 17 30 
3 16 19 
Total 16 33 49 
*Fishers exact test, p=0.043 
   
 
(ii)  School age 
asthma 
Total  yes no 
Maternal 
history asthma 
yes 
no 
5 7 12 
11 26 37 
Total 16 33 49 
*Fishers exact test, p=0.49 
 
   
(iii)  School age 
asthma 
Total  yes no 
Paternal 
history asthma 
yes 
no 
5 1 6 
11 32 43 
Total 16 33 49 
*Fishers exact test, p=0.01 
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2.13.2 School age allergic rhinitis and eczema 
Parents were asked to complete the ISAAC core questionnaires(158) for 
eczema and allergic rhinitis. Children with school age asthma were more likely 
to have co-existing eczema (p=0.0001) and allergic rhinitis (p=0.001) than 
those without, table 2.6. 
 
Table 2.6: Contingency table comparing school age asthma and school 
age allergic rhinitis and eczema (Children with school age asthma were 
more likely to have school age eczema and allergic rhinitis.) 
 School age 
Allergic Rhinitis* 
School age 
Eczema** 
 
Total 
Yes No Yes No 
School age Yes 7 9 12 4 16 
Asthma No 1 34 6 29 35 
Total  8 43 18 33 51 
Fishers exact test p=0.001*, p=0.0001** 
 
 
2.13.3 School age asthma and preschool total IgE 
There was no difference in preschool IgE between CW (n=26), RW (n=19) 
and controls (n=18), (p=0.22), figure 2.9 (i). Total IgE at preschool age was 
higher in those children who developed school age asthma (n=15) than those 
who did not develop asthma (n=31), (p=0.036), figure 2.9 (ii), however there is 
considerable overlap between the groups. 
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Figure 2.9: Total IgE at preschool age related to (i) preschool wheeze 
and (ii) school age asthma status 
p=0.22
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2.13.4 School age asthma status & preschool age RASTs 
Blood samples were taken to measure RASTs and total IgE while children 
were anesthetised for bronchoscopy at preschool age. Atopic sensitisation 
was initially considered as a simple dichotomous variable. Sensitisation was 
considered positive if the RAST test had a value of 0.35 or higher. Of 48 
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children who had RASTs measured at preschool age for 3 common food and 
5 aero-allergens, 16 children had one or more positive RAST test. There was 
no increased risk of asthma at school age in this group (Pearson’s Chi Square 
p=0.45). Further analysis excluding the subgroup of five children who had 
isolated positive RASTs to milk showed there was still no increased risk of 
asthma (Pearson’s Chi Square p=0.2). All 3 children had a positive RAST for 
egg at preschool age who were followed up at school age had asthma. 
Children with one or more positive aero-allergens (n=7) also did not have an 
increased risk of asthma at school age (p=0.15).  
 
School age asthma status was also compared with quantified atopy in the 
preschool period, both as the sum of all specific IgE to both aero and food 
allergens and as the sum of all aeroallergens (house dust mite, cat, dog, 
grass and tree pollen)(196). The sum of all allergens showed was no difference 
between those who developed school age asthma (n=14, median 2.72 (2.72-
110.2)KU/L) and those who did not (n=30, 2.72 (2.72-11.64)KU/L). However, 
the sum of all aeroallergens was greater in those who developed asthma 
(n=14, 1.7 (1.7-109.2)KU/L) when compared to those who did not (n=30, 1.7 
(1.7-8.3)KU/L), p=0.009, figure 2.10. 
 
Figure 2.10: Sum of all aeroallergens is increased in those who 
developed school age asthma when compared with those who did not 
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2.14 Prevalence of asthma at school age 
Population prevalence of asthma at school age varies with the diagnostic 
criteria selected(156). The asthma prevalence in the current cohort of children 
using the definition of asthma given above (parental report of doctor 
diagnosed asthma ever and wheeze in the last 12 months) was compared 
with that using other definitions of asthma used in other longitudinal cohort 
studies, table 2.2 and table 2.7. 
 
Prevalence of school age asthma in the group of preschool wheezers 
recruited from RBH between 2002 and 2005 varied from 38 to 57% depending 
on the criteria used to diagnose asthma, table 2.7. A report of wheeze in the 
last 12 months had the highest prevalence (57%) and an asthma definition 
that required wheeze and use of asthma medication in the last 12 months plus 
a parental report of doctor diagnosed asthma had the lowest (38%), table 2.7. 
The definition of asthma used in this thesis had a prevalence of 40.5%, table 
2.7. 
 
Prevalence of asthma at school age is higher as expected in the children with 
wheeze at preschool age (38-57)% than that of controls (29-45)%. Prevalence 
of wheeze reported in the UK using ISAAC questionnaire was 20.9% in 
children aged 6-7 years old(155). 
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Table 2.7: Prevalence of asthma in preschool wheezers varies depending on definition used 
 
Original cohort 
Number of children followed up at school age 
 
Criteria for current asthma diagnosis at school age 
Preschool wheezers 
n=47 
n=37 (78.7%) 
All cohort 
n=68 
n=51 (75%) 
Wheeze in last 12 months (ISAAC questionnaire)(12;80;158) 
21 (56.7%) 23 (45%) 
Wheeze in the last 12 months and parental report of doctor diagnosed asthma 
ever(156) 
15 (40.5%) 16 (31.4%) 
Doctor’s diagnosis of asthma ever(156) 
18 (48%) 20 (39.2%) 
Wheeze in the last 12 months and one or both of(10) 
 doctor diagnosed asthma ever 
 use of asthma medications* during the past 12 months 
19 (51%) 19 (37.3%) 
Wheeze in the last 12 months and  
Parental report of doctor diagnosed asthma ever 
And use of inhaled corticosteroids during the past 12 months 
14 (37.8%) 15 (29.4%) 
*Asthma medication one or more of the following (inhaled corticosteroids, long or short-acting ß-agonists, sodium cromoglycate, leukotriene antagonists 
and/or aminophylline)  
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2.15 Demographics of children who attended for a research visit 
Thirty nine of the 51 children who answered the clinical questionnaire 
attended for a research visit for lung function, airway inflammation and atopy 
assessment, figure 2.11. Several children were less than seven years old or 
had learning or behavioural problems (discussed above) which made it 
difficult for them to complete all of the assessments.  
 
Five children were unable to perform either exhaled FeNO50 or spirometry  
- 3 of the children were aged 5.9-6.1 years (one of whom also had 
learning disability) 
- 1 child had behavioural problems and became very upset and refused 
to participate 
- 1 child had learning disability and was unable to perform either test 
 
A further child refused to do FeNO50 but subsequently was persuaded to 
perform spirometry. Demographics of children who attended for the research 
visit are shown in table 2.8. All lung function analyses have been performed 
for all children (both preschool wheezers and controls) with and without school 
age asthma and both including children with other lower airway pathology and 
also as a separate subgroup analysis excluding them.  
 
Table 2.8: Demographics of children who attended for research visit  
 Asthma 
(n=12) 
No Asthma 
(n=27) 
p 
Male / Female 8/4 17/10  
Age (years) 8.2 (6-10.4) 7.3 (5.8-11) 0.09 
Height (cm) 
Height (z score) 
127.9 (110-157) 
-0.13 (-3.79-2.66) 
135.4 (109-146.1) 
0.06 (-3-2.16) 
0.6 
0.61 
Weight (kg) 
Weight (z score) 
24.7 (21.5-48) 
0.26 (-1.66-3.13) 
26 (16.7-37.1) 
0.35 (-2.07-2.81) 
0.64 
0.98 
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Figure 2.11: School age follow up (2009-10) of preschool cohort, lung 
function, airway inflammation and skin prick test measurements at 
school age  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.15.2 Video questionnaire at school age 
Of those parents who reported that their child had wheezed over the past 12 
months and were shown a video questionnaire (n=17) only 12/17 (71%) 
identified wheeze on the video questionnaire. There was no relationship 
between reported wheeze frequency and parental identification of wheeze on 
video questionnaire (Chi squared test, p=0.45) or between wheeze pattern 
(episodic or multiple-trigger at school age) and video questionnaire (Chi 
squared test, p=0.2). Furthermore, parents of children with current wheeze 
and a diagnosis of current asthma were not more likely to identify wheeze on 
video questionnaire than those who reported current wheeze but not a 
doctor’s diagnosis of asthma (Fisher’s exact test p=0.47).  
Children recruited 2002-2005 
Wheezers (n=47) 
Controls (n=21) 
 
 
Lost to follow up (n=17) 
 
Successfully completed 
FeNO50 (n=33) 
Spirometry (n=35) 
Multiple breath washout (n=36) 
Skin prick tests (n=34) 
 
 
Attended for research visit (n=39) Declined to attend (n=12) 
Followed up by questionnaire (n=51) 
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5/17 children’s parents reported school age wheeze but did not identify it on 
video questionnaire. All of these children were attending the Royal Brompton 
Hospital for respiratory follow up. Two children were being followed with mild 
to moderate asthma, one child had scimitar syndrome and a congenitally 
small right lung, one child had Carpenter’s Syndrome with recurrent 
respiratory infections and reported wheeze only with colds and one child had 
bronchiectasis. Interestingly none of the parents recognised any other 
respiratory noises on video questionnaire including stridor, wet cough or 
stertor. Cohen's kappa coefficient showed moderate agreement between the 
video and written questionnaire (kappa 0.46, p=0.005).  
 
2.15.3 Comparison of RASTs at preschool age with skin prick tests at 
school age 
Thirty four children had atopy measured by skin prick tests at school age, of 
whom 32 also had RASTS measured at preschool age. The skin prick tests 
performed at school age were the same 3 food allergens (egg, milk, peanut) 
and 6 aeroallergens (grass, tree, cat, dog, Aspergillus fumigatus and 
Dermatophagoides pteronyssinus). Aspergillus RAST was not measured at 
preschool age. Children with school age asthma (8/12) were more likely to 
have one or more positive RASTs for aero-allergens than those without 
asthma (3/22) (Fishers exact test p=0.005).  
 
Of 23 children with no positive RASTs at preschool age, 5 (20%) had one or 
more positive skin prick tests at school age. Total IgE at preschool age in 
those with no positive RASTs at preschool age showed a trend for a higher 
IgE in those that subsequently had one or more positive skin prick tests (n=5, 
median IgE 42 (range 4-526)IU/ml) when compared with those who did not 
(n=18, median IgE 5 (range 1-292)IU/ml) (p=0.16). Of the children (n=5) with 
no positive RASTs at preschool age but with positive skin prick tests at school 
age, all 5 had school age eczema, and 3 had asthma and allergic rhinitis.  
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2.15.4 Tobacco smoke exposure at school age 
Thirty six children had salivary cotinine measured successfully and 3 children 
refused to participate. Four samples had insufficient saliva collected. Of those 
children (n=32) who had salivary cotinine measured only 4 families reported 
one or more parents smoking. Five children had salivary cotinine levels 
greater than the upper limit of normal (1.2μg/l)(170). One child had a salivary 
cotinine level of 10.3μg/l. Mean reported salivary cotinine in children where 
one or both parents smoked is reported as 3.7 (range 1.3-9.8)μg/l(170). There 
was no difference in salivary cotinine from the homes where smoking was 
reported (n=4 median 1.8 (range 0.1-10.3)μg/l) and those where it was not 
(n=28, median 0.2 (range 0.1-1.8)μg/l), p=0.15, figure 2.12. There was no 
difference in salivary cotinine between children with asthma (n=13, median 
0.2 (range 0.1-10.3)μg/l) and children without school age asthma (n=19, 
median 0.2 (range 0.1-1.7)μg/l), p=0.59. 
 
Figure 2.12: Salivary cotinine at school age compared between houses 
where one or more persons and non smoking homes (There is no 
difference between the groups; the horizontal dotted line shows the upper limit 
of normal for salivary cotinine 1.2µg/l) 
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2.15.5 Spirometry 
Spirometry was successfully performed in 35 children(192). All children had 3 
flow volume loops recorded after a period of practice. Repeatability as 
measured by the CoV between manoeuvres for FEV1 was 4.4% (standard 
deviation 2.9)% and for FVC 5.6% (standard deviation 3.6)%.  
 
There was a significant difference in FVC measured between preschool CW 
(median z score -0.4) and RW (median z score -1.6), p=0.03, figure 2.13 (i). 
However, there was no difference in school age FEV1 z score (p=0.45) or the 
ratio of FEV1/FVC (p=0.14) between preschool wheezers (confirmed (n=12) 
and reported (n=13)) and children with no lower respiratory symptoms at 
preschool age (n=10), figure 2.13 (ii) and (iii). Children with asthma (n=12) at 
school age had similar FEV1 (p=0.43), FVC (p=0.48) and FEV1/FVC (p=0.84) 
z scores to those without asthma (n=23), figures 2.13 (iv)-(vi). A subgroup 
analysis of children with persistent wheeze (n=15) (i.e. wheezing during 
preschool years and reported wheeze in the previous 12 months) and children 
who did not report wheeze either at preschool age or in the past 12 months 
(n=9) again showed no significant difference in FEV1 (p=0.8), FVC (p=0.76) or 
FEV1/FVC (p=0.18) z scores. 
 
Four children with co-morbid lower airway pathology other than asthma known 
to decrease spirometry were excluded for the purpose of comparing lung 
function between asthmatics and non-asthmatics. The children excluded from 
the second analysis are as follows; 
- a girl with bronchiectasis at school age (school age asthma; FVC z score= -
0.3, FEV1 z score=-0.12)  
- a boy with evidence of gas trapping and atelectasis on computerised 
tomography at school age (no asthma at school age; FVC z score=-2.64, 
FEV1 z score=-3.01)  
- a girl with scimitar syndrome and a congenitally small right lung (no asthma 
at school age; FVC z score= -2.69, FEV1 z score= -2.08)  
- a boy with evidence of upper airway obstruction caused by tracheal 
compression secondary to a right sided aortic arch (no asthma at school age; 
FVC z score=-0.01, FEV1 z score= -0.29). 
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After exclusion of the 4 children with other airway pathology (1 with school 
age asthma and 3 children without school age asthma) no difference was 
seen between children with and without asthma at school age for FVC 
(p=0.7), FEV1 (p=0.8) and FEV1/FVC, (p=0.76), figure 2.14. 
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Figure 2.13: No difference in school age spirometry related to school age asthma status 
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Figure 2.14: Lung function measures compared between children with 
and without school age asthma after exclusion of children with 
comorbid respiratory diagnosis  
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2.15.6 Multiple breath washout 
Twenty two children had 3 acceptable washouts and 14 children had 2 
acceptable washouts. Mean coefficient of variation between multiple breath 
washout measurements in the same child with 3 acceptable washouts was 
4.9% (standard deviation 2.5%). Similarly mean FRC was 1.08L (standard 
deviation 0.28L) with the mean coefficient of variation between measures for 
the same child of 5% (standard deviation 2.5%). A randomly selected subset 
(n=14) of the multiple breath wash out studies were analysed by a second 
more experienced observer, Ms Samantha Irving, to ensure quality control 
and there was good correlation between the two observers (Bland Altman 
plot, standard deviation +/-0.19, bias 0.14), figure 2.15. 
 
Figure 2.15: Difference between lung clearance index measurements by 
Dr R O’Reilly (measurement 1) and Ms S Irving (measurement 2) plotted 
against the mean of the 2 measurements (No significant bias seen) 
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2.15.6.2 Lung Clearance Index 
There was no difference in LCI between the children either stratified by their 
preschool age wheeze status (n=36, p=0.44) or by the presence or absence 
of asthma at school age (p=0.5), figures 2.16 (i) and (iv) and table 2.9.  
 
Three children with airway pathology other than asthma known to affect the 
distal airways were excluded from the MBW sub-analysis, bronchiectasis n=2, 
(LCI=10.99, LCI=8.17), and atelectasis and gas trapping n=1, (LCI=7.98). I 
included in this analysis the boy with tracheal compression (LCI=6.93) and the 
girl with a congenitally small right lung (LCI=7.27) as both had normal LCIs. 
There was still no difference between groups stratified either by preschool 
wheeze status (CW [n=12, LCI median 7.23 (6.34-10.99)], RW [n=11 LCI 
median 7.6 (6.2-7.75)] and controls [n=10, LCI median 7.4 (6.24-7.88)], 
p=0.72, or by school age asthma status (asthma [n=11, LCI median 7.25 
(6.34-10.99)] versus no asthma [n=22, LCI median 7.13 (6.2-7.83)]), p=0.3. 
 
There was no difference in LCI between children that persistently wheezed 
from preschool age and were still wheezing at school age (n=15, median LCI 
7.37 [6.34-10.99]) and those who never wheezed (n=9 median LCI 6.94 [6.24-
7.88]), p=0.15. Similarly there was no difference in LCI between parental 
reported wheeze phenotypes at school age, either multiple-trigger (n=10, LCI 
median 7.44 [6.34-10.99]) or episodic (viral) wheeze (n=6, LCI median 7.24 
[6.65-7.78]) and children who did not report wheeze at school age (n=20, LCI 
median 7.12 [6.2-10.95]), p=0.33. FRC was similar in all groups, 1.05 (0.71-
2.09) litres, table 2.9.  
 
The upper limits of normality for LCI reported in another study are 7.42, range 
(7.25-7.59)(62). If these limits are applied to this study in the absence of 
reference data from our own department, 12 children in this study had LCI 
greater than 7.42. However seven of these were just above this range (7.42-
7.8). Of the remaining children (n=5) two had had evidence of mild to 
moderate bronchiectasis on CT (LCI: 8.17, 10.95), the third had evidence of 
gas trapping and atelectasis (LCI=7.98), and two children had no obvious 
reasons (LCI 10.99, 8.41).  
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2.15.6.3 Scond & Sacin 
Scond (conductive airways inhomogeneity) and Sacin (acinar airways 
inhomogeneity) were analysed in 29 children who had two or more technically 
acceptable washouts. Seven children were excluded because they did not 
have two or more traces from which a phase III slope could be reproducibly 
analysed.  
 
There was no difference when Sacin was compared in preschool wheeze 
(p=0.21), figure 2.16 (ii), or school age asthma status (p=0.97), figure 2.16 (v). 
Although CW (n=9, 0.032) showed a trend to higher Scond when compared with 
RW (n=11. 0.014) and controls (n=9, 0.015) it was not statistically significant 
(p=0.2), figure 2.16 (iii). Children with asthma at school age (n=7, 0.043) had 
a higher Scond when compared to those who did not (n=22, 0.014) p=0.049, 
figure 2.16 (vi). However on exclusion of the 2 children included in the 
analysis with co-morbid lower airway pathology (1 with a diagnosis of school 
age asthma and 1 without asthma) there was still a trend to higher Scond in the 
school age asthmatics (n=6, Scond=0.039, range [0.003-0.061]) compared to 
those children without asthma at school age (n=21, Scond= 0.014, range [-
0.027-0.032]), but was no longer statistically significant, p=0.1. There was 
also no difference when children were compared by preschool wheeze groups 
episodic (viral) and multiple-trigger at school age. 
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Table 2.9: Lung clearance index, functional residual capacity, Scond and 
Sacin related to school preschool age wheeze status and school age 
asthma status. (Scond is increased in those children who developed school 
age asthma) 
 Preschool age   
 Confirmed 
wheezers 
n=13 
Reported 
wheezers 
n=13 
Controls 
 
n=10 
 
p 
FRC (l) 
Range 
1.055  
(0.75-2.09) 
0.996  
(0.71-1.61) 
1.027  
(0.75-1.43) 
0.83 
LCI 
Range 
 
 
Scond 
Range 
Sacin 
Range 
7.37 
(6.3-10.99) 
 
n=9 
0.032 
(0.003-0.06) 
0.099 
(0.028-0.5) 
7.25  
(6.2-8.17) 
 
n=11 
0.014 
(-0.027 -0.044) 
0.13 
(0.033-0.24) 
7.17  
(6.24-7.88) 
 
n=9 
0.015 
(-0.027-0.023) 
0.076 
(0.034-0.62) 
0.44 
 
 
 
0.2 
 
0.21 
 School age  
 Asthma 
n=12 
No Asthma 
n=24 
 
FRC 1.06 
 (0.75-2.09) 
1.05 
(0.71-1.61) 
0.69 
LCI 
Range 
 
 
Scond 
Range 
Sacin 
Range 
7.33 
(6.1-10.99) 
 
n=7 
0.043 
(0.003-0.06) 
0.08 
(0.06-0.21) 
7.24 
(6.28-10.95) 
 
n=22 
0.014 
(-0.027-0.03) 
0.1 
(0.028-0.62) 
0.5 
 
 
 
0.0498 
 
0.97 
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Figure 2.16: Increased Scond in children with school aged asthma
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2.15.7 Exhaled nitric oxide 
Thirty three children successfully performed FeNO50. CW (n=10, 11.95 [7.7-35] ppb) 
had higher FeNO50 when compared to RW (n=13, 5.9 [2-20.6]ppb) but not controls 
(n=10, 7.33 [3.8-42.6]ppb), p=0.06, figure 2.17 (i). Of the 2 children from the original 
control group with raised FeNO50 one had asthma, eczema and positive skin pick 
tests to cat, milk and peanut at school age and the second child had eczema and 
allergic rhinitis but no positive skin prick tests. Children with school age asthma 
(n=11, 13.3 [4.9-40.3] ppb) had higher FeNO50 when compared to children without 
school age asthma 7.08 [2-42.6]ppb), p=0.02, figure 2.17(ii). FeNO50 was greater in 
atopic (n=13, 16.3 [4.96-42.6]ppb) compared to non-atopic children (n=20, 7.15 [2-
20.6]ppb) irrespective of current wheeze status (p=0.01), figure 2.17 (iii).  
 
Figure 2.17: (i) FeNO50 greater in confirmed rather than reported wheezers, (ii) 
Increased FeNO50 in children with school age asthma when compared to 
children without asthma, (iii) Increased FeNO50 in children with school age 
atopy 
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2.15.8 Hypertonic saline challenge 
Hypertonic saline (4.5%) provocation testing was used to measure AHR. The test 
was considered complete if either the FEV1 had fallen by 15% from baseline or the 
total inhalation period of 15.5 min had been reached. ß-agonists were withheld for 
the previous 12 hours and inhaled corticosteroids for the previous 24 hours. Two 
children with severe asthma requiring maintenance daily oral prednisolone were 
asked not to withhold medication. Twenty six children had bronchial challenges: 22 
were full studies and 4 studies had to be prematurely discontinued, table 2.10. Two 
children disliked the salty taste and were reluctant to continue, a third child spat pink 
liquid into the tubing and the fourth became bored and despite repeated 
(ii) 
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encouragement was not using maximal effort at spirometry. The median participation 
time in these children was 5.5 minutes (range 1.5-11.5 minutes).  
 
In children (n=5) with FEV1≤75% bronchial challenge was not performed. Three of 
the five children had bronchodilator reversibility (BDR) assessed 20 minutes after 
inhalation of 1000mcg salbutamol. The fourth child had a congenitally small right 
lung explaining her low lung function. The fifth child recently had surgery for Cor 
Triatriatum and the mother was reluctant to give him medication. Four children were 
unable to perform repeatable lung function and 4 children refused to participate, 
table 2.10. The reasons given were ‘fear of the nebuliser and dislike of the salty 
taste’.  
 
Table 2.10: Acceptability and tolerance of bronchial challenge with hypertonic 
(4.5%) saline 
Assessment of bronchial  
hyper-responsiveness 
Number  
Full bronchial challenges 22 
Incomplete bronchial challenges 4 
Unable to perform repeatable lung function 4 
Refused test 4 
Not performed as lung function ≤75% 5 
Total 39 
 
 
2.15.8.2 Amount of hypertonic saline inhaled 
There was considerable variation in the amount of saline inhaled among children 
who completed the full inhalation period, figure 2.19. The median amount was 22.4g 
(range 2-31.1g). Only 5 children inhaled > 23g of hypertonic (4.5%) saline. A further 
5 children were just under this threshold value with amounts of inhaled saline 
between 21-23g. There was only moderate correlation between duration of time and 
amount of inhaled saline (Spearman r=0.59, p=0.004), figure 2.18. Two patients 
were nebulised for an additional 4 minutes until an inhalation dose of 23g was 
reached. The remainder of the children were reluctant to prolong the nebulisation 
period.  
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Figure 2.18: Variability of amount of inhaled hypertonic saline (4.5%) inhaled at 
end point time of 15.5 minutes 
Spearman r=0.59, p=0.004
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2.15.8.3 Airway hyper-responsiveness, multiple breath washout and exhaled 
nitric oxide 
There was no relationship between either AHR or bronchodilator response to LCI or 
Sacin. However, there was a trend towards higher FeNO50 in those with evidence of 
bronchodilator reversibility or AHR, table 2.11. Scond was higher in those with reactive 
airways although numbers are very small (n=4). 
 
2.15.8.4 Induced Sputum 
All except 3 of the children had a dry non-productive cough when sputum induction 
was attempted (3/25, 12%). Several of the children on expectorating produced 
samples of saliva which were not analysed as there were no sputum plugs. All the 
children that produced a sample had a wet cough prior to induction despite parents 
reporting absence of symptoms over the preceding 3 weeks. One of the sputum 
samples was processed incorrectly and only 2 sputum results were obtained so no 
further analysis has been performed. Both sputums were predominantly neutrophilic 
(72% and 84%). 
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Table 2.11: No significant difference between children with evidence of 
bronchodilator response or airway hyperresponsiveness and those without at 
school age 
 Evidence of Airway Hyper-responsiveness 
or 
Bronchodilator Reversibility 
 Positive 
n=5 
Negative 
n=20 
p 
Male / Female 4/1 13/7 0.1 
 
Age (range) 
 
9.28 (7.15-10.4) 
 
7.74 (6.8-9.8) 
 
0.06 
 
Symptomatic 
(wheezy, chest tightness) 
 
 
3 
 
 
0 
 
 
Change in FEV1 ≥ 15% 
 
BDR ≥+15%  
 
AHR ≥-15% 
 
 
n=2 
17.7%  
n=3 
-17 (15-36) % 
 
 
n=1 
9% 
n=19 
+2 (-14 to +17)% 
 
 
Wheeze last 12 months  
 
3 
 
9 
 
0.45 
Asthma 
 
LCI 
(Range) 
 
Scond 
(Range) 
 
Sacin 
(Range) 
 
FeNO(50ml/s ppb) 
 
3 
 
7.74 (n=5) 
(6.88-8.41) 
 
0.0435 (n=4) 
(0.03-0.05) 
 
0.1245 (n=4) 
(0.028-0.2357) 
 
(n=5) 
19.4 (8.7-38) 
9 
 
7.24 (n=20) 
(6.21-10.99) 
 
0.009 (n=17) 
(-0.0275-0.061) 
 
0.083 (n=17) 
(0.033-0.61) 
 
(n=19) 
8.1 (3.8-42.6) 
0.38 
 
0.29 
 
 
0.01 
 
 
0.89 
 
 
 
0.055 
 
 
2.16 Summary of Results 
 Seventy five percent of the original preschool cohort (51/68) were followed up 
at school age 
 Forty percent of the original preschool wheezers that were followed up had a 
diagnosis of asthma at school age (defined as parental report of wheeze in 
the last 12 months and a doctor diagnosis of asthma ever)  
 Children with pre-school video confirmed wheeze at preschool age had a 
higher risk of school age asthma compared with parental reported wheezers 
and controls.  
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 Children with school age asthma had increased prevalence of allergic rhinitis 
(p=0.001), eczema (p=0.0001), positive skin prick tests (p=0.006) and FeNO50 
(p=0.02) when compared to those without asthma. 
 Scond was higher in children in school age asthma and in children with airway 
reactivity, but no difference was seen for spirometry measurements, LCI or 
Sacin. 
 There was no correlation between AHR or bronchodilator reversibility and 
wheeze in the last 12 months or current asthma, but the numbers who were 
positive are too small for any conclusions to be drawn. 
 
2.17 Discussion 
2.17.1 Review of aims and objectives 
The primary aims and objectives of this part of the study have been partly achieved 
1) A diagnosis of asthma was established in 51/68 (75%) of the original 
preschool cohort.  
2) A subgroup of this cohort 39/68 (58%) were characterised in terms of lung 
function and atopy. 
 
2.17.2 Limitations of the study 
The main limitation was that some children (18%) could not or would not attend for 
the research visit so pulmonary function and atopy measurements were available in 
all children. Final numbers followed up at school age were small and the preschool 
‘control’ group while wheeze free at preschool age had other medical problems and 
were not truly ‘normal controls’. Several of the children had co-morbid or alternative 
diagnoses at school age. Importantly this group of preschool children represented a 
cohort with severe recurrent wheeze with only 6 children reporting no hospital 
admissions with wheeze at school age. Children had a median of 8 hospital 
admissions with wheeze over their lifetime at follow up. These children are not 
representative of preschool wheezers in the general population but rather a specific 
group with more severe disease. This also partly explains why some of the children 
had overlap with other respiratory pathology at school age.  
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2.17.3 Strengths of the study 
Seventy five percent of the preschool children were followed up in one way or 
another at school age, figure 2.11. Other studies report similar subject retention of 
between 54-91%(1;10-12;14;15).  
 
2.17.4 Asthma diagnosis 
The absence of standardised criteria for the diagnosis of asthma in children was one 
of the most challenging aspects of this study. Seventy eight percent of the original 
preschool wheezers were followed up at school age. Asthma prevalence in this study 
varies from 29 to 45% depending on the definition used, table 2.7. Although 
symptoms (wheeze, chest tightness) are sensitive for the presence of asthma, they 
may also be influenced by perception, culture and the interviewer. In order to prevent 
interviewer bias as much as possible all parents that attended for a research visit 
were shown the video questionnaire first followed by the written questionnaire and 
questions were asked in the same order each time. In all but 3 families, the parents 
that attended with the child for the research visit were Caucasian and English was 
their first language.  
 
Parental identification of wheeze on video questionnaire at preschool age improved 
asthma prediction at school age (p=0.015). However, several of the parents still 
reported wheeze at school age but did not identify it on a validated video 
questionnaire, confirming that parental and physician perception of wheeze 
differs(16;153).  There was only moderate correlation between reporting wheeze in the 
last 12 months and identifying it as a respiratory symptom in the last 12 months on 
video questionnaire (kappa 0.46, p=0.005). A Canadian English speaking study has 
also shown limited agreement between the ISAAC questionnaire and video 
identification of wheeze(194). In a more recent ISAAC study involving over 40 
countries responses to a video questionnaire gave lower prevalence’s of wheeze 
than with the written questionnaire, which was more apparent in English speaking 
countries(197). Parental recall bias may also contribute to this discrepancy with two 
mothers who previously identified wheeze at preschool age no longer able to identify 
it on video questionnaire at school age despite reporting persistent wheeze. 
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The definition of asthma used in this study was parental report of wheeze in the last 
12 months and a parental report of doctor diagnosed asthma ever. This definition 
has been used to assess wheeze and asthma prevalence in many studies(156;198-204). 
The group of children with asthma at school age by this definition had higher 
paternal history of doctor diagnosed asthma, higher IgE at preschool age, and a 
greater prevalence of allergic rhinitis, eczema and FeNO50 at school age when 
compared to those without, suggesting that this definition selected children likely to 
have asthma. Spirometry did not detect significant differences between those with 
and without school age asthma, however it is known to be a poor marker of asthma 
severity(42;205). 
 
Several longitudinal cohort studies have shown parental asthma to be an important 
factor in predicting school age asthma(10;12;27). It is difficult to explain why paternal 
asthma was associated with school age asthma, rather than maternal asthma which 
has previously been shown to be a stronger predictor of school age asthma, table 
2.5(72;204;206;207). Importantly, an objective report was not obtained from health care 
providers for either maternal or paternal asthma. Paternal rather than maternal 
history of asthma is associated with AHR, an important determinant of disease 
severity in children with asthma(203). However, given the small size of the study, 
which was not powered for or intended to study parental contributions to asthma in 
the offspring, it would be wrong to draw any conclusions from these data. 
 
2.17.5 Lung function 
Previous large epidemiological studies have shown that early wheezing associated 
with poor airway function in the late preschool years tracks with age and is 
associated with asthma in adulthood(6;208). A limitation of this study was that 
preschool lung function was not available and thus it was not possible to compare 
preschool and school age lung function. 
 
School age children who successfully performed spirometry were able to perform 
very repeatable manoeuvres with less than 5% variability between attempts 
comparable with other studies(209;210). Interestingly there was no difference in lung 
function at school age as measured by spirometry between those with asthma and 
those without, figure 2.13 (iv-vi). The ratio of FEV1/ FVC which has been shown to be 
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more sensitive in classifying asthma severity in children also showed no difference 
between the children with and without asthma at school age(42). This may have been 
because the study was not powered to detect a difference in lung function between 
the two groups. Secondly, all children who attended for a research visit were 
symptom free at the time. The majority of children with persistent asthma have 
normal lung function during symptom-free periods with abnormal pulmonary function 
only during acute exacerbations(42;211). Furthermore, spirometry is not a helpful 
marker for asthma severity in children (above)(42;205). 
 
The decision whether to include children in the lung function analysis with both 
bronchiectasis and asthma was difficult. Confusion of asthma and bronchiectasis is 
common and the diagnostic process is further complicated by the fact that the two 
may co-exist(161). In adults with severe asthma, bronchiectasis is particularly 
common(212). Secondly, it remains unclear whether bronchiectasis in patients with 
asthma is a comorbidity or whether it represents structural change or remodelling 
with natural progression of the disease(213). However, in this study data were 
analysed both with and without these patients. When children with other airway 
pathology at school age were excluded there was no longer a difference in FVC 
between preschool RW and CW or between Scond in children with or without school 
age asthma.   
  
There was also no difference in LCI at school age by preschool wheeze phenotypes 
(confirmed and reported, multi-trigger and episodic) or by school age asthma status. 
This study showed a higher Scond in seven year old school age asthmatics (0.043) 
when compared to children without school age asthma (0.014), p=0.049. However, 
although there was still a trend towards higher Scond in school age asthmatics (Scond 
asthma 0.039, range [0.003-0.061] versus non asthmatics 0.014, range [-0.027-
0.032]) this was no longer significant when children with lower airways disease not 
due to asthma at school age were excluded. This study was not powered to detect a 
difference between the two groups. The number of children necessary to detect a 
10% difference in MBW indices between children with and without school age 
asthma was calculated as 56 with 80% power at the 5% significance level(62). 
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Scond has been shown in other studies to be the most sensitive marker of small 
airways disease in asthma(62;172). LCI in children with asthma, while often slightly 
higher than controls is still within the normal range and cannot be used as a useful 
indicator of disease in the individual child(62;171;172). Children aged 4-5 years with 
multiple-trigger wheeze have been shown to have significantly higher LCI (multiple-
trigger 7.4 (7.1-7.8) vs episodic 6.7 (6.5-6.9) vs controls 6.6 (6.5-6.7)) and Scond 
(multiple-trigger 0.042 (0.030-0.058) vs episodic 0.014 (0.009-0.023) vs controls 
0.010 (0.007-0.014)) when compared to episodic wheezers and healthy controls(62). 
The differences from the current study likely reflect the greater numbers reported by 
Sonnapa et al(62). Older children with well controlled asthma aged 10 years also had 
a higher LCI (6.69 (standard deviation (SD) 0.91) vs 6.24 (SD 0.47), p=0.02) and a 
trend towards a higher Scond (0.026 (SD 0.02) vs 0.017 (SD 0.02)), p=0.06
(171). A 
Swedish study of asthmatic children with positive skin prick tests to aero-allergens 
aged 13 years showed that elevated Scond correlated with increased levels of AHR 
and exhaled NO(172). This study, although numbers were small (n=21), also showed 
increased Scond in those children who demonstrated AHR or bronchodilator 
reversibility but no relationship to exhaled NO. This again suggests that disease of 
distal airways is an important part of asthma. It would have been useful to to 
calculate alveolar NO and bronchial flux NO concentration in children as a marker of 
distal airway inflammation, but the children were not able to perform FeNO at higher 
flow rates(190). 
 
2.17.6 Atopic status and school age asthma 
Children with higher total IgE at preschool age were more likely to develop asthma at 
school age, p=0.036. Sensitisation to one or more aeroallergens was not predictive 
of asthma at school age, p=0.15, but the cumulative sum of sensitisation to all 
aeroallergens was, p=0.009(196). Of the 37 preschool wheezers followed up at school 
age over half had been atopic at preschool age (defined as the presence of eczema 
and or one more positive RASTs tests). There was no difference between the atopic 
preschool wheeze group when compared to the non-atopic preschool wheeze group 
in prevalence of current wheeze (Fishers exact test p=0.74) or current asthma 
(Fishers exact test p=0.73) at school age.  
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One third of the non atopic preschool wheeze group were still wheezing at school 
age. In contrast the much larger German MAS study showed that 90% of children 
with wheeze before age 3 years but no atopy lost their symptoms at school age(32). 
Sensitisation to perennial allergens (house dust mite, cat and dog hair) developing in 
the first 3 years of life was associated with persistent wheeze and loss of lung 
function at school age(155). The difference in results is likely explained by the small 
number of children in the current study and also that they represent a group of more 
severe wheezers.  
 
In early life IgE antibodies are often first directed to food allergens and later to indoor 
and outdoor aero-allergens(214). As the median age of this group of children was just 
2 years this would suggest that more children would become sensitised by school 
age. In fact four children had no positive skin prick tests at school age having 
previously had one or more positive RASTs at preschool age (3 children had positive 
RASTs to milk and 1 child had a positive RAST to dog). Conversely, two children 
who did not have a positive RAST at preschool age had one or more positive skin 
prick tests to aeroallergens at school age. It is important to remember in comparing 
RASTs that there is only limited agreement with skin prick tests and the extent of 
agreement also varies between allergens(164;215). 
 
2.17.7 Airway hyper-responsiveness 
Twenty percent of children (5/25) demonstrated either AHR or bronchodilator 
reversibility at the research visit. However, the bronchial challenge was poorly 
tolerated with 8/30 either not completing the challenge or refusing to participate. This 
may be attributed to the median age of the children involved being 7 years and 
bronchial challenge being performed at the end of the assessment period when 
children were more likely to be tired.  
 
According to the protocol a complete bronchial challenge lasted 15.5 minutes and 
23g of saline was nebulised(163). The correlation between amount of inhaled 
hypertonic saline (4.5%) and time of inhalation was only moderate (Spearman 
r=0.59) suggesting that there is either not consistent output from the nebulisers or 
steady inhalation by the children. Similar lack of correlation between inhaled saline 
and length of inhalation have been found in other studies of 9-11 year olds in 
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Germany(216). Other studies have also found variation in the output in different 
models of the same nebuliser(217). Variable doses of hypertonic saline (2-31.1 g) 
were nebulised over the 15.5 minute period with (12/25) children achieving a 
nebulised concentration of 23g or just under of hypertonic saline. Similarly in a study 
of German children aged 9-11 years the investigators found it was not possible to 
nebulise 23g of hypertonic saline in 15.5 minutes in over half of the cohort(216). The 
nebulisation period was extended by 4 minutes to achieve 23g of saline in 2 of the 
children. However the remaining children declined to prolong the provocation test. 
Other studies have also found that increasing the inhalation time is not practical in 
this age group(216). 
 
Previous epidemiological studies in children have shown that inhalation time as 
opposed to hypertonic saline dose does discriminate between those with asthma and 
those without(216). In contrast to this only 3 children in this study had a positive 
bronchial challenge (defined as a dichotomous variable). All 3 children were 
symptomatic with acute wheeze and chest tightness and also demonstrated ≥ 15% 
bronchodilator reversibility on administration of 1000µg salbutamol following the 
bronchial challenge. There was no relationship between AHR and presence of 
wheeze in the last 12 months (p=0.45) or asthma (p=0.38). This may have been 
because of the small numbers (n=22) that had a complete bronchial challenge. It is 
not possible to exclude the possibility that variations in nebuliser output and 
inhalation on the part of the child may also be partly responsible for the low numbers. 
A washout period of 24 hours may not have been sufficient for ICS and may have 
suppressed bronchial reactivity. Two children were also on maintenance oral 
corticosteroids during the challenge. 
 
2.17.8 Sputum induction 
There was very poor success with sputum induction in this study. Jones et al 
reported that it was more difficult to get an adequate sample of sputum using the 
combined challenge protocol with 65% of children producing the sample compared 
with a much higher rate of (92%) of children who had sputum induction alone(175). Of 
note the mean age of children involved in that study was 11 years as opposed to 7 
years in the current study. Furthermore success of sputum induction is better in 
children older than 12 years(218). 
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2.18 Conclusion 
There was reasonable subject retention for this preschool cohort at school age. A 
diagnosis of asthma has been confirmed in 75% of the original cohort, which is 
supported by higher levels of atopy, exhaled nitric oxide and Scond when compared to 
those without school age asthma. There were insufficient AHR data to draw any 
conclusions. 
 
The next chapter will discuss the pathological changes in the preschool 
endobronchial biopsies which have previously been associated with asthma in adults 
and older children. In particular the next chapter will look at RBM thickness at 
preschool age and relate this to the presence or absence of school age asthma. 
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Chapter 3 
Reticular basement membrane thickness in preschool 
wheezers and its relationship with childhood asthma. 
 
3.1 Introduction 
The bronchial epithelial basement membrane is an acellular matrix composed of two 
structurally distinct layers, the basal lamina (true basement membrane) and the 
RBM. The basal lamina can be visualised only by electron microscopy since its width 
(~80nm) is below the resolution of the light microscope. In contrast, the RBM is 
considerably thicker (~3-5µm in children)(9;87) and can be seen using light 
microscopy. Abnormal thickening of the RBM is a feature of airway remodelling and 
is seen in several inflammatory airway diseases including cystic fibrosis(219), 
COPD(220), chronic cough(221) and post lung transplant(222) but is particularly 
characteristic of asthma(95).  
 
The relationship between RBM thickness and lung function remains uncertain. While 
some adult studies show that increased RBM thickness is associated with worse 
airway obstruction(112), others show that RBM thickening is associated with reduced 
AHR(223). RBM thickness positively correlated with the dose of metacholine needed 
to cause a 20% decrease in FEV1 and negatively correlated with the FVC/ FEV1 ratio 
in adult patients (n=33) with asthma, allergic rhinitis or COPD(223). In contrast adults 
with mild-moderate and severe asthma have demonstrated a relationship between 
bronchodilator responsiveness and increased RBM thickness(224). However, in 
children no association has been found between RBM thickness and lung 
function(116;219).  
 
Preschool children, median age 2-3 years, recruited from the Royal Brompton 
Hospital from 2002-2005 with severe recurrent wheezing were found to have 
increased RBM thickness when compared with non-wheezing controls(9). It was 
unknown at that time which of the children with severe recurrent wheeze at 
preschool age would persistently wheeze throughout childhood and develop 
asthma(9). RBM measurements were repeated so there was consistency with only 
one observer making all pathology measurements throughout this study. 
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3.1.2 Hypothesis 
The hypothesis to be tested in this chapter: 
Preschool wheezers who have asthma at school age have increased RBM thickness 
in preschool endobronchial biopsies compared to wheezy preschool children whose 
symptoms subsequently regressed.  
 
3.1.3 Aims and Objectives 
1. To re-measure RBM thickness in preschool endobronchial biopsies 
(previously measured by Dr S Saglani) blinded to preschool and school age 
clinical status  
2. To relate RBM thickness at preschool age to the presence or absence of 
asthma at school age 
 
3.2 Methods: Measurement of reticular basement membrane thickness in 
preschool children 
Biopsy processing and evaluation 
At the time of bronchoscopy and EB up to 4 biopsies had been taken and fixed in 
10% formal saline and processed to paraffin blocks 4-24 hours after fixation. Three 
5μm thick sections were then taken at 25-50μm step intervals, dependent on biopsy 
size. These sections were stained using haematoxylin and eosin (H&E). Sections 
containing only glandular tissue or strips of epithelium and RBM without associated 
subepithelial mucosa were not used. Children had only 1 or 2 suitable biopsies for 
analysis. Biopsies had previously been assessed for quality and suitability of 
measurement of RBM thickness by 2 observers, Dr S Saglani (SS) and Dr D Payne. 
A formal clinical report had also been provided by Professor A Nicholson, Royal 
Brompton Hospital at the time of biopsy. For this thesis, sections were counted in 
random order by Dr R O’Reilly (RO’R) blinded to both the children’s preschool group 
(wheezer or control) and school age asthma status. 
 
Measurement of RBM thickness 
During the time period between 2005 and 2009 further sections had been cut and 
stained with H&E so it is likely that different sections were measured for a given child 
by SS and RO’R. Biopsies were considered suitable for RBM measurement if 
epithelium, subepithelium and RBM were present. RBM thickness was measured 
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using computer aided image analysis (NIH image 1.55: National Institute of Health, 
Bethesda MD) starting from the upper left corner of each biopsy and measured at 
20µm intervals anticlockwise along a length of 1mm RBM for each biopsy. If the 
RBM could not be recognised it was not measured. Each measurement was made 
by drawing a line at a tangent to the luminal edge of the RBM (the luminal edge was 
adjacent to the epithelium) across its full length, figure 3.1. Forty measurements 
were made 20µm apart(225). The geometric mean of the 40 measurements taken was 
used to represent the mean RBM thickness for that biopsy(225).   
 
Figure 3.1: Haematoxylin and eosin stained endobronchial biopsy section 
showing reticular basement membrane thickness measured at right angles to 
a tangent marking the outer perimeter of the reticular basement membrane at 
that point 
 
 
 
 
3.2.2 Statistical analysis 
This section describes the statistical methods used for chapters 3-6. Non-parametric 
tests were applied in all calculations as the numbers of subjects in all groups were 
small. Kruskal-Wallis was used to assess differences between 3 or more groups and 
Dunn’s post test used to detect differences between pairs groups. The Mann 
Whitney U test was used to detect differences between 2 groups. Repeatability for 
repeated biopsy measurements over time was assessed using the CoV. Variability of 
measurements within biopsy was also assessed using the CoV. Agreement between 
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2 observers was assessed using intraclass correlation coefficient and Bland-Altman 
plots. Sample size was determined by recruitment to the previous study and success 
of follow up at school age. However, for adult EB studies, 15 patients for 
inflammatory studies and 10 for RBM thickness in each limb are usually sufficient to 
give positive results(225).  
 
3.3 Results  
3.3.1 Repeatability of RBM thickness measurements 
Three sections were measured on 3 occasions at intervals of a week and a month by 
RO’R. The mean CoV for the 3 sections measured on 3 occasions was 5.7% (3.5%, 
4.7% & 8.8%), table 3.1. 
 
Table 3.1: Variability between measurements in the same section by the same 
observer at day 1, day 7 and day 30 
 Day 1 
µm 
Day 7 
µm 
Day 30 
µm 
CoV 
% 
Section 1 5.5 5.3 5.1 3.5 
Section 2 5.1 4.8 5.2 4.7 
Section 3 4.3 4.5 3.9 8.8 
 
 
3.3.2 Comparison with previous reticular basement membrane thickness 
measurements 
The values for RBM thickness measured by RO’R are similar to those reported by 
SS, in 2007(9). The ICC for measurements in the same child compared between 
RO’R and SS is 0.67. There was no significant bias between the 2 observers shown 
by using a Bland-Altman plot, figure 3.2.  
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Figure 3.2: A Bland-Altman plot showing variability between measurements as 
reported by observer 1 (RO’R) and observer 2 (SS). No significant bias is 
detectable  
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3.3.3 Reticular basement membrane thickness related to preschool clinical 
status 
Biopsies were suitable for measurement of RBM thickness in 37 wheezers. Children 
had been further divided into 2 groups using the video questionnaire at preschool 
age into CW (n=21) and RW (n=16). There were 16 controls. The RBM was 
significantly thicker in all wheezers both confirmed and reported (median thickness 
4.5µm [1.41-7.3µm]) compared to controls (median 3.58µm [1.2-5.99 µm]), p=0.009, 
figure 3.3. The RBM was significantly thicker in CW (median 4.76µm [3.1-7.3µm]) 
compared to controls (median 3.58µm [1.2-5.99µm]), p=0.02, but there was no 
difference between both CW and RW (median 4.19µm [1.4-5.77µm]), or RW and 
controls, figure 3.4.  
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Figure 3.3: Increased reticular basement membrane thickness in 
endobronchial biopsies from preschool wheezers compared to age matched 
controls (RO’R measurements) 
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Figure 3.4: Increased reticular basement membrane thickness in preschool 
confirmed wheezers compared to controls (RO’R measurements)  
(There was no difference between confirmed and reported wheezers or reported 
wheezers and controls) 
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3.3.4 Relationship of reticular basement membrane thickness at preschool age 
to asthma at school age 
Thirty nine children with RBM thickness measured at preschool age were followed 
up at school age. There was no difference between children with RBM 
measurements who were followed up at school age and those not followed up in 
terms of age at EB (p=0.4), RBM thickness (p=0.54) or sex (p=1). Preschool RBM 
thickness was similar in children with school age asthma (median 4.77µm [range 
3.14-7.02µm]) when compared to those without asthma (median 4.14µm [range 1.2-
5.99µm]), p=0.15, figure 3.5.  
 
Figure 3.5: No difference in preschool reticular basement membrane thickness 
when compared with presence or absence of asthma at school age (RO’R 
measurements – all children included) 
p=0.15
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On examining the children who wheezed at preschool age (excluding preschool 
controls), there was a trend towards increased RBM thickness in preschool 
wheezers who developed childhood asthma (n=11, median 4.79 [3.38-7.02]µm), 
when compared to those preschool wheezers who stopped wheezing (n=18, median 
4.17 [1.4-5.72]µm) but it was not statistically significant, p=0.12, figure 3.6. There 
was a significant difference between age at EB of those preschool wheezers who 
developed school age asthma (42 [24-57] months) and the preschool wheezers who 
did not (15.5 [7-55] months), p=0.002.  
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Figure 3.6: No difference in reticular basement membrane thickness in severe 
recurrent preschool wheezers when compared with presence or absence of 
asthma at school age- (RO’R measurements-preschool wheezers alone)  
p=0.12
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3.3.5 Comparison of Dr Saglani’s reticular basement membrane measurements 
with asthma status at school age 
SS’s measurements of RBM thickness in preschool children showed a significant 
difference between groups classified by asthma status at school age, in that those 
children who developed asthma (n=11, median 5.1µm [range 3.1-8µm]) had 
increased RBM thickness when compared with those who did not (n=28, median 
3.94µm [range 2-5.44µm]), p=0.02, figure 3.7. However, individual measurements for 
children showed no significant bias between the 2 observers. Further sections had 
been cut and stained with H&E since the original study so one child with asthma at 
school age had not had RBM measured by SS but had by RO’R.  
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Figure 3.7: Dr S Saglani’s measurements showing increased reticular 
basement membrane thickness at preschool age in children with school age 
asthma (all children followed up) 
p=0.02
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Preschool wheezers compared with school age asthma status 
On examining just the children who had wheeze at preschool age there was again 
significantly greater RBM thickness in those who developed school age asthma 
(n=10, median 5.25 [3.4-8]µm) compared with those who did not (n=18, median 4.15 
[2.12- 5.44] µm), p=0.02, figure 3.8. 
 
Figure 3.8: Dr S Saglani’s measurements showing increased reticular 
basement membrane thickness in severe recurrent preschool wheezers who 
developed school age asthma when compared to preschool wheezers who did 
not develop asthma (preschool wheezers alone) 
p=0.02
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3.3.6 Comparison of preschool reticular basement membrane thickness with 
clinical findings at school age 
All RBM thickness measurement reports are as measured by RO’R unless otherwise 
stated. RBM thickness at preschool age correlated with the number of overnight 
hospital admissions as reported by the child’s carer at school age over that child’s 
lifetime (r=0.56, p=0.001), figure 3.9. However there was no association between 
wheeze frequency at school age or reported medication use at school age, and RBM 
thickness at preschool age, table 3.2.  
 
Figure 3.9: Positive correlation with number of lifetime overnight admissions 
to hospital with wheeze reported at school age and reticular basement 
membrane thickness at preschool age 
r=0.50, p=0.008
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Table 3.2: Clinical findings at school age related to reticular basement 
membrane thickness at preschool age 
 Asthma No Asthma p 
 
 
RBM (µm) 
 
n=12 
4.77(3.14-7.02) 
 
n=27 
4.14(1.2-5.99) 
 
 
0.15 
Age at asthma diagnosis (years) 
Age at FOB (months) 
Male/ Female 
 
Symptoms at school age 
8.6 (6-10.4) 
38.5 (3-57) 
8/4 
7.2 (5.9-11) 
17 (6-55) 
16/11 
0.09 
0.005 
0.73 
 
Wheeze in the last year 
RBM (µm) 
 
n=17 
4.55 (3.1-7.02) 
  
n=22 
4.11 (1.2-5.99) 
 
 
0.41 
Wheeze 4-12 times/ last year* 
RBM (µm) 
n=12 
4.63 (3.38-7.02) 
n=12 
3.73 (1.2-5.99) 
 
0.16 
Wheeze > 12 times/ last year* 
RBM (µm) 
n=5 
5.07 (3.38-7.02) 
n=12 
3.73 (1.2-5.99) 
 
0.44 
ICS use at school age 
RBM (µm) 
n=13 
4.76 (3.38-7.02) 
n=16 
4.19 (1.4-5.7) 
 
0.39 
 
Positive skin prick tests school 
age 
RBM (µm) 
 
n=9 
 
4.5 (1.4-4.97) 
 
n=18 
 
4.07(1.2-7.02) 
 
 
 
0.37 
*When compared to children who did not wheeze either at preschool or school age 
(All reported values are Dr R O’Reilly’s measurements) 
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3.3.7 Comparison of preschool reticular basement membrane thickness with 
measurements of airway inflammation and lung function at school age 
There was no correlation between spirometry, LCI or Scond and preschool RBM 
thickness, table 3.3. Similarly there was no relationship between FeNO50 and RBM 
thickness. There was a negative correlation between Sacin and RBM thickness at 
preschool age (r=-0.53, p=0.008), figure 3.10. 
 
Table 3.3: Correlation between lung function and airway inflammation at 
school age with reticular basement membrane thickness at preschool age 
 RBM thickness (µm) 
Correlation 
(Spearman) 
p value 
FEV1 (z score) n=27 
FVC ( z score) n=27 
0.18 
-0.1 
0.38 
0.6 
 
LCI n=28 
Sacin 
Scond 
 
0.04 
-0.54 
0.22 
 
0.82 
0.008 
0.29 
 
FeNO (ppb) n=26 
 
0.09 
 
0.65 
*Over child’s lifetime (with wheeze) 
 
 
Figure 3.10: Negative correlation between reticular basement membrane 
thickness (n=23) at preschool age and Sacin at school age 
Spearman r=-0.53, p=0.008
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On comparing RBM thickness in the preschool wheezers alone there was a non- 
statistically significant trend with FEV1 (n=20, Spearman r=0.42), p=0.07, figure 3.11 
(i) and FeNO50 (n=19, Spearman r=0.44), p=0.06, figure 3.11 (ii). There was no other 
positive correlation between preschool wheezers and lung function measurements. 
 
Figure 3.11 No correlation between RBM thickness in preschool wheezers and 
(i) FEV1 and (ii) FeNO50 at school age  
Spearman r=0.42, p=0.066
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3.4 Summary of findings RBM thickness 
Review of hypothesis 
Preschool wheezers who persistently wheeze and have asthma at school age have 
increased RBM thickness on endobronchial biopsy compared to those wheezy 
preschool children whose symptoms subsequently regressed.  
 
In summary;- 
 Measurement of RBM thickness by a second blinded observer (RO’R) 
confirmed previous findings showing increased RBM thickness in severe 
recurrent wheezers when compared with non wheezing controls 
 There was no difference in preschool RBM thickness as measured by RO’R 
when compared with presence or absence of school age asthma. The SS 
measurements showed increased RBM thickness in preschool wheezers who 
developed school age asthma. Both observers had similar coefficients of 
variation of RBM measurements, and this discrepancy (which likely arises 
because different sections were analysed by the two observers) makes RBM 
thickness unlikely to be a robust predictor of school age asthma in the 
individual child. 
 RBM thickness at preschool age correlated with the number of lifetime 
hospital admissions with wheeze (at the time of the research visit) 
 
3.5 Discussion:-Preschool RBM thickness and school age asthma 
RBM thickness in severe recurrent wheezy preschool children, at least as measured 
by RO’R, did not discriminate which children developed school age asthma, 
suggesting RBM thickness in preschool wheezers may relate to current symptoms 
rather than future asthma risk. Even the SS measurements showed a marked 
overlap between the two groups. RBM thickness in severe recurrent CW (median 4.6 
µm [3.1-7.3µm]) is greater than controls (median 3.5µm [1.2-5.99 µm]), but much 
less than older children with severe asthma (median 8.2µm [range 5.4–11.1µm])(116) 
and adults with asthma (8.1µm [5.8–10.0µm])(116). This suggests remodelling is not 
yet fully developed in the RBM of children with preschool wheeze which may reflect 
symptom duration. It would have been very interesting but unethical to repeat the 
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endobronchial biopsy at time of asthma diagnosis to correlate RBM thickness at 
preschool and school age.  
 
There was a discrepancy between measurements of RBM thickness by RO’R and 
SS related to school age asthma status. The CoV for SS (mean 7%) for 
measurement of RBM thickness was very similar to RO’R (mean 6%). It is likely 
observers did not measure the same section for a given child and there can be 
between biopsy variability for the same child as reported by SS which may have 
contributed to the different results. The between biopsy variability for RBM thickness 
was assessed by SS for 6 patients who had 2 good quality biopsies. The results are 
shown in table 3.4. 
  
Table 3.4: Between biopsy variability of RBM thickness for 6 preschool 
children as measured by SS  
Subject  
number  
RBM thickness (μm) 
Biopsy 1 Biopsy 2 
1 6.0 5.7 
2 4.9 4.9 
3 3.9 3.8 
4 4.3 4.8 
5 3.3 4.0 
6 6.0 7.0 
 
Unfortunately but unavoidably, there was also a significant difference between age of 
EB in children with RBM measured who developed asthma at school age (median 
age 38.5 months) and those who did not develop asthma (median age 17 months), 
p=0.002. The natural history of RBM development has been recently established and 
shows that RBM thickness increases during infancy, childhood and adolescence until 
age 17 years, figure 3.12(113). In particular the rate that RBM thickness increase is 
greater in children less than 6 years old than in children older than 6 years(113). Data 
suggests that RBM thickness should increase at least 1µm between age 1 year and 
2.5 years, which is approximately the difference in RBM thickness and difference in 
age at EB seen between children with and without school age asthma as measured 
by SS. This suggests that the increased RBM thickness in the preschool years seen 
in those who went on to develop school age asthma may be related to age rather 
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than airway remodelling. However, a larger study with age-matched controls is 
required to confirm or refute this. 
 
Figure 3.12: RBM thickness related to age in post-mortem sections from 
children without known lung pathology (Adapted from Tsartsali et al)(113) 
 
 
 
Severity of wheeze (as measured by the number of overnight hospital admissions 
with wheeze over the child’s lifetime to point of research visit) was related to RBM 
thickness at preschool age (Spearman r=0.56, p=0.001). This observation is 
vulnerable to recall bias over a 7-10 year time period. Other markers of severity 
including frequency of wheeze over the past 12 months or current use of ICS were 
not related to RBM thickness at preschool age. There is no obvious reason why Sacin, 
a measure of ventilation inhomogeneity in the acinar airways correlated with RBM 
thickness, measured in larger, very proximal airways.  
 
RBM thickness did correlate weakly with FeNO50 at age 7 years, but only in the 
children who had wheezed at preschool age. This was similar to the findings when 
some of this group of wheezers were followed up at 5 years(63). There was also a 
non-significant association between FEV1 z score at school age and RBM thickness 
at preschool age in the preschool wheeze group, with those with increased RBM 
thickness having better lung function. It is unlikely this is related to a protective effect 
of RBM thickness on the airway as suggested by other studies(223;226), but rather that 
several of the wheezy children had other lower airway pathology at school age. 
Increased RBM thickness has been reported in adults with chronic cough(221) and in 
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children with bronchiectasis (related to cystic fibrosis)(219). Finally, the small numbers 
preclude definitive conclusions. 
 
At preschool age there was a large overlap in RBM thickness between wheezers and 
controls suggesting that RBM thickness alone was unlikely to be a good predictor for 
future asthma. This was confirmed when preschool RBM thickness was compared 
with school age asthma status. The next hypothesis to be tested was that individual 
components of the RBM may be a more sensitive marker of future asthma in 
preschool wheezers. 
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Chapter 4 
Components of the reticular basement membrane in 
preschool wheezers and their relationship  
with childhood asthma. 
 
4.1 Components of the reticular basement membrane 
The extracellular matrix (ECM) which includes the interstitial matrix and the RBM is 
composed of macromolecules that form the scaffolding of the airways. It consists of 
a complex network of proteins which affect many aspects of cellular behaviour 
including proliferation, differentiation, survival, adhesion and migration(227). Increased 
thickness of the reticular basement membrane results from increased extracellular 
matrix protein deposition. There are many extracellular matrix glycoproteins including 
collagen I, III and V, fibronectin, laminan, versican and tenascin(227). The quantity of 
ECM proteins is increased in asthmatic airways(227). This may be due to increased de 
novo protein synthesis, decreased activity of their degrading enzymes, i.e. matrix 
metalloproteinases (MMPs), or increased activity of tissue-specific inhibitors of 
metalloproteinase (TIMPs).  
 
Tenascin-C (TN-C) is a particularly relevant ECM glycoprotein as its expression is 
increased in lung development and in inflammatory, fibrotic and neoplastic diseases 
but is almost absent otherwise. Five isoforms of tenascin (TN) have been 
characterised, namely TN-C, TN-R, TN-X, TN-Y and TN-W(228). TN-R is found in the 
developing and adult nervous system, TN-X is primarily found in loose connective 
tissue, TN-W is found in the kidney and in developing bone and TN-Y in the 
developing skeleton of zebra fish(141). TN-C was the first to be identified and it is the 
best studied(229). It is TN-C that is referred to throughout this thesis. TN-C was 
selected for further investigation, in particular since its absence in health and 
presence in disease states in the airways suggested it may be a more accurate 
predictor of future asthma in preschool children than RBM thickness alone(141). 
Limited biopsy tissue was available for staining and for this reason TN-C was the 
only component of the RBM that could be studied. 
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4.1.2 Tenascin-C expression during foetal lung development 
During foetal development TN-C is expressed maximally at 12-23 weeks gestation, 
particularly at sites of airway branching during the canalicular phase (17-23 weeks) 
of development(230). During the saccular phase (24-40 weeks) of development TN-C 
expression is weaker but still present below the alveolar and bronchiolar epithelium, 
and strongly expressed in the RBM(230;231). It has been suggested that the increased 
expression of TN-C in basement membranes surrounding the glandular, acinar and 
vascular structures of the developing lung might have an important function in the 
morphogenesis of the dividing bronchial and vascular trees, and in determining 
whether specific cells will adhere to the matrix(231). This is further supported by 
evidence from embryonic mice TN-C(-/-) who had significantly decreased airway 
branching when compared to wild type mice(232).  
 
4.1.3 Tenascin-C expression in the lung during health and disease 
TN-C expression is associated with tissue injury and repair(141). TN-C has also been 
shown to be specifically and transiently upregulated during acute inflammation and 
persistently expressed in chronic inflammation(141). In the lung increased TN-C 
expression in the pleura can be used as a marker of active pleural involvement in 
inflammatory and fibrotic diseases(233). The most positive areas of TN-C 
immunoreactivity are newly formed areas of fibrosis(233), suggesting it may be active 
in acute inflammation. TN-C concentration in the airway epithelial lining fluid is 
increased in patients with usual interstitial pneumonia, sarcoidosis, and extrinsic 
allergic alveolitis(234). It is also widely expressed in the stroma of lung 
carcinomas(235;236). 
 
4.1.4 Tenascin-C expression in the airways in asthma 
TN-C expression is also increased within the RBM in asthma(142-144). TN-C 
expression within the RBM is elevated in adult asthmatics when compared with non-
asthmatic, non-atopic controls(144). TN-C thickness within the RBM was shown to be 
significantly thicker in atopic when compared to non-atopic adult asthmatics (7.6 vs 
6.3µm)(143). The thickness of TN-C correlated with eosinophils, T lymphocytes, 
macrophage counts and IL-4 positive submucosal cells only in atopic asthmatics(143). 
Acute inhalational allergen challenge of atopic adult patients with asthma increased 
collagen synthesis and TN-C deposition within the RBM(237). This was associated 
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with increased eosinophilic inflammation and evidence of IL-4 / IL-13 expression in 
the airway epithelium(237). However, TN-C deposition within the RBM was only 
increased at 24 hours post allergen challenge, and had returned to baseline levels 
by 7 days(238).  
 
It has been shown that TN-C(-/-) mice that had been sensitised and challenged with 
ovalbumin had decreased airway hyperreactivity, NF-kB activation and 
concentrations of monocyte chemoattractant protein-1, IL-5, IL-13, 
metalloproteinase-9 and IgE in the bronchoalveolar lavage fluid compared to their 
wild type counterparts(239). The authors suggested that future work should explore 
TN-C in the pathogenesis of bronchial asthma(239).  
 
The next hypothesis tested was that TN-C expression 
1) is greater in preschool children with recurrent wheeze when compared with age 
matched controls. 
2) is greater in preschool children with recurrent wheeze who develop future asthma 
 
Aims and objectives 
1. To establish the most discriminative and repeatable method of measuring TN-
C expression within the reticular basement membrane in endobronchial 
biopsies archived in paraffin. 
2. To compare TN-C expression at preschool age between wheezers and 
controls and with presence or absence of asthma at school age 
 
4.2.1 Methods- Tenascin–C immunohistochemistry staining 
All previous studies in adult asthmatics quantifying TN-C expression in the RBM 
have used snap frozen endobronchial tissue and either immunofluorescence(142-144) 
or immunohistochemistry(220). All preschool endobronchial biopsies archived from 
2002-2005 had been formalin fixed and paraffin embedded and there was no frozen 
tissue available. However, TN-C expression has been measured in paraffin 
embedded neoplastic breast tissue(240), myocardium(241), glomeruli(242) and the 
developing fetal lung(230;231;243). This is the first attempt at quantifying TN-C in the 
RBM of endobronchial biopsies processed in paraffin.  
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Details of endobronchial biopsy procedure, processing and evaluation are given in 
chapters 2 and 3. The preschool endobronchial biopsy tissue studied in this chapter 
was processed and stained by Dr J Zhu. Unstained tissue sections (5µm) from 
biopsy blocks were plated on poly-l-lysine-coated glass slides then deparaffinised in 
xylene and dehydrated. Next all sections were treated for 30 min with 1.5% hydrogen 
peroxide in distilled water to quench endogenous peroxidase activity. Sections were 
rinsed and bathed in phosphate buffered saline (PBS) twice for 5 minutes each time 
and then treated with 10% normal goat serum in PBS for 20 minutes. Slides were 
then incubated with mouse monoclonal antibody to tenascin-C (T2H5 ABCAM cat: 
3970)(240) dilution 1:40 with PBS at room temperature for 2 hours. Sections were 
again rinsed and bathed in PBS twice for 5 minutes each time. The sections were 
then incubated with HRP labelled polymers (which did not contain avidin-biotin 
complex) conjugated with secondary antibodies at room temperature for 40 minutes 
(Dako EnVision+ system, HRP, K4007). Rinsing and bathing with PBS twice for 5 
minutes was repeated. The antigen–antibody reaction was visualized using 3,3′-
diaminobenzidine tetrahydrochloride (DAB) substrate chromagen which results in a 
brown coloured precipitate at the antigen site. The slides were then rinsed in distilled 
water and counterstained in Harris’ H&E stain, dehydrated and mounted.  
 
4.2.2. Quantification of tenascin-C within the reticular basement membrane  
It was important to establish a method that was both discriminative and repeatable in 
quantifying TN-C expression within the RBM of immunohistochemically stained 
sections. Three different methods were used -  
1) measurement of TN-C thickness using computer aided image analysis 
2) a semi-quantitative method using a picture grading system 
3) measurement of TN-C using stereology techniques.   
 
All biopsies were identified by number only. TN-C was measured in all sections that 
included recognisable epithelium, RBM and subepithelial mucosa. Leica DM2500 
microscope, Leica DFC 300fx camera and LEICA Qwin version 3 software were 
used for all 3 methods. 
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4.2.2.1 Method 1- Measurement of tenascin-C thickness using computer aided 
image analysis 
The mean of all TN-C thickness measurements at 20µm intervals along the whole 
RBM, using computer aided image analysis were calculated. This method has 
previously been used to measure total RBM thickness(225), see chapter 3. The first 
measurement was taken at the upper right hand corner and the biopsy followed 
anticlockwise with subsequent measurements at 20 µm intervals for the whole length 
of the RBM. At each point a line perpendicular to the length of RBM was drawn, 
figure 4.1 (a), and TN-C was considered positive if any level of staining was present, 
figure 4.1 (b). ‘0’ was recorded if no staining for TN-C was present, figure 4.1 (c). 
The mean of all measurements was taken to represent RBM TN-C thickness for that 
biopsy. 
 
Figure 4.1: (a): Measuring tenascin-C thickness  
TN-C thickness is measured perpendicular to the length of RBM 
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Figure 4.1: (b): Tenascin-C positive staining in the RBM (magnification x400) 
 
 
 
 
 
 
Figure 4.1: (c) Tenascin-C negative staining in the RBM (magnification x400) 
 
 
 
 
 
4.2.2.2 Method 2- Semi-quantitative measurement of tenascin-C using a picture 
grading system  
A semi quantitative scale was used to grade the TN-C positive proportion of RBM in 
the biopsy. Similar scales have been used to quantify TN-C expression in the 
myocardium of patients with myocarditis(241), the glomeruli of adults with IgA 
nephropathy(242) and within the RBM of adults with COPD and asthma(220). Each 
   30µm 
 144 
section was photographed at magnification X100 and re-numbered by an 
independent observer (Dr N Ullmann). Where more than one photomicrograph of a 
section was taken it was labelled with the same number and the pictures were 
reviewed together. The photographs were scored 0, 1 or 2 using a picture coded 
scale one week later, figure 4.2. Grade 0 represented <1/3 of the RBM stained 
positive for TN. Grade 1 represented 1/3-2/3 of the RBM stained positive for TN and 
grade 2 represented > 2/3 of the RBM stained positive for TN-C. They were 
assessed by a single blinded observer (RO’R) on a computer screen with the picture 
scale as reference. The same photographs were again reassessed by RO’R using 
the same method 1 week and 1 month later, in each case blinded to any previous 
measurements. 
 
Figure 4.2: Reference pictures used to grade tenascin-C expression in the 
reticular basement membrane using a semi quantitative scale  
 
 Grade 0: <1/3 of the total RBM stained positive for tenascin-C 
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 Grade 1: 1/3-2/3 of the RBM stained positive for tenascin-C 
 
 
 
 Grade 2: ≥ 2/3 of the RBM stained positive for tenascin-C 
 
 
 
4.2.2.3 Method 3- Measurement of tenascin-C using stereology 
Stereology is the study of the three-dimensional properties of objects usually seen in 
two dimensions. Thus, by using stereology-based techniques, one can obtain 
quantitative three-dimensional information from measurements in the two 
dimensions of conventional histology(85). The biopsy section was examined using oil 
emersion at magnification x1000. The image was projected onto a computer screen 
and a virtual graticule containing 100 points each a fixed distance apart was overlaid 
on the top right hand corner of the biopsy at random but it was ensured that at least 
TN 
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one point landed on the RBM, figure 4.3. The graticule was then moved along the 
total length of the RBM. Care was taken not to overlap the graticule overlay by using 
biopsy landmarks. 
 
Figure 4.3: Tenascin-C staining overlayed by graticule (magnification X1000) 
 
 
Only TN-C positive and negative points within the RBM were counted. A point on the 
graticule was considered positive if it overlay an area stained positive for TN-C. Two 
quadrants or more, or the top right hand quadrant had to overlay an area stained 
with TN-C to be considered positive, figure 4.4. Similarly the same criteria applied to 
all points falling on the RBM. The number of points that were TN-C positive were 
expressed as a proportion of the total number of points on the RBM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20µm 
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Figure 4.4: Criteria for tenascin positive and negative points. 
A point was positive if it overlayed 2 or more quadrants or the upper right quadrant 
  +    +   +   + 
A point was negative if it overlayed 1 or less than 1 single quadrant other than the 
upper right quadrant 
  +    +   +  +  
 
4.2.3 Repeatability of measurements 
The intra-observer repeatability of measurements was calculated by assessing the 
same biopsy 3 times at least a week and a month apart, and represented as the 
CoV. This was done for the same 4 sections using both methods 1&3. The mean of 
the 4 measurements of the CoV was used as a measure of repeatability for that 
method. The intraclass correlation coefficient was used to measure the repeatability 
of method 2 where all biopsies were assessed using a semi-quantitative scale a 
week and a month apart.  
 
4.3 Results 
4.3.1 Biopsy size and number 
Biopsies of good quality to assess RBM TN-C were available in 48 preschool 
children, of which there were 31 wheezers (median age 24 months) and 8 controls 
(median age 19.5 months). Wheezers were subdivided into CW (n=15, median age 
31 months) and RW (n=16, median age 15.5 months). Length of RBM was 
measured at magnification x100 using computer aided image analysis. There was no 
significant difference in the length of RBM measured between wheezers and controls 
(p=0.29). RBM thickness measured by RO’R and not that measured by SS in 2007(9) 
was compared with RBM TN-C expression.  
 
X
X 
X
X 
X
X 
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Table 4.1: Number of patients in each group with at least 1 biopsy of good 
quality for (i) tenascin measurement, (ii) reticular basement membrane 
thickness 
 CW RW Control P 
Number of patients with biopsies available  
for TN measurement  
 
Number of patients with good quality biopsy 
for RBM and TN measurement 
 
Median length of RBM in (µm) 
(Tenascin immunostained biopsies) 
Range (µm) 
15 
 
 
15 
 
 
1509 
 
729-6412 
 
16 
 
 
15 
 
 
2130 
 
881-5248 
8 
 
 
7 
 
 
1760 
 
998-2233 
 
 
 
 
 
 
0.4 
 
 
4.3.2 Comparing methods of quantifying TN-C 
 
1. To compare 3 methods of quantifying TN-C expression within the RBM in 
endobronchial biopsies from preschool wheezers and controls to find the 
most discriminative and repeatable method for measuring TN-C  
 
Method 1- Measurement of tenascin-C thickness using computer aided image 
analysis  
There was no significant difference between the 3 groups at magnification X400 
(p=0.07), figure 4.5 (a). The median TN RBM thickness did show a trend for higher 
values in CW (2.7µm) when compared with controls (0.89µm) and RW (0.85µm), 
p=0.07. The CoV for biopsies from 4 children measured on 3 occasions a week and 
a month later was 34%, 29%, 8.8% and 8.25% giving a mean of 20%.  
 
Measurement of TN-C thickness at higher magnification (x1000) improved 
repeatability of measurements and again showed a trend for a difference between 
CW (2.35µm) and controls (0.96µm) (p=0.05), figure 4.5 (b). However, Dunns post 
test did not detect a difference between confirmed CW, RW or controls. Mann 
Whitney U test detected a significant difference between CW and controls (p=0.02). 
Repeatability was also improved at X1000, the coefficient of variation in the same 4 
biopsies was 29%, 10.5%, 3% and 1.1%, giving a mean of 10.9%. RBM TN-C 
 149 
measurements at magnification 400 and 1000 correlated well (Spearman r =0.91, (CI 
0.84-0.95), p<0.0001). 
 
Figure 4.5: Measurement of tenascin-C thickness within the reticular basement 
membrane of endobronchial biopsies at (a) magnification x400 and (b) 
magnification x1000 
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(b) Magnification X1000 
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Method 2 – Semi-quantitative method using a picture grading system  
The scale completely failed to differentiate the groups, figure 4.6. Repeatability for 
this method was measured using the ICC, a week and a month later. All biopsies 
were assessed on each occasion. The ICC was 0.93 (p<0.001) and 0.87 (p<0.001) 
at 1 week and 1 month respectively. 
 
Figure 4.6: Tenascin-C expression quantified by a semi quantitative scale. 
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Method 3:- Measurement of tenascin-C using stereology techniques  
The third method assessed the proportion of the RBM that stained positive for TN-C. 
This showed significant difference between CW (median 83%) and controls (median 
38%) (p=0.04), figure 4.7(ii). Although the Kruskal Wallis test was significant 
(p=0.04), Dunns post test did not detect a difference between the 3 groups. Mann 
Whitney U test detected a difference between CW and controls (p=0.04). 
Repeatability for this method was assessed measuring the same 4 biopsies on 3 
occasions a week and a month apart. CoV were 23%, 12.5%, 1% and 2.5% 
respectively, mean of 9.75%.  
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Figure 4.7: Proportion of the RBM occupied by tenascin-C measured using 
stereology techniques  
p=0.25
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Summary 
Intra-observer repeatability (CoV) was more reliable at higher magnification (x1000) 
for method 1 (measuring TN-C thickness) and method 3 (measuring proportion of 
TN-C occupying the RBM), table 4.2, as it was easier to distinguish TN-C positive 
and negative areas of the RBM at higher magnification. Both methods also showed 
TN-C expression to be increased in CW when compared with controls when 
quantified as TN-C thickness within the RBM and proportion of the RBM occupied by 
TN-C. Method 2 (semi-quantitative scale) had excellent repeatability (ICC= 0.87) but 
very poor group discrimination. Either method 1 or 3 was therefore suitable for 
quantifying TN-C at magnification 1000, as both have similar repeatability. It is these 
results that are reported throughout the rest of the analysis. 
 
Table 4.2: Repeatability of measuring of tenascin-C thickness at x400 & 1000, 
and of measuring the proportion of tenascin-C occupying the reticular 
basement membrane using stereology x1000. 
 
 Coefficient of Variation (%) 
TN thickness x400 TN thickness x1000 Stereology x1000 
Biopsy 1 
Biopsy 2 
Biopsy 3 
Biopsy 4 
34 
29 
8.8 
8.25 
29 
10.5 
3 
1.1 
23 
12.5 
1 
2.6 
Mean 20 10.9 9.75 
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4.4 RBM Tenascin-C compared by viral and multiple-trigger wheeze 
phenotypes 
There was no difference in TN-C thickness (n=6, 1.59(1.04-2.64)µm vs n=25,1.66(0-
7.2)µm, p=0.98) or proportion of RBM TN-C (n=6, 82.5 (43.5-92.9)% vs n=25, 57 (0-
100)%, p=0.26) between children with viral or multiple-trigger wheeze at preschool 
age, figure 4.8. 
  
Figure 4.8: No difference between (i) RBM tenascin-C thickness and (ii) 
proportion of RBM tenascin-C between viral and multiple-trigger wheezers at 
preschool age 
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4.5 Inhaled corticosteroids and RBM tenascin-C 
There was no difference in RBM TN-C thickness between those treated with ICS 
(n=16, median 1.44(0-7.2)µm) at time of EB and those who were not treated with 
ICS (n=15, median 2.28 (0-4.25)µm), p=0.62, figure 4.9 (i). Similar results were seen 
for proportion of RBM TN-C. Four of the children not on ICS had been treated with 
oral corticosteroids in the month prior to biopsy. However there was still no 
difference when children on oral corticosteroids were included in the analysis. 
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Figure 4.9: No relationship between inhaled corticosteroids and (i) RBM 
tenascin-C thickness and (ii) proportion of RBM tenascin-C 
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Table 4.3: Summary of reticular basement membrane tenascin-C composition 
in preschool wheezers compared with preschool controls. There is an increased 
proportion of RBM tenascin-C in preschool wheezers when compared to controls. 
 Wheezers 
n=31 
 
Controls 
n=8 
 
P 
 CW n=15 RW n=16 
Median age (months) 
(Range) 
24 
(7-58) 
 
19.5 
(11-42) 
0.9 
CW=31 
(7-57) 
RW=15.5 
(8-58) 
0.23 
Male/ Female 17/14  
4/4 
1 
 CW=7/8 RW=10/6 
 
 0.65 
 
Inhaled corticosteroids* 
Median BDP (mcg)* 
(Range mcg) 
n=16 
800 
(200-2000) 
 
n=3 
500 
(200-500) 
0.2 
CW n=8 
900 
(500-2000) 
RW n=8 
400 
(200-1000) 
0.025 
Magnification x400 
TN-C thickness (µm) 
Median (range) 
 
1.89 
(0-7.47) 
 
0.895 
(0-2.77) 
0.19 
CW=2.74 
(0-7.47) 
RW=0.85 
(0-5.03) 
0.07 
Magnification x1000 
TN-C thickness (µm) 
Median (range) 
1.66 
(0-7.2) 
 
0.97 
0-2.7 
0.32 
CW=2.35 
(0.29-7.2) 
RW=1.02 
(0-4.25) 
0.056 
Magnification x1000 
Proportion of RBM TN-C 
median % 
(Range) 
61.5 
(0-100) 
 
41.2 
(0-92) 
0.25 
CW=82.9 
(12.6-100) 
RW=37.7 
(0-94.7) 
0.04 
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4.6 Relationship between reticular basement membrane tenascin-C expression 
and reticular basement membrane thickness  
There was a weak correlation between RBM TN-C thickness (method 1) and total 
RBM thickness (Spearman r=0.34, CI= (0.012-0.61), p=0.04, figure 4.10 (a). 
However, comparing RBM TN-C (method 3) and RBM thickness (Spearman r=0.33, 
p=0.04), the confidence interval included zero (-0.001-0.60) showing it is not 
significant, figure 4.10 (b).   
 
Figure 4.10: Relationship between tenascin-C and total reticular basement 
membrane thickness when measured as (a) tenascin-C thickness within the 
reticular basement membrane, and (b) as the proportion of tenascin-C 
occupying the reticular basement membrane. 
     (a)                                                                  (b) 
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4.7 Preschool reticular basement membrane tenascin-C and school age 
asthma 
RBM TN-C thickness (method 1) at preschool age was similar in children who 
developed school age asthma (n=9, median 2.27 [0.29-7.2]µm) and children who did 
not develop asthma (n=20, median 1.35 [0-3.67]µm), p=0.1, figure 4.11 (a). The 
proportion of the RBM occupied by TN-C was also similar in those that did and did 
not develop asthma (method 3) (median 61.5 [12.6-100]%) vs (median 50.4% [0-
94.7]%), p=0.11, figure 4.11 (b). When preschool wheezers alone were considered, 
there was no difference in RBM TN-C thickness between those who developed 
asthma (median 2.27µm [range 0.29-7.2]µm) and those who did not (median 1.99µm 
 155 
[range 0 -3.67]µm), p=0.18. Similarly, there was no difference in the proportion of 
RBM TN-C between those preschool wheezers who developed school age asthma 
(median 61.5% [range 12.6-100]%) and those who did not (median 62.3% [range 0-
94]%), p=0.19. There was however a significant difference between age at EB in 
children who had RBM TN-C measured who developed school age asthma (42 [24-
57] months) and those who did not (17.5 [7-55] months), p=0.003. 
 
Figure 4.11:  
a) No difference in reticular basement membrane tenascin-C thickness 
(method 1) at preschool age in children who developed school age 
asthma when compared with those who did not 
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b) No difference in the proportion of reticular basement membrane 
tenascin-C (method 3) at preschool age between children who 
developed asthma by school age and those who did not 
p=0.11
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4.8 Tenascin-C expression within the reticular basement membrane and age 
While TN-C expression is absent in developed lungs, the age at which normal 
developmental TN-C expression ceases in the lungs is unknown. There was no 
relationship between RBM TN-C expression and age in the controls, figure 4.12. 
However, the numbers studied (n=8) are very small. It was not possible to assess 
the relationship of TN-C expression within the RBM with age further because of 
subsequent difficulties with immunostaining described below. 
 
Figure 4.12: Relationship between age and (a) tenascin-C thickness within the 
reticular basement membrane and (b) the proportion of tenascin-C occupying 
the reticular basement membrane in control preschool children 
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(b) 
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4.9 Difficulties with tenascin-C staining in paraffin embedded tissue 
The sections from the severe preschool wheezers and age matched controls were 
stained successfully in 2 batches in 2007. The immunohistochemistry run was kept 
constant on both occasions. It had been planned to explore the role of TN-C in older 
children with severe asthma and also the natural history of TN-C expression in the 
RBM of infants and children. However, subsequent immunohistochemical staining for 
TN-C expression in the RBM of paraffin embedded tissue from adult resected 
neoplastic lung tissue, and from endobronchial biopsies from older children with 
severe asthma failed on several occasions in 2009 and 2010. Endobronchial tissue 
archived in paraffin both before and after 2005 was used. The antibody initially used 
in 2007 had been used up. The experiment was repeated by Dr J Zhu using two 
further antibodies for TN-C from batches of mouse monoclonal antibody from the 
original source (T2H5 cat no. abcam ab3970) using the previously successful 
method, but still no TN-C staining was found on the previous positive controls of 
tonsillar tissue. 
 
A second investigator, Mr T Oates also tried staining the paraffin embedded 
endobronchial tissue by changing reagents and the initial protocol in stages with no 
success. The changes to the initial experiment are listed below. 
1. The first change made was to dewax the slides from Histoclear® through alcohol 
to PBS and this was done for all subsequent experiments.  
2. After dewaxing sections an antigen retrieval step was added. The sections were 
microwaved in pre-heated 10mM sodium citrate (2.941g in 1 litre milliQ water) on 3 
occasions for 3 minutes. After each 3 minutes of heating a small amount of citrate 
liquid was poured out and topped up.  
3. The incubation period with mouse monoclonal antibody to tenascin-C (T2H5 
ABCAM cat: 3970) was increased to 12 hours.  
4. The sections were incubated with an avidin-biotin complex using biotinylated 
mouse IgG (Vectastain Immunoperoxydase Elite ABC kit Cat No. PK6102, Vector 
Laboratories) instead of labelled polymer HRP (Dako EnVision+ system, HRP, 
K4007).  
 
 158 
After these changes to the original protocol failed, a second TN-C mouse antibody 
(Clone T2H5 Monosan, Cat No. MON7025) from a different manufacturer was used 
throughout all the following experiments (numbers 5-7). 
5. After dewaxing the sections the slides were left for 1 hour in PBS containing 1% 
saponin to permeabilise the cell membranes. The same protocol was followed as in 
the original experiment except PBS containing 1% saponin was used throughout all 
incubations and washes. The slides were incubated with tenascin mouse antibody 
(Clone T2H5 Monosan, Cat No. MON7025) overnight.  
6. Antigen retrieval was performed by incubating the sections with pronase (1mg/ml) 
at room temperature for 10 minutes (Sigma Aldrich, Cat No. 81748).   
7. Finally, antigen retrieval was tried using Tris ethylenediaminetetraacetic acid 
(EDTA) after dewaxing slides. The sections were treated with pre-heated Tris-EDTA 
plus 0.05% Tween (pH 8.0) and heated for 4 times for 5 minutes topping up with 
more Tris-EDTA after each 5 minutes. Slides were left to cool for 20 minutes after 
treatment. This initially stained positive for tenascin-C on the tonsillar positive control 
with completely clear negative IgG controls, figure 4.13 (a). However on repeating 
the experiment 3 days later there was no tenascin-C staining of the same tonsillar 
controls, figure 4.13 (b). This suggests that TN-C monoclonal antibody is unreliable 
in paraffin embedded tissue.  
 
Figure 4.13:  
(a) Tenascin-C positive staining of the tonsillar tissue 
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(b) Absent tenascin-C staining of the same tonsillar tissue 3 days later. 
 
 
 
 
Part of the difficulty in achieving consistent runs with the antibody may have been 
because the endobronchial tissue had been processed in paraffin. In order to 
compare TN-C measurement in paraffin sections and frozen tissue, 2 pieces of 
adjacent lung tissue from excised solid lung tumours (n=5) were immersed in 
formalin and preserved in paraffin, or snap frozen (-80C). The biopsies were snap 
frozen by submerging in thawing iso-pentane, which had previously been frozen 
solid in liquid nitrogen after mounting in optimum cutter (Bayer UK Ltd, United 
Kingdom) on a cork base. They were then stored at -80C. 5μm sections were cut 
from the frozen biopsies and were stained using the immunoperoxidase protocol 
(Vectastain Immunoperoxidase Elite ABC kit Cat No. PK6102, Vector Laboratories). 
The sections were incubated for 1 hour at room temperature with tenascin mouse 
antibody (Clone T2H5 Monosan, Cat No. MON7025). Three of the 4 sections with 
RBM stained strongly positive for TN-C despite no staining having been evident in 
repeated experiments where immediately adjacent tissue had been processed in 
paraffin.  
 
The conclusion is TN–C staining using immunohistochemistry is not consistent in 
paraffin processed tissue. It is unclear despite repeated experiments whether this is 
due to length of tissue fixation or to a change in tenascin antibody since 2005. For 
this reason a decision was made not to proceed with TN-C in further paraffin 
embedded tissue sections. 
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4.10 Summary of findings 
Review of hypothesis 
School-aged children with asthma have evidence of airway remodelling and airway 
inflammation in endobronchial biopsies taken while symptomatic at preschool age, 
when compared to school-aged children without asthma. 
 
TN-C within the RBM was greater in preschool children with severe recurrent 
wheeze when compared with age matched controls, but did NOT discriminate which 
children developed future asthma. 
 
In the initial, successful staining runs: 
 Measurement of TN-C thickness was both discriminative and repeatable using 
stereology techniques at magnification X1000. Higher magnification aided 
discrimination of TN-C positive areas within the RBM. TN-C staining in some 
biopsies extended from the RBM into the surrounding stroma making it 
difficult to quantify at lower magnification. 
 TN-C expression within the RBM is increased in CW compared with controls, 
(p=0.04)  
 There was no difference in RBM TN-C at preschool age between children that 
developed asthma and those that did not.  
 However, TN-C staining in paraffin embedded tissue was not repeatable in 
subsequent runs. 
 
4.11 Discussion: RBM tenascin-C expression 
Strengths 
This is the first study to stain for TN-C in the RBM of preschool wheezers and to 
relate this to the presence or absence of school age asthma. Although RBM TN-C 
expression was increased in preschool confirmed wheezers when compared to 
preschool controls, p=0.04, it did not discriminate between those children who 
developed asthma at school age and those who did not develop asthma. This 
suggests that TN-C expression, similar to RBM thickness, may relate to current 
symptoms rather than future asthma prognosis. Importantly, there was no difference 
in age between wheezers and controls at the time of EB for this part of the study, 
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suggesting the differences in RBM TN-C expression directly related to wheezy 
symptoms. However, the reported thickness of TN-C within the RBM (6-7µm) 
measured in adult studies(143;144) was significantly greater than in the preschool 
wheezers (2.35µm). There are three possible reasons for this; 1) different 
methodology used in adult studies, immunofluorescence in frozen sections rather 
than immunohistochemistry in paraffin sections(142-144); 2) development of TN-C 
within the RBM continues throughout childhood similar to RBM development(113); 3) 
longer duration of symptoms in adults when compared to preschool children. The 
data reported here are not able to distinguish between these possibilities. 
 
This is the first study to relate TN-C within the RBM to total RBM thickness. Previous 
adult studies did not measure TN-C as a proportion of the RBM or relate TN-C 
expression in the RBM to its thickness(142-144). The role of TN-C in contributing to 
RBM thickening is unknown. TN-C knockout mice sensitised with ovalbumin had 
decreased airway hyper-reactivity and airway goblet cells when compared with wild 
type mice(239). However, other markers of airway remodelling such as peri-
bronchiolar collagen deposition were not measured. Adult asthmatics showed no 
increase in collagen III (the predominant collagen in the RBM) but an increase in TN-
C 24 hours post allergen challenge, but after 7 days the reverse was shown, TN-C 
levels had returned to baseline and collagen III levels significantly increased(238). This 
suggests that increased RBM TN-C expression and RBM thickening may occur via 
different mechanisms.  
 
Limitations  
The biggest limitation of this study is that TN-C staining is not consistent in paraffin 
embedded tissue. Children in whom TN-C was quantified within the RBM, and who 
developed asthma were older at time of EB when compared to those who did not (42 
vs 17.5 months). The natural history of TN-C expression in early childhood is 
unknown and it was not possible to characterise the relationship of RBM TN-C with 
age further because of difficulties with immunohistochemistry staining as previously 
described. TN-C is absent in adult lungs but present at birth(230). It is likely that it is 
still present in the lungs during the alveolar phase (where terminal saccules, alveolar 
ducts, and alveoli increase in number), and it is not known when this is complete. 
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Although the control subjects in the current study (median 41%, range 0-92%) had 
significantly less TN-C within RBM when compared with CW (median 83%, range 
12.6-100%), only 1 control child had no detectable RBM TN-C. The thickness of the 
RBM TN-C layer was significantly less in the RBM of controls compared to CW 
(0.77µm versus 2.35µm). Interestingly, there was no correlation between RBM TN-C 
and age in controls. This may have been because of the small number of patients 
(n=8), and the likely natural biological variability of TN-C expression in healthy 
controls. However, given the small sample size this study is not able to answer this 
question. 
 
4.11.2 RBM TN-C and corticosteroid use 
RBM TN expression was decreased in atopic adults with seasonal asthma after 4-6 
weeks of treatment with inhaled budesonide (400µg) twice a day(144). In addition, in 
vitro studies have shown fluticasone decreases TN-C expression in human lung 
fibroblasts(244). In the present study, there was no difference in TN-C expression 
between wheezers treated with either inhaled or oral corticosteroids at time of 
endobronchial biopsy and those not on steroid treatment. However, information on 
length of treatment with inhaled corticosteroids and adherence to prescribed therapy, 
prior to endobronchial biopsy is not available, and it is not possible to draw any firm 
conclusions.  
 
4.11.3 Conclusion 
There is considerable overlap between total RBM thickness and RBM TN-C 
expression between preschool wheezers and controls, and neither total RBM 
thickness nor TN-C within the RBM are predictive of asthma at school age. It is 
possible that both RBM thickness and RBM TN-C are related to current symptoms 
rather than future asthma risk, and that neither will be useful in predicting outcome. 
Hence an alternative approach is needed. 
 
Increased airway smooth muscle is another characteristic feature of airway 
remodelling in adults and older children with asthma but has not previously been 
explored in preschool children with severe recurrent wheeze. The next chapter will 
examine smooth muscle in preschool children and determine whether this feature of 
airway pathology is a more accurate predictor of school age asthma. 
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Chapter 5 
Airway smooth muscle in preschool wheezers and the 
development of school age asthma 
 
5.1. Introduction 
ASM is now recognised as playing a pivotal role in the pathophysiology of asthma, in 
particular inducing airway narrowing (bronchoconstriction) in asthma after exposure 
to stimuli such as allergens, infection, exercise or environmental triggers (for 
example, cold air)(245). The ASM cell is also pro-inflammatory and immunomodulatory 
by virtue of producing a variety of cytokines and chemokines and expression of cell 
surface receptors(246). Increased ASM is an established feature of chronic asthma in 
adults and school aged children(114;121). In particular, alterations in ASM are most 
consistently associated with abnormalities in lung function. Increased ASM in school 
aged children with asthma has been significantly related to reversible airflow 
obstruction(118;121) and increased asthma symptoms(118). Bronchial thermoplasty, a 
therapy aimed to reduce ASM mass in the airways using thermal energy has been 
used in adult patients with severe asthma who continue to be symptomatic despite 
maximal medical treatment(247). Randomized controlled clinical trials of bronchial 
thermoplasty have suggested an improvement in quality of life and reduction in the 
rate of severe exacerbations in adults with severe asthma, but have not been able to 
show a reduction in AHR or change in FEV1
(247).  
 
5.1.2 Characteristics of increased airway smooth muscle in asthma 
Increase in ASM mass in children and adults with asthma results both from smooth 
muscle hyperplasia and hypertrophy(110;121;122). Further ultrastructural analysis shows 
that the increase in bronchial muscle bundle mass in asthma is multifactorial and 
includes ASM cell hypertrophy, basal lamina thickening, increased extracellular 
matrix deposits, and collagen deposition within and around ASM bundles(248). 
However, not all authors agree that myocyte hypertrophy is present in all asthmatics 
and suggest it may only be a feature of increasing asthma severity. In a group of 
adults with mild-moderate asthma, Woodruff et al found that there was hyperplasia of 
airway smooth muscle myocytes, but that myocyte hypertrophy was absent(122). 
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However, Benyaoun et al suggested that the increase in ASM size was secondary to 
myocyte hypertrophy with the severest asthmatics having the largest myocyte 
size(110). Most recently it has been shown that hypertrophy occurs in adults with both 
non-fatal (history of asthma but died from other causes) and fatal cases of asthma, 
but hyperplasia is present predominantly in cases of fatal asthma and involves large 
and small airways(249). In school age children with moderate-severe asthma both 
hypertrophy and hyperplasia contributed to increased ASM(121). It is likely that 
increases in ASM mass are secondary to both cell hypertrophy and hyperplasia, and 
that this varies both with asthma duration, severity and phenotype.  
 
5.1.3 Asthma duration and airway smooth muscle 
There are conflicting reports of ASM and asthma duration. A post-mortem study 
showed that ASM was four fold greater in adults aged 40-49 years than age matched 
controls when compared to younger adults (17-23 years) with fatal asthma where it 
was 2 fold greater than age matched controls(123). However a more recent autopsy 
study in fatal and non-fatal asthma suggests that ASM thickness (indexed to the 
perimeter of the basement membrane) in adults with an asthma duration of 7-27 
years was not related to duration of asthma, age of onset of asthma, sex or 
smoking(125). However, these studies measured ASM in different ways which may 
account for the disparity in their results. 
 
5.1.4 Asthma severity and airway smooth muscle 
ASM increases with severity of asthma, with the proportion of smooth muscle in the 
airway increasing with worsening airflow limitation(124;125). In adult asthmatics with 
intermittent, mild-moderate and severe asthma fibroblast numbers and ASM cell size 
were negatively associated with pre and post bronchodilator spirometry(110). The 
thickness of the ASM layer has also been associated with asthma severity as 
determined by oral corticosteroid use, reported asthma hospitalisations and 
frequency of symptoms(125). 
 
5.1.5 Functional effects of increased airway smooth muscle 
Increased airway smooth muscle mass in asthmatics is thought to generate 
increased ASM shortening velocity, leading to increased AHR(250). Muscle 
contraction is triggered by phosphorylation of myosin, catalyzed by calcium / 
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calmodulin-dependent myosin light chain kinase (MLCK), which in turn is activated 
as calcium increases. Airway smooth muscle cells from mild-moderate adult 
asthmatics isolated from endobronchial biopsies showed significant increases in 
maximum shortening capacity when compared with controls, which was associated 
with increases in smooth muscle types of MCLK(251). Myocyte hypertrophy was also 
associated with an increase MCLK in adults with asthma(110), which was further 
amplified in patients with severe persistent asthma(110). Contractile proteins, 
associated with increased ASM shortening velocity, including myosin isoforms, 
transgelin and MCLK are also increased in endobronchial biopsies from adults with 
mild asthma(252). However, in contrast there was no evidence of increased gene 
expression levels of contractile proteins, MCLK or α-smooth muscle actin in adults 
with mild-moderate asthma with ASM hyperplasia but not hypertrophy(122). This may 
suggest that variations in gene expression levels of contractile proteins considered 
markers of a hypercontractile phenotype may vary with disease severity and 
duration. 
 
5.1.6 Smooth muscle signalling pathways 
Early research studies regarding ASM function in asthma focussed on its contractile 
properties, however a growing body of evidence suggests the ASM cell also displays 
proinflammatory and immunomodulatory functions(246). Smooth muscle may 
contribute to bronchial inflammation by secreting a range of mediators, recruiting and 
activating inflammatory cells, such as mast cells, T lymphocytes or eosinophils in 
response to a variety of triggers, including allergens, viruses or bacteria(245;246). In 
particular ASM cells participate in the inflammatory and remodelling process by 
expression of cellular adhesion molecules, receptors for cytokines (e.g., TNF-α), 
chemokines (RANTES, eotaxin, macrophage inflammatory protein 1a and IL-8), and 
Toll-like receptors(246). 
 
Recent evidence suggests that airway constriction itself promotes remodelling, 
presumably via effects on ASM(70). Endobronchial biopsies from adult asthmatics 
showed similar increases in collagen III deposition in the RBM and epithelial TGF-β 
expression 4 days after methacholine (not pro-inflammatory) challenges and allergen 
(pro-inflammatory) challenges(70). ASM cells can release biologically active TGF-β, 
which is involved in various structural alterations such as epithelial cell apoptosis 
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resulting in the detachment of epithelial cells, increased RBM thickness, mucus 
hypersecretion, goblet cell hyperplasia, and angiogenesis(253). TGF-β is increased in 
the airways of patients with severe asthma compared with patients with less severe 
disease(253). 
 
5.1.7 Airway smooth muscle cell migration 
Cell migration could be partly responsible for the pathogenesis of ASM cell 
hyperplasia and hypertrophy in asthma. TGF-β in the presence of platelet-derived 
growth factor, upregulates the expression of MMPs and TIMPs in ASM cells, thereby 
enhancing ASM cell migration toward the epithelium to form new bundles(254). 
 
5.1.8 Development of airway smooth muscle 
Smooth-muscle cells are present in the human fetal trachea, primary, and lobar 
bronchi by the 6th-8th week of gestation(255) and ASM can be identified by light 
microscopy in the small bronchi of fetal airways from 24 weeks gestation(256). Early in 
gestation ASM becomes innervated and responsive to contractile and relaxing 
stimuli, where changes in intraluminal pressure are suggested to produce a 
mechanical signal, resulting in the release of growth factors, signalling molecules, or 
the regulation of gene expression(255). It has been suggested that in particular ASM 
helps regulate early lung morphogenesis by fibroblast growth factor 10 production 
necessary for branching morphogenesis and pulmonary differentiation(257). However, 
little is known about the natural history of ASM postnatally. A single post-mortem 
study measured ASM in the lungs from infants (n=20) without cardiopulmonary 
disease, who died aged 22 weeks postconceptional age to 8 months postnatal age 
and showed a linear increase in ASM when related to airway size(256).  
 
5.1.9 Airway smooth muscle in preschool wheezers 
Although ASM has been extensively investigated in adult asthmatics, little is known 
about its role in children with asthma. Children with asthma as young as 7 years 
have evidence of increased ASM(121), but nothing is known about ASM in preschool 
wheezers. Therefore, the next hypothesis developed in this thesis is that increased 
ASM may already be present in severe recurrent preschool wheezers and 
particularly in those children who go on to develop asthma at school age. This 
chapter will compare ASM in endobronchial biopsies at preschool age from severe 
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recurrent wheezers to age matched controls, and relate preschool ASM to school 
age asthma status. 
 
5.1.10 Hypotheses 
The overarching hypotheses of this thesis are: 
1. School-aged children with asthma have evidence of airway remodelling and 
airway inflammation in endobronchial biopsies taken at preschool age when 
compared to school-aged children without asthma. 
2. A combination of clinical and airway pathological characteristics at preschool 
age may be able to be used to predict asthma at school age, better than clinical 
features alone. 
In this chapter, the contribution of ASM to remodelling and prediction of future 
asthma will be explored.  
 
5.1.11 Aims 
1. To quantify ASM in endobronchial biopsies from wheezy preschool children  
2. To relate ASM at preschool age to the presence of asthma at school age in 
the Royal Brompton cohort 
 
5.2 Methods 
 
5.2.1 Characteristics of preschool wheezers 
The clinical characteristics of preschool wheezers recruited from the Royal Brompton 
Hospital have been discussed in detail in chapter 2. Children had severe recurrent 
noisy breathing which had been assessed as wheeze during acute symptoms or 
from parental reports. Children were divided into confirmed wheezers (CW) and 
reported wheezers (RW) on the basis of parental identification of wheeze on video 
questionnaire. Exclusion criteria were children with isolated cough, those whose 
main problems were recurrent lower respiratory tract infections, chronic lung disease 
of prematurity and a history of long term oxygen therapy. Use of inhaled or oral 
steroids was not an exclusion criterion. Non-wheezing controls were children who 
mainly had bronchoscopy for evaluation of upper airway problems including stridor.  
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5.2.2 Evaluable biopsies 
Details of the flexible bronchoscopy and EB processing are reported in chapter 2 and 
3. Children with total area of evaluable biopsy tissue ≤0.2mm2 were excluded. 
Smooth muscle was quantified in biopsies fulfilling the following criteria:  
i. presence of recognisable epithelium, RBM, subepithelial tissue and smooth 
muscle  
ii. minimal crush artefact, oedema or blood within the biopsy, figure 5.1.  
 
Figure 5.1: An evaluable biopsy for assessment of airway smooth muscle: 
endobronchial biopsy section stained with haematoxylin and eosin from a 
preschool child with recognisable epithelium, subepithelium, reticular 
basement membrane and smooth muscle 
 
 
5.2.3 Measurement of airway smooth muscle 
The area below the RBM and epithelium is referred to as the subepithelium and 
includes both ASM, mucosa (lamina propria) and submucosal glands (if present). 
Lamina propria is recognised as a highly cellular loose connective tissue, located 
beneath the RBM. Smooth muscle cells were recognised by their characteristic 
spindle shape of variable size with a longitudinal orientation and a centrally placed 
Smooth muscle 
Subepithelium
mmucosa 
RBM 
Epithelium 
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nucleus per cell. Clusters of smooth muscle cells are organised as smooth muscle 
bundles. ASM was measured in two ways. 
 
Method 1: 
Areas of ASM and subepithelial area were identified by morphologic examination. 
ASM area and total subepithelial area were measured at magnification x100 by 
drawing around the outer limits of the smooth muscle bundles and the subepithelial 
area of the biopsy(221), figure 5.2. The subepithelial and ASM area was then 
calculated using computer aided image analysis (Leica DM2500 microscope, Leica 
DFC 300fx camera and Leica Qwin version 3 software, Olympus BH2, Japan). ASM 
mass was then expressed as a fraction of the total subepithelial area.  
 
Figure 5.2: Smooth muscle bundles were traced using a computer mouse and 
then the area was calculated using computer aided analysis. (Scale not shown- 
image shown for illustration purposes) 
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Method 2: 
ASM was measured using a stereology technique, point and line intersection 
counting, allowing three dimensional information from measurements in the two 
dimensions of conventional histology(85). The is done by using a multipurpose test 
system, a Weibel M168 grid which combines area, point and lines which has the 
advantage of allowing a large amount of information to be collected from a single 
grid, figure 5.3(258).  
 
Figure 5.3: Smooth muscle volume fraction was quantified by overlaying a 
weibel grid (M168) at x 200 magnification over the section and performing 
point counting. Length between 2 points (68µm). 
 
 
A virtual Weibel (M168) grid was overlaid the section at random and moved 
systematically until the whole section had been measured. Point counting was used 
to measure ASM. Each end of the horizontal lines on the grid represented a point. A 
point was recorded as smooth muscle if it entirely fell on smooth muscle. Points 
falling on the total subepithelial area (submucosa, ASM and glands) were also 
recorded but those falling on empty space were not. ASM volume fraction was 
measured at magnification x200 and expressed as a fraction of the total number of 
points falling on smooth muscle over the total number of points falling on the 
subepithelium(118;121). The formula used to calculate this was: 
Vv (sm/subepithelium) = (Σ points on ASM) / (Σ points on subepithelial tissue).  
 171 
As there was considerable variation in biopsies between children, the hypothesis 
was that relating ASM to the RBM surface area may reduce variability, rather than 
indexing ASM to total subepithelial area. ASM volume fraction was indexed to the 
surface area of the RBM by counting the number of lines intersecting the apical 
surface of the RBM. The line had to completely cross the RBM to be counted. Lines 
that only partly crossed the RBM were not counted(121). The following formula was 
used: 
volume fraction of ASM indexed to surface area of RBM: V/S (sm/rbm) = (Σpoints on 
ASM x l(p)) / (2 x Σ line intersections with RBM) where l(p) denotes the length per 
point (68µm). 
 
Inter-observer repeatability 
ASM area-fraction was measured by a second observer (Dr N Ullmann) blinded to 
clinical and pathological details of the children using method 1. Measurements for 
ASM area-fraction by the 2 observers are represented by a Bland-Altman plot.  
  
5.3 Assessment of smooth muscle proliferation 
Children who had remaining EB tissue had anti-proliferating cell nuclear antigen 
(PCNA) monoclonal antibody applied to paraffin sections to identify proliferating 
smooth muscle cells by Mr Tim Oates(118). Paraffin sections were dewaxed in xylene 
and endogenous peroxidase activity was quenched by immersing sections in 3% 
H2O2 for 30 mins at room temperature. Sections were then incubated with primary 
mouse anti PCNA (Dako) followed by incubation with biotinylated mouse IgG (Vector 
Laboratories). Slides were counterstained with H&E. All nucleated PCNA positive 
smooth muscle cells were enumerated and expressed per mm2 smooth muscle(118). 
 
Statistical analysis 
Data was analysed on a per individual as opposed to a per biopsy basis, e.g. the 
sum of all measurements obtained from all biopsies of a given child was taken as the 
value for this child(121). Non parametric tests were used. Sample size was 
opportunistic as the number of children in this group was predetermined based on 
the cohort of preschool children recruited between 2002 and 2005. Any power 
calculations performed are retrospective and of limited value. However, power 
calculations showed that the groups (wheezers (n=28) and controls (n=14)) had 80% 
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power to detect a difference between means of 0.06 ASM area-fraction or ASM 
volume fraction with a significance level of p<0.05 (two-tailed t test).  
 
5.4.1 Biopsy size and quantity in Brompton preschool wheezers 
At least 1 good quality biopsy was available from 56 patients. 42/68 children were 
included in the preschool ASM analysis. Forty children had 1 evaluable biopsy and 2 
children had 2 evaluable biopsies. Reasons for exclusion were: no evaluable biopsy 
(n=12), no identifiable ASM (n=7) and total cumulative biopsy area < 0.2mm2 (n=7, 1 
control and 6 wheezers), figure 5.4  
 
Figure 5.4: Airway smooth muscle biopsy quantity 
 
 
 
 
There was no difference between children with ASM on endobronchial biopsy and 
those without ASM in EB in terms of age at fibreoptic bronchoscopy, sex, preschool 
wheeze status and IgE at the time of EB, table 5.1. Similarly there was no difference 
between those children with ASM in EB who were followed up and the rest of the 
preschool cohort, table 5.2. 
 
 
 
Preschool children 
n=68 
Evaluable biopsies 
n=56 
Biopsies with smooth muscle 
n=49 
Biopsies ≥ 0.2mm2 
n=42 
12 biopsies excluded 
evaluable 
7 children no ASM 
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Table 5.1: No difference in clinical characteristics of children with and without 
ASM in evaluable endobronchial biopsies  
 ASM 
n=49 
No ASM 
n=7 
p 
Age at biopsy* 19(3-58) 13(6-55) 0.39 
Male/ Female 31/18 3/4 0.42 
0.67 
Wheezers/ Controls 34/15 4/3 
Preschool IgE (IU/ml) 16 (1-635)† 17 (2-559) 0.89 
*Data is reported as median and range. 
†Results not available on 3 children 
 
Table 5.2: No difference in clinical characteristics of children followed up at 
school age with ASM in endobronchial biopsy and those who were either lost 
to follow up or did not have ASM in endobronchial biopsy 
 Followed up 
n=32 
Lost to follow up 
n=36 
p 
Age at biopsy* 18.5 (3-57) 20 (3-58) 0.5 
Male Female 19/13 25/11 0.45 
0.6 Wheezers/ Controls 21/11 26/10 
Preschool IgE (IU/ml) 28.5 (1-635)† 17 (1-2605) ‡ 0.99 
*Data is reported as median and range. 
†Results not available on 2 children 
‡Results not available on 3 children 
 
5.4.2 Repeatability of stereology and computer aided analysis methods 
The CoV was calculated for ASM volume fraction and ASM area fraction 
measurement as a measure of variability. Each method was assessed by measuring 
4 biopsies at 3 intervals with the following 2 measurements a week and a month 
later. The mean CoV for 4 biopsies measured using computer aided image analysis 
was 7.5% (3.6%, 6.1%, 9.6% and 10.8%). The mean coefficient of variation for ASM 
measured using stereology was higher at 15% (2.9%, 15.8%, 18% and 23.8%). The 
higher CoV associated with the stereology technique is probably because the 
average number of points counted per patient was low (median 79 (range 28-276)). 
ASM area-fraction was measured by a second observer showing good agreement 
between observers (Bland Altman plot, bias 0.0074, SD +/- 0.037, (-0.066-0.081)) 
figure 5.5. The mean CoV for V/S (ASM indexed RBM surface area) was very poor 
121% (50.7%, 76.2%, 209.4%, 148.9%). The mean number of line intersections with 
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the RBM per section was low 3.85 (standard deviation +/-2.7) for all biopsies 
measured. 
 
Figure 5.5: A Bland Altman plot showed good repeatability of ASM area-
fraction measurements between observer 1 and observer 2  
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5.4.3 Comparing ASM volume-fraction measured using stereology and ASM 
area-fraction measured using computer aided image analysis 
There was good correlation between ASM volume fraction measured using 
stereology and ASM area-fraction measured using computer aided analysis, 
Spearman r=0.75, p=0.001, figure 5.6. The ICC using computer aided analysis and 
point and line counting method to measure ASM was 0.78.  
 
Figure 5.6: Correlation between measurements of airway smooth muscle 
volume fraction and airway smooth muscle area-fraction  
Spearman r=0.75, p=0.001
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5.4.4 Variability of ASM within and between biopsies 
Fourteen children had 3 or more sections measured from the same biopsy. The 
within biopsy CoV for ASM was very high both for method 1 (ASM area fraction 
measured using computer aided analysis, median 37% (range 4-70%) and for 
method 2 (ASM volume fraction measured using stereology, median 57% (range 5-
79%)). Within biopsy variability for the 12 children who had 2 sections measured by 
both methods is represented by a Bland Altman plot for method 1, figure 5.7 (i) and 
method 2, figure 5.7 (ii). Between biopsy variability is described for the 2 children 
who had two biopsies measured (ASM area-fraction (child 1; biopsy 1= 0.112, biopsy 
2= 0.102) and (child 2; biopsy 1=0.1246, biopsy 2=0.08)).  
 
Figure 5.7: Wide ASM variability within biopsy represented by a Bland Altman 
plot for (i) method 1 (ASM area fraction) and (ii) method 2 (ASM volume 
fraction). There is no significant bias. 
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  (ii) 
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5.4.5 Airway smooth muscle area fraction measured using computer aided 
analysis 
There was no difference in ASM area fraction between preschool wheezers (n=28, 
median 0.08 (range 0.038-0.163)mm2) and controls (n=14, median 0.077 (range 
0.02-0.23)mm2), p=0.96, figure 5.8 (i). Similarly there was no difference in ASM area 
fraction between CW (n=15, median 0.096 (range 0.04-0.16)mm2), RW (n=13, 
median 0.075 (range 0.04-0.16)mm2) and controls (n=14, median 0.077 (range 0.02-
0.23)mm2), p=0.32, figure 5.8 (ii). 
 
Figure 5.8: Airway smooth muscle area fraction in endobronchial biopsies 
measured using computer aided image analysis compared between (i) 
wheezers and controls and (ii) confirmed and reported wheezers and controls 
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5.4.6 Airway smooth muscle measured using stereology techniques 
There was no difference in ASM volume fraction between preschool wheezers 
(n=28, median 0.1088 (range (0.018-0.27)) and controls (n=14, median 0.099 (range 
0.016-0.314)mm2), p=0.6, figure 5.9 (i). Similarly there was no difference in ASM 
volume fraction between CW (n=15, median 0.11 (range 0.018-0.27)), RW (n=13, 
median 0.076 (range 0.059-0.23)) and controls (n=14, median 0.099 (range 0.016-
0.314)), p=0.77, figure 5.9 (ii). 
 
Figure 5.9: Airway smooth muscle volume fraction in endobronchial biopsies 
measured using stereology compared between (i) wheezers and controls and 
(ii) confirmed wheezers, reported wheezers and controls 
p=0.6
Wheezers (n=28) Controls (n=14)
0.0
0.1
0.2
0.3
0.4
No difference in airway smooth muscle measured
using stereology between wheezers and controls
s
m
/ 
s
u
b
e
p
it
h
e
liu
m
p=0.77
CW (n=15) RW (n=13) Controls (n=14)
0.0
0.1
0.2
0.3
0.4
No difference in airway smooth muscle measured
using stereology between
confirmed and reported wheezers, and controls
s
m
/ 
s
u
b
e
p
it
h
e
liu
m
(i)
(ii)
 
 
 
 178 
5.4.7 Volume fraction of ASM indexed to the surface area of RBM 
The volume fraction of ASM indexed to surface area of RBM (V/S) was also 
compared between wheezers (n=28, median 34.5 (range 4.25-340)) and controls 
(n=14, median 45.9 (range 5.7-374)), p=0.25, figure 5.10 (i). There was also no 
difference between subgroups, confirmed wheezers (n=15 median 34.95 (range 
4.25-136)), reported wheezers (n=13, median 34, (range 17-340)) and controls, 
p=0.19, figure 5.10 (ii). There was also no correlation between RBM thickness and 
either ASM area-fraction or ASM volume-fraction. 
 
Figure 5.10: No difference in volume fraction of airway smooth muscle indexed 
to surface area of reticular basement membrane between (i) preschool 
wheezers and controls and (ii) confirmed and reported wheezers and controls 
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Table 5.3: Characteristics of preschool children with airway smooth muscle in 
endobronchial biopsy 
 Wheezers 
n=28 
Controls 
n=14 
p 
Age (months) 25.5 (7-58) 17.5 (4-42) 0.18 
(CW=31 (8-58) / RW=17 (7-57)) 0.25 
Male/ Female 16/12 10/4 0.5 
(CW= 8/7 / RW= 9/4) 
Inhaled 
corticosteroids* 
(BDP (mcg)*) 
 
14 (50%) 
(500 (200-2000)) 
2 (14%)  
500 
0.04 
CW= 8 (53%) / RW=6 (46%) 
(CW 800 (200-2000) /RW 400 (200-1000)) 
 
Biopsy area (mm
2
) 0.49 (0.26-1.27) 0.66 (0.27-1.54) 0.26 
 (CW=0.5 (0.29-1.15) /RW=0.49 (0.26-1.27))  0.52 
ASM  
area-fraction 
0.08 (0.038-0.163) 0.077 (0.02-0.23) 0.97 
(CW=0.096 (0.04-0.16) / RW=0.075 (0.04-0.16)) 0.33 
ASM  
volume-fraction 
0.1088 (0.018-0.27) 0.099 
(0.016-0.314) 
0.6 
(CW=0.11 (0.018-0.27) / RW=0.076 (0.059-0.23)) 0.77 
V/S 34.5 (4.25-340) (n=13) 
45.9 (5.7-374) 
0.25 
(CW=34.95(4.25-136)/ RW= 34(17-340)) 0.19 
All data expressed as median and range. 
CW= Confirmed preschool wheezers 
RW= Reported preschool wheezers 
*BDP= Beclometasone dipropionate or equivalent 
V/S volume fraction of smooth muscle indexed to surface area of reticular basement membrane 
 
 
5.5 Atopic status and airway smooth muscle in preschool children 
There was no correlation between ASM and total serum IgE at preschool age 
(Spearman r=-0.08, p=0.62), figure 5.11. There was also no difference in ASM 
between children who had one or more positive aeroallergens and children who were 
not sensitised to any aeroallergens, figure 5.12. Analysis of ASM volume fraction 
showed similar results. 
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Figure 5.11: No correlation between ASM area fraction and total preschool IgE 
in preschool wheezers 
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Figure 5.12: No difference in ASM area fraction in endobronchial biopsies from 
children sensitised to one or more positive aeroallergens compared with 
children not sensitised to any aeroallergens  
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5.6 Airway smooth muscle in different preschool wheeze phenotypes  
Children were divided into clinical wheeze phenotypes viral (episodic) or multiple-
trigger wheezers at preschool age(61). Thirty four children had ASM in their biopsy, of 
these 6 were excluded because the biopsy size was less than 0.2mm2. There was 
no difference in ASM area fraction between the 2 phenotypes, viral (n=5, median 
ASM 0.096 (range 0.056-0.163)) and multiple-trigger (n=23, median ASM 0.077 
(range 0.038-0.156)), p=0.33, figure 5.13. However, numbers of children with 
episodic or viral wheeze are small. Similar results were shown for ASM volume 
fraction. 
 
Figure 5.13: Comparing airway smooth muscle area fraction in preschool 
children with viral and multiple-trigger wheeze 
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5.7 Inhaled corticosteroids and airway smooth muscle 
Almost all of the preschool wheezers had a trial of ICS of varying duration before 
proceeding to bronchoscopy and endobronchial biopsy. There was no difference in 
ASM area fraction between those prescribed ICS (n=13, median 0.096 (range 0.039-
0.156)) at the time of EB and those who not prescribed ICS (n=15, median 0.069 
(range 0.038-0.163)), p=0.40, figure 5.14. Six of the children on daily ICS and 5 of 
the children not on ICS had been treated with oral corticosteroids in the month prior 
to biopsy. However there was still no difference when this was considered: (n=18, 
ICS and / or oral corticosteroids in the last month) and (n=10, no ICS / oral 
corticosteroids), p=0.48.  
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Figure 5.14: No difference in airway smooth muscle area-fraction compared 
between preschool wheezers on inhaled corticosteroids and those not on 
inhaled corticosteriods 
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5.8 School age asthma and preschool airway smooth muscle 
Of 51 children followed up at school age, 38 children had ASM in their EB. Six 
children were excluded as they had a biopsy area of less than 0.2mm2. The clinical 
characteristics of children with ASM in their endobronchial biopsy at preschool age 
and who were followed up at school age are reported in table 5.4. 
 
Children with asthma at school age had increased ASM area fraction (n=8, median 
0.12, (range 0.08-0.16)) when compared to those without (n=24, median 0.066, 
(range 0.024-0.23)), p=0.007, figure 5.15 (i). These findings were confirmed with 
increased ASM volume fraction in children with school age asthma (n=8, median 
0.153, (range 0.094-0.266)) when compared with those without school age asthma 
(n=24, median 0.097, range (0.02-0.314)), p=0.016, figure 5.15 (ii). However, there 
was no relationship between ASM indexed to the surface area of the RBM between 
children who did and did not develop asthma at school age, p=0.15.  
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Figure 5.15: Increased preschool airway smooth muscle in children with 
asthma at school age measured using (i) area fraction (computer aided image 
analysis) and (ii) volume fraction (stereology point counting techniques) 
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When preschool wheezers were considered alone, those who developed asthma 
had increased ASM area-fraction (n=7, median 0.127, [range 0.083-0.156]) when 
compared with those who did not develop asthma (n=14, median 0.058, [range 
0.038-0.163]), p=0.006, figure 5.16 (i). Similarly ASM volume fraction was increased 
in children with school age asthma (n=7, median 0.16, [range 0.094-0.266]) when 
compared with those who did not develop asthma (n=14, median 0.08, [range 0.033-
0.227]), p=0.006, figure 5.16 (ii).  
 
Figure 5.16: Increased preschool airway smooth muscle in preschool 
wheezers alone classified by the presence or absence of asthma at school age 
(i) area fraction and (ii) volume fraction  
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Table 5.4: Clinical characteristics of children with ASM in endobronchial 
biopsy related to school age asthma status. (Children with asthma at school age 
had increased ASM, were younger at time of biopsy and had higher preschool IgE.) 
 
 Asthma (n=8) No asthma (n=24) p 
Male/ Female 5/3 10/14 0.1 
Age at FOB, months, median (range) 
Weight at FOB (kg) 
45 (3-57) 
14.75 (5.6-25) 
17 (6-55) 
11.25 (7-18.7) 
0.01 
0.03 
Birth Weight, kg, median (range) 3.49 (2.72-3.8) 3.5 (2.55-4.99) 0.71 
Gestation, weeks, median (range) 40 (33-42) 40 (35-42) 0.6 
 
Preschool group 
  Confirmed wheezer 
  Reported wheezer 
  Control 
 
Preschool wheeze phenotype 
Viral 
Multiple trigger 
Age at onset, months median (range) 
Admission to hospital  
 
Preschool inhaled/ Oral steroids, n (%)  
 
Parental history of asthma 
Maternal asthma 
Paternal asthma 
 
Enviroment 
Maternal smoking in pregnancy 
Maternal / paternal smoking 
 
 
6 
1 
1 
 
7 
0 
7 
15.5 (3-24) 
7 
 
7 (87.5) 
 
4 
2 
2 
 
 
2 
3 
 
 
6 
8 
10 
 
14 
2 
12 
7 (0.5-66) 
10/14 
 
9 (37.5) 
 
7* 
6 
1 
 
 
2 
5 
 
 
 
 
 
 
 
 
 
0.15 
 
 
 
 
0.41 
Day care < 1 year 
Pets (Cat/ Dog) 
 
Preschool IgE (IU/ml) 
≥1 positive RAST, n (%) 
≥1 positive RAST aero-allergen, n (%) 
 
Preschool eczema, n (%) 
 
Preschool ASM measurements 
ASM area fraction 
2 
0 
 
126.5 (4-635) 
5 (62.5) 
3 (37.5) 
 
6 (75) 
 
 
0.12 (0.08-0.16) 
4 
5 
 
8.5 (1-292)# 
6# (25) 
3 (13.6) 
 
6 (25) 
 
 
0.066 (0.024-0.23) 
 
 
 
0.01 
0.1 
0.3 
 
 
 
 
0.006 
Median biopsy area mm
2 
0.81 (0.35-1.27) 0.52 (0.26-1.54) 0.043 
V/v – sm/ subepithelium 0.153 (0.094-0.266) 0.097 (0.02-0.314) 0.015 
V/S  73.45 (28.3-127.7) 34 (9.3-374) 0.15 
Clinical details at school age 
Frequency of wheeze 
None 
1-3 attacks of wheezing 
4-12 attacks of wheezing 
>12 attacks of wheezing 
Exercise induced wheeze 
Dry cough at night§ 
Number of hospital admissions with 
wheeze 
 
No of children taking ICS at school age 
Dose of ICS (mcg)** 
Immunomodulating agent 
 
 
0 
2 
3 
3 
6 
7 
10 (1-160) 
 
 
6 
800 (400-1000) 
1 
 
 
21 
2 
0 
1 
1 
6 
6 (0-20) 
 
 
3 
400 (200-400) 
0 
 
*Family history unknown in 2 children, #IGE or Specific RASTs not known in 2 children 
**mcg Budesonide or equivalent, §Dry cough at night apart from a cough associated with a cold or chest 
infection, V/v volume fraction of smooth muscle indexed to subepithelium 
V/S volume fraction of smooth muscle indexed to surface area of reticular basement membrane 
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5.9 Age & preschool airway smooth muscle 
When considering just children with ASM in EB, children with school age asthma 
(median 45 (range 3-57) months) were older than those who did not have school age 
asthma (median 17 (range 6-55) months) at time of biopsy, p=0.01. There was no 
relationship between age and ASM volume-fraction or ASM area-fraction in the 
controls, but the numbers were small.  
 
To assess the relationship between ASM and age further, endobronchial biopsies 
from non-wheezing school-aged children had ASM volume fraction measured using 
point counting by a second investigator CB(119). These children had been recruited as 
controls for a study investigating airway remodelling and inflammation in children 
with severe therapy resistant asthma(119). Children (n=13) median age 10.5, range 
(5.9-14.2) years had clinically indicated bronchoscopy for evaluation of recurrent 
croup or a barking cough (n=6), noisy breathing (n=1), stridor (n=2) and shortness of 
breath (n=1). Three children had bronchoscopy for investigation of haemoptysis but 
had normal anatomical appearances on bronchoscopy. All parents consented to EB 
for research purposes. Biopsies were processed and stained in an identical manner 
to the preschool EBs. There was no correlation between age and ASM volume 
fraction in non-wheezing preschool children (n=14) and school age children (n=13), 
aged (0.25-14.2) years, Spearman r=0.027, p=0.89, figure 5.17. 
 
Figure 5.17: No relationship between age and ASM volume fraction in non-
wheezing controls  
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5.10 Airway smooth muscle hyperplasia 
ASM proliferation was assessed by myocyte proliferating cell nuclear antigen in 
children with remaining EB tissue, and no difference was seen between wheezers 
(n=12) and controls (n=3) or those with school age asthma (n=3) and those without 
school age asthma (n=7), figure 5.18.  
 
Figure 5.18: No difference in smooth muscle proliferation between wheezers 
and controls (figure A); No difference in smooth muscle proliferation between 
children with and without school age asthma (figure B).  
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5.11 Can airway smooth muscle in endobronchial biopsies from preschool 
wheezers help predict school age asthma? 
The receiver operator curve (ROC) evaluates the discriminatory power of a test, in 
this case using ASM in endobronchial biopsies at preschool age to discriminate 
between preschool wheezers who developed school age asthma and those whose 
symptoms resolved. An area under the curve (AUC) of 1 would represent 100% 
sensitivity (no false negatives) and 100% specificity (no false positives). The area 
under the ROC curve in this case is 0.88 (standard error 0.08, CI (0.69-0.97), 
p=0.005) for ASM area fraction, figure 5.19, and similarly the AUC was 0.79 
(standard error 0.08, CI (0.61-0.91), p=0.0008) for ASM volume fraction, figure 5.20. 
The ROC curve being based on sensitivity and specificity does not take any account 
of asthma prevalence. The PPV of ASM area fraction >0.1 at preschool age in 
preschool wheezers for asthma at school age was 75% (35-96%) and NPV was 92% 
(64-99%), table 5.5. 
 
Figure 5.19: Area under the receiver-operator characteristics curve for airway 
smooth muscle area fraction (measured using computer aided analysis) in 
preschool wheezers in the diagnosis of future school age asthma was 0.88 
(standard error 0.08, confidence interval (0.69-0.97)), p=0.005. (Confidence 
intervals are represented by broken line, area under the curve by the continuous 
line) 
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Figure 5.20: Receiver operator characteristics curve for airway smooth muscle 
volume fraction (measured using point counting) in preschool wheezers 
related to school age asthma (area under the curve 0.79, standard error 0.08, 
confidence intervals 0.61-0.91, p=0.0008). (Confidence intervals are represented 
by broken line, area under the curve by the continuous line) 
AUC=0.79
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Asthma predictive indexes 
Preschool ASM was compared to two other asthma predictive indexes, the Castro-
Rodriguez ‘stringent index’(27) and a wheeze severity score(79). Clinical data at 
preschool age was used to classify preschool wheezers using the Castro-Rodriguez 
stringent index, frequent wheeze plus 1 major or 2 minor criteria (major criteria; 
parental doctor diagnosed asthma or doctor diagnosed eczema in the child, minor 
criteria; wheezing apart from colds or peripheral blood eosinophilia)(27). A history of 
doctor diagnosed allergic rhinitis had not been recorded so wheezing apart from 
colds or peripheral blood eosinophilia were used as the minor criteria. All children 
had at least 3 episodes of wheeze at the time of EB, however the exact number was 
not recorded. For application of the wheeze severity score 3-4 episodes of wheeze 
plus the number of hospital admissions was used to approximate the score(79). Both 
clinical predictive indexes were compared with current asthma at school age. Of the 
children followed up at school age (37/47), data was available to apply the Castro-
Rodriguez ‘stringent predictive index’ to 34 children, 22 satisfied the criteria (major 
(n=21) and minor (n=1))(27). This index did not significantly predict the development 
of asthma in this group of preschool wheezers, p=0.27, table 5.5. When the wheeze 
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severity score (wheeze frequency and hospital admissions) was compared with 
current asthma at school age, the area under the curve (AUC) was 0.70 (standard 
error 0.08, [CI 0.53-0.84], p=0.01), figure 5.21, and in this group of preschool 
wheezers a score >6 was predictive of asthma(79). There was no significant 
difference between the AUC for ASM or for the wheeze severity score, p=0.13. As 
the study number was small all predictive indices and ROC curves have very wide 
confidence intervals. 
 
Figure 5.21: Receiver operator characteristics curve for wheeze severity score 
related to school age asthma (area under the curve 0.7, standard error 0.08, CI 
0.53-0.84, p=0.01). (Confidence intervals are represented by broken line, area under 
the curve by the continuous line) 
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Table 5.5: Sensitivity, specificity, positive and negative predictive values and 
likelihood ratios for a proportion of endobronchial biopsy greater than 0.1 ASM 
area-fraction, Castro-Rodriguez ‘stringent index’ and Devulapalli wheeze 
severity score in preschool wheezers 
 Sensitivity 
(%) 
Specificity 
(%) 
NPV (%) PPV (%) p Likelihood 
ratio 
ASM  
area-fraction> 0.1 
86 
 (42-99) 
86 
(57-98) 
92  
(64-100) 
75  
(35-97) 
0.003 6 
Stringent index 79 
 (49-95) 
45  
(23-69) 
50  
(28- 72) 
75  
(49-94) 
0.27 1.6 
Severity score >6 60  
(32-84) 
77  
(55-92) 
64 
 (35-87) 
74 
(52-90) 
0.03 2.6 
*ASM measured using computer aided analysis as a proportion of the total subepithelial area 
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5.12 Preschool ASM and lung function at school age 
There was no correlation between preschool ASM area fraction and school age lung 
function; LCI (n=28, Spearman r=0.12, p=0.54), Sacin (n=23, Spearman r=0.04, 
p=0.87), Scond (n=23, Spearman r=-0.1, p=0.63), FEV1 z score (n=28, Spearman r=-
0.12, p=0.53), FVC z score (n=28, Spearman r=-0.18, p=0.35), FEV1/FVC (n=28, 
Spearman r=0.09, p=0.35). Similar results were seen for ASM volume fraction. When 
the preschool wheezers were considered alone there was a positive correlation 
between school age FeNO50 and both preschool ASM area fraction (Spearman 
r=0.58, p=0.01), figure 5.22 (i), and ASM volume fraction (Spearman r=0.44, 
p=0.08). There was also a positive correlation between FEV1 / FVC and both ASM 
area fraction (Spearman r=0.52, p=0.03), figure 5.22 (ii) and ASM volume fraction 
(Spearman r=0.49, p=0.04). 
 
Figure 5.22: Positive correlation between (i) FeNO50 and (ii) FEV1/FVC and ASM 
area fraction 
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Eighteen children with ASM in endobronchial biopsy had assessment of AHR using 
hypertonic saline (defined as positive airway challenge if there was a decrease in 
FEV1≥ 15%). A further child with ASM on EB and lung function less than 75% had 
assessment of BDR (≥15% increase in FEV1 20 minutes post bronchodilator 
challenge). Two children were excluded because biopsy size was less than 0.2mm2. 
There was no difference in ASM at preschool age between children who had either 
positive bronchodilator response (n=1) or a positive AHR challenge (n=2), [(n=3, 
median ASM= 0.127, range (0.05-0.156)], to those who did not at school age [n=14, 
median ASM 0.08, range (0.03-0.199)], p=0.57, figure 5.23. However, the numbers 
who were reactive were so small that no firm conclusion can be drawn. 
 
Figure 5.23: Preschool airway smooth muscle is not increased in those with 
school age airway hyper-responsiveness or positive bronchodilator response 
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In summary 
Although there was no difference in ASM at preschool age between wheezers and 
controls, preschool wheezers who went on to develop school age asthma had 
increased ASM at preschool age when compared to those who did not. One 
limitation of the study was that lung function at the time of the EB was not available. 
ASM has been significantly related to airflow obstruction in adults and children. In 
particular ASM in the airway wall increases as airflow limitation worsens in 
adults(124;125). Furthermore, increased ASM has been related to reversible airflow 
obstruction in older school age children with asthma(118;121). Infants with AHR at 1 
year of age are more likely to have asthma at age 11 years, which might suggest 
ASM is already increased at this age(39). A previous study showed no evidence of 
increased RBM thickness or subepithelial eosinophils in wheezy infants (median age 
1 year) who had lung function measured at time of EB(138). However, the next step 
further to explore the role of ASM was to study these wheezy infants with reversible 
airflow obstruction aged 1 year. 
 
5.13 Airway smooth muscle measurement in the ‘Helsinki’ wheezy infants 
 
5.13.1 Clinical description of infant cohort 
The characteristics of the infant cohort have previously been reported. The infants 
were originally recruited by Dr K Malmstrom and co workers in Helsinki, Finland and 
all clinical assessments were performed there. Dr Sejal Saglani measured both 
reticular basement membrane thickness and quantified submucosal eosinophils in 
these infant endobronchial biopsies(138).  
 
Infants were recruited between 3 months and 2 years of age from 2 paediatric 
centres, The Skin and Allergy Hospital and the Hospital for Children and 
Adolescents, Helsinki where they had been referred for assessment for chronic 
dyspnoea, cough and wheeze. Children were referred for evaluation by 
bronchoscopy and lung function tests if clinically indicated in order to guide future 
management. Rigid bronchoscopy was routine clinical practice in both hospitals at 
that time and was performed under general anaesthesia, with a 3.0mm rigid 
bronchoscope, using biopsy forceps (No. 10378L; Karl Storz, GmbH and Co., 
Tuttingen, Germany) at the carina. 
 193 
Infants all had clinically indicated bronchoscopy for wheeze and cough. Exclusion 
criteria were: 
1. 3 days of oral corticosteroids in the previous 8 weeks 
2. >400µg of inhaled corticosteroids within 4 weeks of the assessment and 
lung function 
3. non-Caucasian ethnicity 
4. birth at gestational age < 36 weeks or small for gestational age (birth 
weight <-2SD) 
5. respiratory distress syndrome 
6. bronchopulmonary dysplasia 
7. respiratory infection in the 14 days preceding lung function 
8. severe atopic dermatitis (>20% of area at the first visit) 
9. obvious bronchomalacia or other anatomical malformation on 
bronchoscopy 
10. specific airways conductance (sGaw)< 35% predicted for age combined 
with dyspnoea at rest 
 
5.13.2 Infant Lung Function 
Lung function was assessed with an infant body plethsmograph up to 3 weeks 
before the bronchoscopy (BabyBody, Jaeger GmbH, Wurtzburg, Germany)(259). 
Paired sets of measurements of FRC and sGaw were performed and between test 
variability assessed. FRC higher than the 95th centile (z score ≥ 1.65) and sGaw 
lower than that of the 5th centile (z score ≤1.65) of the reference range were 
considered abnormal. Bronchodilator response was assessed by repeating the 
measurements 15 minutes after inhalation of 600mcg (Ventolin® Glaxo, United 
Kingdom) delivered with a metallic spacer (Nebunettte®, Astra, Sweden). 
Bronchodilator response was considered significant if there was increase in sGaw of 
at least 30% and if the increase exceeded 2 standard deviations of the variability(259). 
 
Infants were divided into 3 groups based on the basis of their lung function 
Group A: reduced airways conductance with bronchodilator response 
Group B: reduced airways conductance, no bronchodilator response 
Group C: normal lung function 
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5.13.3 Atopy 
Atopy was defined in all subjects by a positive skin prick test (Solu-Prick Sq, Alk-
Abello, Horsholm, Denmark) for at least one of the test allergens (birch, timothy, 
grass, cat, dog, Dermatophagoides pteronyssinus, latex, egg, cows milk).  
 
5.13.4 Rigid bronchoscopy and endobronchial biopsy 
All bronchoscopies were performed for clinical indications in Finland; however 
endobronchial biopsies were taken for research purposes under direct visualisation 
from the main carina. Up to 2 biopsies were fixed in 2.5% glutaraldehyde in 0.05-M 
sodium cacodylate buffer (pH=7.4) for a duration of 2 weeks to 3 months and 
transported to the Royal Brompton Hospital. Secondary fixation was in 1% osmium 
tetroxide in sodium cacodylate buffer for 1.5 hours. Biopsies were dehydrated and 
embedded in epoxy resin (Araldite). Plastic sections (1µm thick) were cut using a 
microtome (Reichert-Jung, Leica UK) and stained with toluidine blue (1% toluidine 
blue in 1% sodium tetraborate).  
 
5.13.5 Quantification of RBM thickness 
Sections stained with toludine blue that contained epithelium, RBM and 
subepithelium were used to measure RBM thickness by Dr Saglani using the 
methods described in chapter 3(138). Briefly, RBM thickness was determined using 
computer aided image analysis as the mean of 40 measurements made at 20µm 
intervals(225). These results have previously been reported(138). 
 
5.13.6 Quantification of smooth muscle 
ASM area fraction was measured in evaluable biopsies stained with toludine blue 
using computer aided analysis, figure 5.24. ASM is reported as a fraction of the 
subepithelial area. Results are reported as the mean of all tissue sections measured. 
 
 
 
 
 
 
 
 195 
Figure 5.24: Evaluable endobronchial biopsy section from an infant stained 
with toluidine blue showing epithelium, RBM, submucosa and smooth muscle. 
 
 
 
 
Results 
5.13.7 Number of children with airway smooth muscle in endobronchial biopsy 
71 sections from 53 infants with evaluable biopsies were reviewed. Of those, 33 
sections from 24 children did not contain ASM. There was no difference in age 
(p=0.45) or atopic status (p=0.65) between children with ASM and without ASM on 
endobronchial biopsy. Twenty nine children had between 1-3 sections with ASM with 
a mean number of 1.3 sections per child. Median biopsy area measured 0.85 (range 
0.21-1.71)mm2. 
 
5.13.8 Variability 
Intra-observer repeatability was assessed by measuring 3 sections chosen randomly 
on 3 occasions a week and a month apart. The mean coefficient of variation for the 3 
biopsies was 4%. The coefficient of variation values for each of the 3 biopsies were 
1%, 4% and 7%. Only 5 children had more than 1 biopsy with ASM from which to 
assess between biopsy variability. Four children had 2 sections with ASM and 1 child 
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had three sections with ASM. The coefficient of variation between the 3 sections was 
very high at 89%. Furthermore a Bland-Altman plot of the 4 children with 2 sections 
also shows high variability, figure 5.25. 
 
Figure 5.25: Bland Altman plot of comparing interbiopsy variability of infant 
airway smooth muscle in the same child  
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5.13.9 Airway smooth muscle in each infant lung function group 
Clinical characteristics of the Helsinki infants with ASM in EB are reported in table 
5.6. Although these children were followed up at 3 years of age in Helsinki, this 
clinical data is not available to me. If anything, there was a trend towards decreased 
ASM area fraction in the infants with airflow obstruction and bronchodilator 
reversibility, group A (n=9, median=0.04, (range 0.008-0.18)), when compared with 
group B (n=11, median=0.099, (range 0.016-0.498)) and group C (n=9, 
median=0.099, (range 0.029-0.23)), but this was not statistically significant, figure 
5.26.  
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Figure 5.26: No increase in ASM area fraction in wheezy infants (Helsinki) with 
airflow obstruction and bronchodilator reversibility when compared to infants 
with normal lung function.  
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Table 5.6: No difference in airway smooth muscle measurements between 
Helsinki infants with one or more biopsies 
 Group A 
n=16 
Group B 
n=22 
Group C 
n=15 
 
p 
Age (median months) 
Range 
11.6 
(3.8-18) 
12.36 
(5-25.9) 
11.52 
(3.36-24.2) 
0.57 
Sex (male) 
Age of onset of symptoms (months) 
Range 
Parental asthma 
RBM (median µm) 
Range 
8 (50%) 
4.5 
(0-16) 
8 (50%) 
4.35 
(2.8-9.2) 
18 (82%) 
5 
(0-14) 
10 (45%) 
4 
(2.7-5.8) 
17 (73%) 
2 
(0-13.5) 
3 (20%) 
3.8 
(2.7-5.8) 
0.58 
No. of children with ASM 9 (56%) 11 (50%) 9 (60%)  
 
Age (months) 
Range 
 
7.3 
(3.8-17.64) 
 
12 
(5-18.24) 
 
16.08 
(4.44-24.2) 
 
0.07 
No. of children with atopy 3 2 4 0.44 
Total IgE (median IU/ml) 
Range 
Median biopsy (area mm
2
) 
Range 
16 
(2-86) 
0.88 
(0.22-0.92) 
20 
(2-377) 
0.859 
(0.3-1.71) 
17 
(7-406) 
0.854 
(0.215-2.8) 
0.2 
 
0.79 
Mean ASM (median mm
2
) 
Range 
0.04 
(0.008-0.18) 
0.099 
(0.016-0.498) 
0.099 
(0.029-0.23) 
0.06 
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5.13.10 Atopy and airway smooth muscle in wheezy infants (Helsinki) 
There was no difference in ASM between atopic (n=9, median 0.08 (range 0.034-
0.176)mm2) and non atopic infant wheezers (n=20, median 0.098 (range 0.008-
0.49)mm2), figure 5.27. There was also no difference in total IgE between the 3 
groups (p=0.2). 
 
Figure 5.27: No difference in airway smooth muscle between atopic and non-
atopic wheezers 
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5.13.11 Correlation of age and RBM thickness with smooth muscle in the 
wheezy infant cohort 
There was no correlation between RBM thickness and fraction of smooth muscle 
(Spearman r=-0.06. p=0.72), figure 5.28 (i). There was also no correlation between 
age of infants with normal lung function and airway smooth muscle, figure 5.28 (ii). 
Biopsies were taken from the carina in infants (Helsinki cohort) and from 3rd and 4th 
generation bronchi in the preschool group (RBH cohort), so ASM results may not be 
directly comparable. ASM distribution is not homogenous throughout the airways 
with the proportion of smooth muscle in the airway wall being relatively more in the 
peripheral airway walls (non cartilaginous, 10%) when compared with the central 
airways (cartilaginous airways, 2.8%)(260). 
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Figure 5.28: (i) Relationship between smooth muscle area and RBM thickness; 
(ii) Relationship between age and smooth muscle area fraction 
Spearman r=-0.03, p=0.72
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5.14 Discussion 
5.14.1 Statement of principal findings 
Hypothesis 
School-aged children with asthma had evidence of airway remodelling and airway 
inflammation in endobronchial biopsies taken at preschool age, when compared 
to school-aged children without asthma. 
 
The main finding of this study is that airway wall smooth muscle area fraction or 
volume fraction, as measured in EB, discriminates to some extent in this highly 
(i) 
(ii) 
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selected group between those severe preschool wheezers who will develop asthma 
at school age and those who will not. This strongly supports the hypothesis that 
evidence of airway remodelling is already present in those severe recurrent 
preschool wheezers who go on to develop asthma.  
 
Summary of findings in this chapter 
 No difference in ASM between preschool wheezers (RBH cohort, median age 2 
years) and controls 
 Increased ASM at preschool age in children who go on to develop school age 
asthma 
 No difference in ASM between wheezy infants (Helsinki cohort, median age 1 
year) with reversible airflow obstruction and those with normal lung function 
 No correlation between age and ASM 
 
5.14.2 Strengths of study 
This is the first study to quantify ASM in endobronchial biopsies from preschool 
wheezers (RBH) and to relate pathological findings at preschool age with asthma 
status at school age. ASM in the biopsies was measured by a single blinded 
observer using two very different techniques, both giving the same results. Findings 
were confirmed by a second independent observer. ASM indexed to the surface area 
of RBM failed to show a difference between children with and without school age 
asthma however repeatability (CoV 121%) for this method was poor.  
 
5.14.3 Limitations of study 
 Results may not be applicable to other wheezy preschool children 
An important limitation was that the preschool wheezers (RBH) enrolled in the 
original study were of necessity very severe otherwise they would not have 
undergone bronchoscopy. Numbers are relatively small, and only 32/42 with ASM in 
endobronchial biopsy could be followed up at school age and only 8 (25%) of these 
children had developed asthma. However, there was no difference in terms of age at 
biopsy, sex or atopy between those analysed at school age and those who were not 
suggesting drop-outs are not likely to have introduced a significant bias. Of the 7 
children with preschool wheeze who had asthma at school age and ASM on their 
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endobronchial biopsy, 4 had been enrolled in the difficult asthma program RBH(195) 
and were prescribed high dose ICS to control their symptoms (median 800mcg 
beclomethasone equivalent).  
 
 Lung function measurement 
Unfortunately, lung function measurements were not performed in the preschool 
children prior to endobronchial biopsy, as standards for measuring lung function in 
preschool wheezers had not been established at the time of the original study(9). No 
correlation was seen at school age between AHR or lung function and preschool 
ASM (RBH), but this is likely to be both due to the delay of several years between 
biopsy and assessing lung function and small sample size. However, wheezy infants 
(Helsinki) with reversible airflow obstruction showed no increase in ASM. This may 
suggest that ASM may not be the driving factor in AHR in this age group. However, 
the sample size is too small to draw any firm conclusions and these infant samples 
were taken at the bifurcation of the trachea where there is typically much less ASM 
(3%) compared with more peripheral airway walls (10%) from where the RBH 
biopsies were taken(260).  
 
 Variability of ASM measurements 
Biopsy size 
The bronchoscope used to biopsy preschool children (2.8 or 3.6mm) was much 
smaller than that used in adults and older children (>4mm). The biopsy channel was 
correspondingly smaller (1.2mm vs >2mm), and as a result the minimum amount of 
tissue measured (0.2mm2) was much less than in studies in adults and older children 
(1mm2).  
 
Within and between biopsy variability 
There is considerable variability in structural characteristics between endobronchial 
biopsies and between sections within biopsies. Within and between biopsy variability 
for the same child was up to 37% (range 4-70)% for ASM. The majority of children 
just had a single good quality biopsy for assessment. Previous studies have also 
shown that the thickness of airway smooth muscle relative to the airway diameter 
varied 10 fold within the same group of airways(260). For this reason ASM was 
 202 
analysed on a per child basis (the mean of the measurements obtained from all 
sections from the 1 or more biopsies available). However, not all sections from the 
preschool children that were assessed for ASM were consecutive as sections had 
also been stained for other inflammatory cell populations. A very superficial EB could 
also underestimate ASM. 
 
Inter and Intra-observer repeatability of ASM measurements  
ASM area fraction measurements showed good correlation between 2 observers. 
The variability for repeated measures of the same section by the same observer was 
higher for point counting than using the computer aided analysis program. The 
increased CoV is likely because of the small number of points counted per subject in 
the preschool biopsies (median 79 (range 28-276), median biopsy area 0.49mm2) 
when compared with (571 (295–864), median biopsy area 1mm2) points per subject 
in older children(121). However, there was good correlation between the 2 methods 
(ICC=0.78).  
 
 Age and airway smooth muscle 
Children with school age asthma were older at the time of EB when compared to 
children without school age asthma. Similarly the children with school age asthma 
also had increased endobronchial tissue measured when compared with controls. 
Data on normal ASM development is scanty. However there was no relationship 
between age and ASM in the preschool and school age non-wheezing controls. A 
post-mortem study showed that ASM increased linearly with airway diameter during 
infancy and childhood(256), but although adults have increased absolute amounts of 
ASM when compared to children, the proportion of ASM, which is what we quantified 
in the airway wall remains similar(261).  
 
 Quantifying smooth muscle further 
Previous studies have shown the distance between the submucosal limit of 
subepithelial basement membrane and the ASM layer is increased in asthmatics(110). 
However, it was not possible to assess this in the preschool or infant wheezers as 
the orientation of biopsies was very variable. Secondly, this study did not assess 
whether the increase in ASM in the subgroup of children who had asthma at school 
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age was secondary to cell hypertrophy or hyperplasia, or both. However, PCNA 
staining to assess smooth muscle hyperplasia was performed in a small number of 
children (n=10) followed up at school age, but showed no increase in PCNA positive 
cells in those with asthma (n=3). 
 
5.14.4 Airway smooth muscle and asthma 
The proportion of ASM in endobronchial biopsies from severe recurrent preschool 
wheezers is less than in older children and adults with asthma. The subgroup of 
children who developed asthma at school age had 12% (8-16)% of the subepithelium 
occupied by ASM, which is similar to the values reported in adults (16-18)% with 
mild-moderate asthma(110;122). Further increases in ASM have been reported with 
increasing asthma severity, with 16-27% of subepithelial tissue occupied by ASM in 
school age children with moderate-to-severe asthma(118;121), compared with 40% in 
adults with severe asthma(110). The proportion of ASM occupying the subepithelial 
tissue in the preschool wheezers and controls who did not develop asthma was 6-
9% (depending on the method used) similar to that reported for children aged 6-16 
years without lower airway disease (4%)(121), but less than that reported in adults 
with no respiratory symptoms (9-11.5%)(110;221). ASM has traditionally thought to 
occupy approximately 10% of non-cartilaginous airways(262). Larger biopsy forceps in 
adults would likely have taken larger and deeper biopsies containing more ASM. 
 
5.14.5 Corticosteroid use and airway smooth muscle 
There is little reported on the action of corticosteroids on smooth muscle of the 
asthmatic airway in adults, and none in young children. Half (14/28) of the preschool 
wheezers had been treated with regular ICS or a course of oral prednisolone in the 
month preceding the biopsy, but no difference was seen in the proportion of ASM in 
the subepithelial area. This is despite the children being treated with high doses of 
ICS (500mcg of budesonide or equivalent). In contrast animal studies have shown 
that ovalbumin sensitised female BALB/c-mice who were treated with intranasal 
fluticasone which was inhaled into the airways had decreased thickening of smooth 
muscle(263).  
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5.14.6 Airway smooth muscle predicts school age asthma 
Increased ASM was evident at preschool age in those children with school age 
asthma when compared to children without school age asthma. The AUC of the 
ROC was high (0.87), but numbers are small with wide confidence intervals. This is 
comparable with scores for wheeze severity age 2 years in children from Oslo 
predicting asthma at 10 years with an area under the ROC of 0.78, and when the 
score was applied to the RBH group of preschool wheezers AUC of 0.70(79). 
However, a higher severity score was needed to predict asthma in this group of 
preschool children compared to the Oslo cohort (>6 versus >5)(79). The median age 
at follow up for the present study was 8 years. By comparison with the Castro-
Rodriguez ‘stringent predictive index’ for asthma at 8 years, ASM biopsy proportion 
>10% had similar NPV (93% versus 88%) but improved PPV (72% versus 44%)(27). 
However, when the ‘stringent index’ was applied to this present group of children it 
did not significantly predict asthma. This is likely because the RBH group of children 
represented a much severer preschool wheeze phenotype and study numbers were 
much smaller. Secondly, some features of the index (i.e. doctor diagnosed allergic 
rhinitis) could not be applied to the present study group. 
 
In summary 
Although increased ASM in preschool wheezers increases the risk of school age 
asthma, the overlap in ASM between children who developed childhood asthma and 
those who did not is too great to be of any clinical prognostic value. However, this 
data suggests that future studies exploring the mechanisms underlying the 
persistence of preschool wheeze and its progression to asthma might profitably 
focus on airway smooth muscle. 
 
Airway inflammation also plays an important role in asthma pathogenesis. However, 
its role in disease progression or disease persistence in preschool wheezers is 
unknown. The next chapter will relate airway inflammation at preschool age to school 
age asthma status.  
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Chapter 6 
Airway Inflammation in Preschool Wheezers and its 
Relationship to School Age Asthma 
 
6.1 Introduction 
Airway inflammation plays an important role in the pathophysiology of school age 
asthma, and indeed the presence of inflammation is built into some definitions of the 
disease(8). Currently anti-inflammatory therapy, particularly ICS, is central to long 
term asthma management. Several cell types are implicated in airway inflammation 
including eosinophils, neutrophils, CD4+ T lymphocytes and mast cells. In particular 
mast cells and eosinophils are thought to play a pivotal role in adult asthma. 
 
Eosinophils 
Eosinophils in sputum(177), BAL(264) and endobronchial biopsies(93;94;265;266) are an 
established feature of asthma in school age children. Eosinophils may also be 
increased in non-wheezing children with atopy. BAL eosinophils and eosinophilic 
cationic protein, were increased in school age asthmatic children when compared to 
non-atopic controls but not in controls with atopy(264). The presence of eosinophilic 
inflammation in endobronchial biopsies is well established in both mild- 
moderate(93;94) and severe asthma(119;265;266) in school age children.  
 
The role of eosinophils in preschool children with wheeze is unclear. Wheezy 
children aged 3-6 years had increased BAL eosinophils (labelled asthmatic)(264) 
when compared to age matched non-atopic non-asthmatic controls, however there 
was no difference in BAL eosinophils seen in children aged less than 3 years when 
compared with controls(264). Asthmatic children aged <6 in the reported study likely 
represented multiple-trigger wheezers as they had repeated episodes of wheezing, 
breathlessness and cough, particularly at night and early morning, which were 
present apart from colds(264). All ‘asthmatic children’ had to be responsive to 
bronchodilators by definition(264). Similarly, wheezy infants (median age 1 year) with 
reversible airflow obstruction had no increase in subepithelial eosinophils in EB(138), 
but children with severe recurrent wheeze aged 2-3 years recruited from the RBH did 
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have evidence of increased subepithelial eosinophils when compared to non-
wheezing preschool controls(9). In children with multiple-trigger wheezing aged 5 
years, eosinophilic inflammation has been demonstrated in endobronchial biopsies 
irrespective of the presence or absence of atopy when compared with controls(107).  
 
Studies also suggest that airway inflammation is present prior to the onset of asthma 
diagnosis. EB performed in 27 children (median age 8 years) who were 
bronchoscoped because of recurrent or chronic respiratory symptoms, subsequently 
followed up 2-6 years later, showed those who were later diagnosed with asthma 
had increased submucosal eosinophils at EB(140). However, this study was limited by 
small numbers, only 3 children were less than 5 years at EB (age range 1.2-11 
years), and there was variable time of follow up post EB. It is likely that several of the 
children had established asthma, reporting chronic cough and wheezing with viral 
infections, although not clinically diagnosed at time of EB(140). A BAL study also 
suggested airway inflammation is present prior to the onset of asthma(267). Children 
(n=81) with a median age 3.2 years who had never wheezed had a non-
bronchoscopic BAL performed during elective surgery for non-pulmonary disease 
and were followed up 7 years later to ascertain whether any children had 
subsequently developed wheezing or other atopic disease (eczema, allergic rhinitis) 
using a modified ISAAC questionnaire(267). Children who were clinically 
asymptomatic in terms of wheeze before the BAL and subsequently developed late 
onset wheezing in childhood had evidence of increased eosinophils on BAL when 
compared with children who did not develop late onset wheezing(267). The increase in 
BAL eosinophils was not associated with elevated TH2 cytokines as observed in 
children with established asthma. Furthermore, preschool atopy did not predict 
eosinophilic airway inflammation as there were no significant differences in blood 
and BAL eosinophils between those who became atopic but never wheezed and 
non-atopic children who did not develop wheeze(267). 
 
Mast cells 
Mast cells are also thought to play an important role in asthma pathogenesis. Mast 
cell activation occurs in response to allergen presentation following IgE mediated 
crosslinking of the membrane bound IgE high affinity receptor (FcεRI) causing 
degranulation and the release of mediators (histamine, leucotrine C4, prostaglandin 
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D2) and cytokines (IL-4, IL-5 and IL-13)
(268). Mast cells originate from pluripotent 
hematopoietic stem cells which circulate as CD34+ precursors until they migrate into 
tissues where they mature into long living effector cells(268). In humans mast cell 
subtypes are classified by their protease content, mast cell tryptase (MCT) cells 
store primarily tryptase in their granules and are found predominantly in the lung and 
the intestinal muscosa. Mast cell tryptase chymase (MCTC) cells store both 
chymase, tryptase and carboxypeptidase in their granules and are found in the skin, 
lymph nodes and submucosa of the stomach and intestine(268). Normally, MCT cells 
predominate in the lung, whereas MCTC cells represent less than 20% of lung mast 
cells. Mast cells are implicated in asthma pathogenesis, but their phenotype, location 
and activation varies with asthma severity(147). In adults with asthma, mast cells 
migrate into the epithelium(146), airway submucosa(147) and ASM(148;150;248).  
 
Epithelial mast cells 
The expression of mast cell tryptases and carboxypeptidase A3 (CPA3) in the airway 
epithelium of steroid naive adult asthmatic subjects (n=42) is increased when 
compared to healthy control subjects (n=28)(146). Mast cell gene expression in the 
airway epithelium related closely to the expression of IL-13 signature genes and 
correlated positively with lung function improvements with subsequent ICS 
treatment(146). The number of intraepithelial mast cells (measured only in those with 
intact epithelium) was higher in those adult asthmatics with high TH2 cytokine profile 
when compared with those with a low TH2 cytokine profile or healthy controls
(146). 
Intraepithelial mast cells were similar between asthmatics with a low TH2 cytokine 
profile and healthy adults. Epithelial chymase positive mast cells were not reported in 
steroid naive asthmatics(146), but epithelial MCTC have been reported in mild 
asthmatics using ICS(147) and in severe adult asthmatics(147). 
 
Submucosal mast cells 
The USA National Heart, Lung, and Blood Institute’s Severe Asthma Research 
Program investigated the expression of epithelial and submucosal mast cells from 
adults with range of asthma severity and normal control subjects(147). Submucosal 
MCT cells were shown to be highest in adults with mild asthma not being treated 
with ICS and decreased with increasing asthma severity(147). In contrast, in severe 
asthma the mast cell population is dominated by the chymase-positive phenotype 
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(MCTC) in submucosa and in the epithelium(147). A limitation of this study is that it did 
not quantify ASM mast cells. 
 
Airway smooth muscle mast cells 
The morphology of mast cells in the ASM of asthmatic patients seen on electron 
microscopy when compared to control groups are of smaller cells with fewer 
cytoplasmic pseudopods with partial or total degranulation(248). Furthermore, in vitro 
studies have shown that ASM hyperplasia may be driven by mast cell derived 
chemokine ligand 19 via the activation of chemokine receptor 7 in ASM(269). The 
relationship between mast cell myositis and asthma severity is unclear. Bequeret et 
al reported no relationship to asthma severity, as measured by AHR and infiltration 
of the ASM by mast cells(248). In contrast, Siddiqui reported location of mast cells in 
the smooth muscle bundle but no other features of airway remodelling were 
associated with AHR in asthma(149). Furthermore, mast cells localised in the smooth 
muscle bundle in contrast to mast cells localised in the submucosa expressed 
fibroblast markers that correlated strongly with the degree of AHR (r=0.61, 
p=0.004)(150). In vitro studies showed that these fibroblastoid mast cells have an 
increased expression of chymase and are in a heightened state of activation with 
increased release of histamine(150). Mast cells and their relationship to both smooth 
muscle and submucosa have not previously been explored in preschool wheezy 
children. Epithelial mast cells in this current study were not quantified as the 
epithelium was not intact in either the RBH preschool wheezers or controls. 
 
T lymphocyte cells 
A predominance of subepithelial TH cells (CD4+) cells in endobronchial biopsies from 
children with well established severe asthma (median age 13 years) is associated 
with persistent airflow limitation(226). Furthermore in two groups of adolescent 
asthmatic children (one with persistent symptoms and the second with few 
symptoms) there were increases in the TH2 cytokines, IL-4 and IL-5 in 
bronchoalveolar lavage(115). However, in the adolescent group with persistent asthma 
symptoms TH2 type inflammation was associated with the presence of activated 
eosinophils in the bronchial epithelium, whereas in children with few asthma 
symptoms there was an increase in levels of the TH1 cytokine IFN and IFN/IL-4 
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ratio, in bronchoalveolar lavage(115). However, in more severe asthma there is limited 
evidence for the role of TH2 cytokines. A recent study showed that children with 
severe therapy resistant asthma were characterised by eosinophilic inflammation 
without increase in TH2 cytokines (IL-4, IL-5 or IL-13) in most patients
(119). 
 
The pattern of airway inflammation is less clear in infants and preschool children with 
wheeze. Children (median age 8 (range 1-15) years) with asthma and atopy had 
evidence of ongoing airways inflammation (increased eosinophils and mast cells) on 
BAL collected during elective surgery while asymptomatic, when compared to 
children with virus associated wheeze or atopy alone(270). Significant T-cell-driven 
airway inflammation (IFN-, IL-2, IL-4, IL-5, and IL-10) is absent in mild or non-atopic 
children (mean age 5 years) with an episodic wheeze pattern who were 
asymptomatic at time of bronchoalveolar lavage(271). However, a BAL study of 
wheezy 1 year olds with persistent symptoms had significantly higher CD8+ 
lymphocytes (a marker for TH1 response), in wheezers compared to controls, 
suggesting the contribution of viruses in the pathophysiology of wheezing in this age 
group(272). However, in this study controls were not free of lower respiratory 
symptoms and were older than the wheezers (mean age 2 years) which may also 
explain the TH1 predominance
(272).  
 
Neutrophils 
The role of neutrophils in childhood severe asthma is controversial. In adults with 
chronic severe asthma neutrophils have been consistently increased in BAL fluid, 
sputum and in both endobronchial and transbronchial biopsies(273;274). Measures of 
airflow obstruction, such as FEV1, correlate with the degree of neutrophilia in sputum 
in adults with chronic severe asthma(274). School age children with severe asthma 
and reduced FEV1 (mean 82%) had raised blood neutrophils
(275), however it is 
possible that the apparent increase may be related to ongoing corticosteroid therapy. 
In contrast school age children with severe asthma did not have evidence of 
neutrophilia in bronchoalveolar lavage or EB(119).  
 
Neutrophils have also been shown to have a role in infant and preschool wheezing. 
There are difficulties in interpreting these studies as neutrophilic inflammation in 
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studies that have used BAL may be confounded by coexistent viral or bacterial 
infection. In particular persistent bacterial bronchitis may mimic asthma. A BAL study 
in wheezy children aged 4-32 months, showed a higher neutrophil count but normal 
eosinophil counts in those with recurrent wheeze compared to controls(276). Over half 
of the infants with wheezing for whom bacterial analysis of BAL was performed had 
positive culture results(276). However, controls who did not wheeze, but did have 
other lower airway pathology did not show an increase in neutrophils despite having 
similar bacteriological growth frequency on BAL. In another BAL study in children 
aged 2.5 years with at least a 6 month history of wheezing, 80% of children had 
evidence of neutrophilic inflammation(277). However, half of this subgroup had raised 
bacterial counts suggesting infection. Furthermore, a weakness of all these studies is 
the lack of molecular data on the airway microbiome. 
 
Current study 
Severe recurrent wheezers recruited from the RBH had increased subepithelial 
eosinophils but no increase in subepithelial neutrophils, CD4+, CD8+ and CD45+ (a 
pan leucocyte marker of subepithelial inflammation) cell counts when compared to 
preschool controls(9). Airway inflammation will be related to asthma at school age in 
this chapter. Mast cells will be quantified for the first time in preschool endobronchial 
biopsies from the RBH. 
 
6.2 Aims 
1. To relate airway inflammatory cells (subepithelial eosinophils, neutrophils, 
CD4+, CD8+ and CD45+) from the preschool endobronchial biopsies to 
school age asthma status 
2. To quantify ASM and submucosal infiltration by mast cells in severe recurrent 
preschool wheezers and relate these findings to school age asthma status 
 
6.3 Methods 
6.3.1 Immunostaining 
Immunostaining: Leucocytes (CD45+), neutrophils, eosinophils, CD4+ & CD8+ 
cells 
Immunostaining for eosinophils, neutrophils, CD4+, CD8+ and CD45+ cells had been 
performed previously(9). Inflammatory cells including CD45+ cells, neutrophils and 
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eosinophils within paraffin sections were identified using the EnVision-alkaline 
phosphatase (EV-AP) technique (DAKO Ltd, Cambridge, UK), and identification of 
CD4+ and CD8+ cells was performed using the EnVision Peroxidase staining 
method (DAKO Ltd, Cambridge, UK), according to the supplier’s instructions. 
Monoclonal antibodies were applied which had been raised from mouse against 
human intracellular epitopes, neutrophil elastase (NE) (Dako, Ely) for neutrophils, 
human eosinophilic cationic protein and eosinophil protein X (EG2) (Pharmacia & 
Upjohn Diagnostics AB, Uppsala, Sweden) for eosinophils, and against the 
membrane-associated epitopes CD4+/CD45RO+ (OPD4) (Dako, Ely, UK) for CD4+ 
T-cells and CD8 (Dako, Ely, UK ) for CD8+ cells. After dewaxing, sections were 
immunostained with the appropriate antibodies for 1 hour. Sections were then 
washed and incubated with labelled polymer, AP (pre-diluted secondary antibodies, 
rabbit anti-mouse/rabbit) (DAKO, Carpinteria, USA). After a further wash, bound 
alkaline phosphatase was detected as a red product following incubation with the 
chromogen, New Fuchsin substrate system. For CD4+ and CD8+ the sections were 
incubated with peroxidase-blocking solution. The sections were incubated with 
EnVision secondary antibody solution for 30 minutes (DAKO). After a further wash, 
sections were incubated with chromogen (liquid DAB and peroxide buffer). Stained 
antigen sites were detected as a brown product. Slides were counterstained with 
H&E to provide nuclear and morphological detail, and mounted in mounting medium. 
Antibody diluents without primary antibody were used as negative controls. Sections 
of resected human tonsillar tissue were used as positive controls. 
 
Immunostaining mast cells 
Endobronchial tissue was only available in small numbers of the original preschool 
cohort and in this study only MCT was stained. Sections were stained for MCT by Mr 
Tim Oates. Children with remaining endobronchial tissue archived in paraffin had 
single sections cut and dewaxed with xylene. They were rehydrated through 
decreasing alcohol concentrations (100%, 90% and 70%) to water. Sections were 
then microwaved in pre-heated 10mM sodium citrate (2.941g in 1 litre water). 
Sections were air dried and washed in Tris Buffer Saline. Biopsies were blocked with 
horse serum to reduce background staining (VECTASTAIN® Elite ABC, Vector 
Laboratories). Sections were then incubated with mast cell tryptase (Dako, Clone 
AA1, Mouse Monoclonal) diluted 1 in 200 in TBS containing 10% normal human 
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serum for 1 hour at room temperature. Sections were incubated with secondary 
biotinylated mouse IgG in blocking serum followed by incubation with avidin biotin 
complex (VECTASTAIN® Elite ABC, Vector Laboratories) to block endogenous biotin 
activity. MCT positive cells were visualised as red nucleated cells when stained with 
chromogen Fast Red. Levamisole was used to suppress endogenous phosphatase 
activity and reduce background staining. Sections were counterstained with H&E. 
Slides were mounted aqueous mountant (Faramount, Dako). 
 
6.3.2 Quantification of neutrophils, eosinophils, and CD4+, CD45+ and CD8+ 
lymphocytes 
Inflammatory cells had previously been quantified by SS(9). Details of biopsy 
processing and evaluation are reported in chapter 3. Neutrophils, eosinophils, CD4+, 
CD45+ and CD8+ cells were assessed by point counting. Point counting is based on 
stereological principles, which is the study of the three-dimensional properties of 
objects seen in two dimensions(278;279). Using point counting, the determination of 
volume density of objects in a reference volume can be estimated using the 
formula(278): 
VVO, R = PO/ PR 
where Vvo, R denotes the volume of objects (O) contained in a reference volume 
(R). PO is the number of points from a grid falling onto the structure of interest and PR 
is the number of points falling into the reference space. Vv is the volume density and 
corresponds to the volume proportion that the structure of interest (the cell) occupies 
in the reference space (the tissue compartment). 
 
In this study, point-counting was performed using a 100 point graticule and light 
microscopy (Leica DM2500 microscope, Leica DFC 300fx camera and LEICA Qwin 
version 3 software, Olympus BH2, Japan) at x400 magnification. The image was 
projected onto a computer screen and a virtual graticule (100 point) was moved 
systematically until all of that particular section had been measured. Points falling on 
smooth muscle, blood vessels, gland and artefactual spaces caused by the 
processing were not recorded. All points falling on positively stained cells were 
counted as positive and those and those falling on cells in other areas of the 
submucosa were counted as negative, figure 6.1. For all cell types, in each child the 
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value for volume density was calculated as the sum of all the positive points (Po) in 
one section analysed for that subject, divided by the total number of points counted 
in the sections (PR), and then multiplied by 100 to express the value as a 
percentage. 
 
Figure 6.1: Nucleated cells stained with neutrophil elastase in an 
endobronchial biopsy section from a preschool child 
 
 
 
 
6.3.3 Quantification of smooth muscle and submucosal mast cells 
Mast cells were counted as total number of cells per unit area(148). Areas of airway 
smooth muscle and submucosa (lamina propria) were identified by morphologic 
examination. The area of submucosa (excluding areas of smooth muscle, blood 
vessels, gland and artefactual spaces caused by the processing) was calculated by 
tracing around the submucosa with a computer mouse and the area was calculated 
by a computer analysis system (Leica DM2500 microscope Leica DFC 300fx camera 
and Leica Qwin version 3 software, Olympus BH2, Japan). The area of smooth 
muscle was calculated in the same way. Nucleated, immunostained cells were 
enumerated in the submucosal tissue and airway smooth muscle, and the number of 
cells was expressed as the number per square millimeter of submucosa and smooth 
muscle, figure 6.2 and 6.3. Cells were counted within the bundles of smooth muscle 
Positively 
stained cells 
Negatively 
 stained cells 
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but those in the adjacent areas were counted as submucosal mast cells. The total 
number of cells was counted for mast cells rather than volume density of cells to 
allow direct comparison with adult ASM and submucosal mast cell counts(148). 
 
Figure 6.2: Preschool endobronchial biopsy showing nucleated mast cells 
stained red with mast cell tryptase within airway smooth muscle 
 
Smooth muscle
mast cell
 
Legend: Both masts cells indicated here were counted as ASM mast cells 
 
Figure 6.3: Preschool endobronchial biopsy showing nucleated mast cells 
stained red with mast cell tryptase in submucosa 
 
mast cells
50µm
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6.3.4 Variability of inflammatory cell counts 
The intra-observer variability of inflammatory cell counts, quantified using both 
methods (point counting and expressing total cell counts per unit area), was 
calculated from counts of the same section on 3 separate occasions, at least 3 days 
apart. As the tissue was limited and biopsies were relatively small, only a very limited 
number of biopsies (n=3) had more than one section stained per inflammatory cell 
for the original study(9). Intra-biopsy variability was assessed in 3 biopsies, from 3 
children, stained with EG2 for eosinophils. Inter-observer variability was assessed 
using Bland Altman plots and the intraclass correlation coefficient for cell counts 
performed by both SS and RO’R.  
 
6.4.1 Results: Variability 
Repeatability for eosinophils, represented by the CoV, for repeated measurements in 
the same section was 20% (20, 22 and 24%). The variability between sections from 
the same biopsy was also high with a coefficient of variation for 3 children 0% 
(biopsy with no eosinophils), 20.7% and 25.6%. On comparing measurements of 
subepithelial eosinophils between 2 observers, there was good agreement in 
children with cell volume density less than 1% but significantly more variability in cell 
volume densities greater than this, figure 6.4. The intraclass correlation coefficient 
for measurements of subepithelial eosinophils by SS and RO’R was 0.68.  
 
Figure 6.4: Difference between measurements of subepithelial eosinophils in 
endobronchial biopsies measured by RO’R and SS plotted against the mean of 
the 2 measurements 
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6.4.2 Subepithelial eosinophils 
Severe recurrent wheezers (n=29, 1.47 [range 0-3.33]%) had increased subepithelial 
eosinophils when compared to controls (n=8, 0 [range 0-0.8]%), p=0.01. Children 
with CW (0.78, [range 0-3.33]%) had no difference in subepithelial eosinophils when 
compared to RW (0.7, [range 0-2.8]%) but were increased when compared with 
controls, p=0.04. However, subepithelial eosinophils in EB were not increased in 
those children who went on to develop school age asthma, p=0.14, figure 6.5, table 
6.1. There was no difference when preschool wheezers (excluding controls) who did 
and did not develop school age asthma were compared, p=0.43. There was no 
correlation between eosinophils and RBM thickness as measured by RO’R. 
 
Figure 6.5: (i) Increased subepithelial eosinophils in severe recurrent 
preschool wheezers when compared to preschool controls. (ii) No difference in 
preschool subepithelial eosinophils between children who developed school 
age asthma and those who did not 
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Preschool subepithelial eosinophils (measured by SS) were significantly different in 
children who developed school age asthma (n=8, 2.19 [range 0-3.52]%) compared to 
those who did not (n=19, 0.69 [range 0-1.85]%), p=0.02, figure 6.6. 
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Figure 6.6: Increased submucosal eosinophils as measured by SS when 
compared to school age asthma status 
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6.4.2.2 Relationship of subepithelial eosinophils and lung function and airway 
inflammation at school age 
There was a positive correlation between school age FEV1 z score (n=22, Spearman 
r=0.54, p=0.01) and FVC z score (n=22, Spearman r=0.49, p=0.02) and subepithelial 
eosinophils at preschool age measured by RO’R, figure 6.7. Similar correlations 
between subepithelial eosinophils in preschool wheezers (n=18) between FEV1 z 
score (Spearman r=0.54, p=0.02) and FVC z score (Spearman r=0.47, p=0.05). No 
correlation was seen between eosinophils and FeNO50 or MBW indices. 
 
Figure 6.7: A positive correlation between preschool subepithelial eosinophils 
and (i) FVC z score and (ii) FEV1 z score at school age 
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6.4.3 Other cell counts: neutrophils, CD45+, CD4+ and CD8+ 
There was no difference in neutrophil, CD45+, CD4+ and CD8+ cell counts either 
between severe recurrent preschool wheezers and non wheezing preschool controls 
or between children with or without school age asthma, table 6.1 and figure 6.8. The 
cells counts measured by SS also showed no difference. There was no difference for 
any of the inflammatory cell counts when wheezers were divided at preschool age 
into CW and RW. There was no correlation with lung function measurements and 
FeNO50 at school age. 
 
Table 6.1: Inflammatory cell counts in endobronchial biopsies taken at 
preschool age related to school age asthma status. 
 Asthma No asthma p 
Submucosal eosinophils (n) 
Median (Range) % 
8 
1.47 (0-3.33) 
19 
0 (0-11) 
0.14 
 
Neutrophils (n) 
Median (Range) % 
8 
0 (0-3) 
13 
0 (0-3.17) 
0.48 
 
CD4+ (n) 
Median (Range) % 
8 
7.23 (0-22) 
13 
6.6 (0-33.8) 
0.71 
 
CD8+ (n) 
Median (Range) % 
8 
7.375 (0-18.1) 
12 
10.9 (1.2-32) 
0.35 
 
CD45+ (n) 
Median (Range) % 
8 
28.3 (3.6- 53.6) 
12 
31.2 (8.9-49.8) 
0.67 
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Figure 6.8: There was no difference in preschool subepithelial neutrophils, 
CD4+, CD8+ or CD45+ cell counts measured by RO’R when compared by 
preschool wheeze group or with school age asthma status. 
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6.4.4 Mast cells in endobronchial biopsies from preschool wheezers 
A subgroup of children (n=34), 25 wheezers and 9 controls, with remaining biopsy 
tissue had further sections stained for MCT. Two biopsies were excluded (2 controls) 
because of crush or distortion of the biopsy. There was very limited endobronchial 
tissue and MCT positive cells were only assessed in 1 section from each child. 
Repeatability, measured by the CoV, for repeated measurements in the same 
section was 5.3% (4.4, 5.4 and 6.2%).  
 
6.4.5 Smooth muscle mast cells 
Twelve children (12/32) did not have smooth muscle in the sections stained with 
MCT. There was a trend to higher mast cells per smooth muscle area in controls 
(n=5, median 88.5 (range 63.8-396.6)/mm2) when compared with wheezers (n=15, 
median 33.6 (range 0-239.3)/mm2) but this was not statistically significant, p=0.08, 
figure 6.9 (i). On analysis of subgroups there was no difference between CW (n=8, 
33.4, (0-239.3)/mm2), RW (n=7, median 33.6 (0-206.4/mm2) and controls, p=0.19, 
figure 6.9(ii). 
 
Figure 6.9: Mast cells per smooth muscle area (mm2) compared between (i) 
wheezers and controls and (ii) confirmed wheezers, reported wheezers and 
controls.  There was a counter intuitive trend towards increased mast cells in the 
control group. 
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6.4.6 Submucosal mast cells 
There was no difference in submucosal MCT positive cells between wheezers (n=25, 
median 139.3 (39.5-552.3)/mm2) and controls (n=7, median 117.4 (61.3-
278.6)/mm2), p=0.41, figure 6.10 (i). Similarly there was no difference when the 
subgroups of wheezers with CW (n=13, median 139.3 (40.8-552.3)/mm2) and RW 
(n=12, 135.4 (range 39.5-327.8)/mm2) were compared with controls, p=0.6, figure 
6.10 (ii). 
 
Figure 6.10: Submucosal mast cells compared between (i) wheezers and 
controls and (ii) confirmed and reported wheezers and controls 
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6.4.7 Smooth muscle and submucosal mast cells & school age asthma  
Irrespective of school age asthma status, there was no difference in preschool 
smooth muscle MCT positive cells, figure 6.11 and table 6.2. Similarly, there was no 
difference in submucosal MCT positive cells when compared with the presence or 
absence of asthma, figure 6.11 and table 6.2. 
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Figure 6.11: There was no difference in preschool smooth muscle mast cells 
when related to school age asthma status (i); or between preschool 
submucosal mast cells when related to school age asthma status (ii) 
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Table 6.2: No difference in smooth muscle and submucosal mast cells 
between wheezers and controls at preschool age and those with and without 
asthma at school age.  
 Wheezers Controls p 
 
Submucosal 
Mast cells (mm
2
) 
n=25 
139.3 (39.5-552.3) 
n=7 
117.4 (61.3-278.6) 
 
 
0.41 
CW n=13 / RW n=12 
139.3 (40.8-552.3) / 135.4(39.5-327.8) 
 
0.6 
 
Smooth muscle  
Mast cells (mm
2
) 
 
n=15 
33.6 (0-239.3) 
 
n=5 
88.5 (63.8-396.6) 
 
 
0.08 
CW n=8 / RW n=7 
33.4 (0-239.3) / 33.6 (0-206.4) 
 
 
0.19 
 School age asthma No asthma  
Smooth muscle  
Mast cells (mm
2
) 
n=5 
22.9 (0-239.2) 
n=10 
91.9 (0-396) 
 
0.16 
 
Submucosal 
Mast Cells (mm2) 
 
n=7 
188.3 (40.8-552.3) 
 
n=17 
129.5 (51.3-278.6) 
 
 
0.28 
 
 
6.4.8 Airway smooth muscle and smooth muscle mast cells 
There was no correlation between ASM area fraction and smooth muscle MCT 
positive cells (Spearman r=-0.01. p=0.94), figure 6.12. Similar, results were seen 
when MCT positive cells were correlated with ASM volume fraction (Spearman r=-
0.03, p=0.86). 
 
Figure 6.12: No correlation between ASM and smooth muscle mast cells 
Spearman r=-0.01, p=0.94
0.00 0.05 0.10 0.15 0.20
0
100
200
300
400
500
smooth muscle/ subepitheliumS
m
o
o
th
 m
u
s
c
le
 m
a
s
t 
c
e
ll
s
/ 
m
m
2
 
 
 
 224 
6.5 Discussion 
6.5.1 Summary of Results 
 Although there was a significant difference in submucosal eosinophil volume 
density between wheezers and non-wheezing controls at preschool age, no 
difference was seen in submucosal eosinophil volume density when 
compared by presence or absence of asthma at school age when measured 
by RO’R. However, SS’s eosinophil measurements in contradiction did show 
a significant increase in children who developed school age asthma, 
underscoring that this variable measurement is unlikely to be clinically useful. 
 No difference was seen in neutrophils, CD4+, CD8+, CD45+ and mast cells in 
those who did and did not wheeze at preschool age or in those who did or did 
not have asthma at school age. 
 
Strengths  
This is the only study where tissue inflammatory cell counts in children with recurrent 
wheeze at preschool age have been related to asthma at school age. Furthermore, 
this was the first time that both ASM and submucosal mast cells were stained for and 
quantified in endobronchial biopsies from severe recurrent preschool wheezers.  
 
Limitations 
Study size 
The number of preschool children who had sections stained for inflammatory cells 
and also the number of children who were followed up at school age was small. This 
study was not powered to detect a difference between groups at school age. A 
minimum sample size of 15 subjects per group has been suggested for studies of 
inflammatory cells in adult endobronchial biopsies(280). Furthermore, a sample size of 
13-48 subjects per group is needed to detect at least one doubling difference in cell 
number per 0.1 mm2 of tissue, for a particular inflammatory cell type, in a study with 
a parallel group design(281). The majority of children in this study had only 1 section 
from a single biopsy stained per inflammatory cells. However inflammatory cell 
biopsy studies of adults with chronic obstructive airways disease suggest one biopsy 
taken from each of two airway generations, from each subject, should be examined 
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in order to maximise statistical power to detect differences between study groups 
(282). 
 
Variability 
The CoV for repeated measurements using the point counting method in this study 
was (0-22)%, similar to that reported by SS (0-17)%. Different factors which 
contribute to the overall variance for point counting have been estimated and include 
70% variability between subjects, 20% between biopsy blocks, 5% between 
sections, 3% between light microscopy fields, and 2% between measurements(85). 
The CoV reported for measuring mast cells (expressed per mm2) was (4-6)% 
comparable with inflammatory cell counts in adult studies (2.3%)(282).  
 
Secondly, there was also considerable variability between observers (RO’R and SS) 
in measuring inflammatory cell counts. However, for consistency, all cell counts 
analysed in this study were performed by a single observer (RO’R) which eliminated 
any inter-observer bias that could have been introduced. Variability between biopsies 
was only assessed for eosinophils because of limited endobronchial tissue. 
Variability was similar between biopsies from the same child (20-25%) to variability 
between children with and without asthma at school age (15%). 
 
Endobronchial biopsy size 
It would have been useful to stain endobronchial tissue for both MCT and MCTC. 
However, this was not possible because there was no endobronchial tissue 
remaining. 
 
One single measurement of inflammation 
As in all chronic diseases, one single measurement of inflammation in an EB at a 
single point in time is unlikely to represent the full inflammatory picture. Other 
assessments of inflammation such as BAL inflammatory cell counts were not 
available in this group of children who had bronchoscopy at preschool age. Sputum 
inflammatory phenotypes were not stable in school age children with severe 
asthma(165), which may suggest that neither are submucosal inflammatory cell 
counts. Secondly, airway submucosa inflammation does not necessarily correlate 
with blood, sputum or BAL inflammation(283). This may be attributed to the fact that 
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sputum and BAL sample the airway lumen, whereas the cellular inflammation in the 
airway submucosa may be distinct. It is not known which compartment is more 
important.  
 
6.5.2 Discussion of principal findings 
 
Subepithelial eosinophils 
Subepithelial eosinophils at preschool age did not predict wheeze persistence at 
school age when measured by RO’R. Although subepithelial endobronchial 
eosinophil measurements performed by Dr S Saglani did show a significant 
difference between children with and without school age asthma, the number of 
subjects was small and variability was large both intra-observer and between biopsy. 
A larger sample size with a least 2 good quality biopsies per child may conclusively 
answer this question. It is possible that increased eosinophils at preschool age may 
represent current symptoms rather than future asthma prognosis, but this study is 
unable to confirm or refute this. Interestingly, children aged 1-3 years with 
eosinophils in nasal secretions during an acute respiratory tract infection had 
significantly higher risk of wheezing over the following 2 months but not over the 
longer term, at 12 months(284).  
 
Features of airway remodelling that are typical of asthma develop in asthmatic 
children even in the absence of a prominent eosinophilic infiltrate, indicating that 
other mechanisms, besides eosinophilic inflammation, may promote airway 
remodelling (increased RBM thickness and epithelial cell loss) early in life(285). There 
are conflicting reports about the correlation between subepithelial eosinophils and 
RBM thickness in children and adults with asthma. Adults with asthma showed a 
positive correlation between subepithelial eosinophils and RBM thickness(286). In 
contrast there was no correlation between subepithelial eosinophils in school age 
children with difficult-to-treat asthma(116) or children with mild-moderate asthma(285) 
and RBM thickness. Supepithelial eosinophils correlated with RBM thickness in the 
severe recurrent preschool wheezers(9), but repeat measurements by a second 
observer (RO’R) showed no correlation. Most of the preschool children were treated 
with ICS at time of EB, however airway inflammation and increased RBM thickness 
do not respond concordantly to ICS treatment(287). Adults with asthma (n=35) who 
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were treated with inhaled fluticasone and had BAL and EB at baseline, 3 months and 
12 months showed a decreased in BAL inflammatory cells at 3 months but not in 
RBM thickness until 12 months after treatment with ICS(287).  
 
Eosinophilic inflammation correlated positively with both FEV1 and FVC z scores at 
school age. Children with no subepithelial eosinophils were more likely to have lower 
FEV1 and FVC at school age, which is counter-intuitive. Several of these children 
had alternative diagnoses at school age unrelated to asthma (including scimitar 
syndrome and a small congenital right lung and repaired congenital heart disease) 
that likely accounted for this. However, although there was a correlation between 
eosinophilic airway inflammation in preschool wheezers and FeNO50 when followed 
up age 5 years(63), there was no correlation with FeNO50 at age 7 years. 
 
Mast cells within airway smooth muscle 
Infiltration of ASM by mast cells is thought to be responsible for the increase in ASM 
mass in adult asthmatics(148). There was no difference in MCT positive cells per ASM 
area between preschool wheezers and controls, or children with or without school 
age asthma. The number of MCT positive cells per ASM area is much higher for both 
wheezers and controls (median 64 (range 0-396) mast cells/mm2) when compared to 
adult asthmatics (median 5.1 (range 0-33) mast cells/mm2)(148). However the 
absolute values for MCT positive cells seen in ASM were similar in children (median 
2 (range 0-12)) and adults (median 2 (range 0-8))(148). Preschool children did 
however have a much smaller ASM area (median 0.02 (0.01-0.12mm2) measured 
than adult patients (ASM area median 0.3 (0.16-0.97) mm2)(148). Although only cells 
within the bundles of smooth muscle were counted, serial sections were not 
available to confirm that mast cells were not juxtaposed from submucosal tissue onto 
smooth muscle owing to biopsy artefact(148). There was no relationship between total 
ASM and mast cells within smooth muscle. However, sample sizes are very small 
and any conclusions drawn are preliminary. 
 
Submucosal mast cells 
There was no difference in numbers of submucosal MCT positive cells between 
wheezers and controls or between children with and without school age asthma. 
However, mast cells quantified in the infant cohort recruited from Helsinki, Finland 
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with reversible airflow obstruction (median age 1 year) had a weakly positive 
correlation with symptom persistence as measured by asthma medication purchase 
at 3 years but school age follow up is not available to date(139). However, mast cell 
quantification in that study was performed using electron microscopy which 
recognises mast cells by their ultra-structural features and included all mast cells 
(chymase and tryptase), so a direct comparison is impossible(138). 
 
Similarly, there was no difference in submucosal mast cells between school age 
children with mild-moderate asthma (most of whom were not treated with ICS) and 
atopic and non-atopic school age controls(93). However in a recent study submucosal 
MCT positive cells were shown to be highest in adults with mild asthma not being 
treated with ICS and decreased with increasing asthma severity(147). In contrast 
MCCT cells were the predominant mast cell phenotype in severe adult 
asthmatics(147). Children with severe therapy resistant asthma also did not have an 
increase in mast cells within smooth muscle or the submucosa(119). A limitation of the 
current study is that 9 wheezers were being treated with ICS and a further 3 
wheezers with oral corticosteroids at the time of biopsy.  
 
Summary 
There was no relationship between inflammatory cell counts at preschool age and 
school age asthma. ASM mast cells were not related to ASM area fraction or volume 
fraction.  
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Chapter 7 
Discussion and Final Summary 
 
Principal findings reported in this thesis 
The aim of this final chapter is to summarise and discuss (i) the implications of the 
results reported in this thesis with regard to the relationship between preschool 
airway pathology and school age asthma status and (ii) how the findings from this 
thesis suggest research directions for future studies. 
 
The hypotheses tested in this thesis were: 
 School-aged children with asthma have evidence of airway remodelling and 
airway inflammation in endobronchial biopsies taken at preschool age when 
compared to school-aged children without asthma. 
 
This hypothesis was discussed in chapters 3-6 and found to be partly true. 
Although EB eosinophilia, RBM thickness (at least as measured by RO’R) and 
RBM TN-C (with all its questionable reliability) were significantly higher at 
preschool age in wheezers compared with controls, they did not discriminate 
between the children who developed asthma by school age and those who 
did not. ASM from preschool endobronchial biopsies to some extent 
discriminated those severe preschool wheezers who developed asthma at 
school age. However, there is significant overlap in ASM (expressed as the 
proportion of the EB area) between preschool wheezers who did and did not 
develop asthma at school age and also between controls who never 
wheezed. This suggests that ASM mass will not be a useful test in predicting 
children who develop asthma but rather points to ASM as a new focus to 
determine what drives the evolution of preschool wheeze to asthma. This 
study has only focussed on quantifying the amount of ASM in preschool 
biopsies, but has not assessed early function, and this may be an important 
determinant of future asthma. The numbers are small, and the results 
hypothesis generating, but this is the key novel finding arising from the work 
of this thesis, and forms the focus of much of this final chapter. Unfortunately 
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there was no further biopsy tissue available in which to perform mechanistic 
studies. 
 
 A combination of clinical and airway pathological characteristics at preschool 
age may be able to be used to predict asthma at school age, better than 
clinical features alone. 
 
Only 7 preschool wheezers who had asthma at school age had airway 
pathology measurements for RBM, ASM and eosinophils. Numbers were too 
small to develop a predictive score and test the hypothesis. Furthermore, 
there was not a second cohort available in which to validate any predictive 
score.  
 
7.1 Strengths and novel data 
This is the first study to quantify ASM, TN–C within the RBM and mast cell infiltration 
of smooth muscle and submucosa in EBs from severe recurrent preschool 
wheezers. All measurements were made by a single observer, blind to both 
preschool and school age clinical status. Secondly, this is the first study to relate 
pathological findings at preschool age with asthma status at school age.  
 
ASM is increased in those preschool children with severe wheeze who go on to 
develop asthma at school age. Neither RBM thickness nor subepithelial eosinophils 
(as measured by RO’R) were significantly increased in those who developed asthma 
at school age. Although SS did show that RBM thickness was increased in those 
who developed asthma, this was likely related to the 12 month age difference in time 
of EB between those who did and did not develop asthma at school age. This could 
suggest that RBM thickness and subepithelial eosinophils at preschool age could be 
related to current symptoms rather than future prognosis, but even this must be 
considered as a preliminary, hypothesis-generating finding, given the variability of 
the measurements. The fact that two experienced observers obtained differences in 
results, which may be in part be due to counting different slides from the same 
patient, underscores the difficulty of using these methods. There was no relationship 
between school age asthma and any other inflammatory cell count at preschool age 
including submucosal and smooth muscle mast cells. 
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This thesis reports on the previously recruited wheezers and non-wheezing controls, 
who were well characterised at entrance to the study at preschool age, at aged 6-11 
years. To my knowledge, this is the only prospective preschool group followed 
longitudinally who had bronchoscopy and EB at entrance to the study in the pre-
school years. Subject retention to school age (75%) was comparable to other studies 
(54-91%)(1;10-12;14;15). Wheeze had been confirmed at preschool age using a video 
questionnaire(9;153), and at school age confirmed wheeze at preschool age was a 
significant predictor of asthma. However, assessment of wheeze at school age 
showed only limited agreement between the video and written questionnaire (kappa 
0.46, p=0.005). Failure of carers who reported wheeze to identify it on video 
questionnaire was more common in children with milder wheeze who may not have 
been as symptomatic as the child in the video questionnaire having an acute asthma 
exacerbation. The majority of children in this study had had at least 1 admission to 
hospital with wheeze and had wheeze confirmed by a doctor at least once. 
 
7.2 Limitations of this thesis 
 Small sample size 
The most obvious limitation of this study was the small numbers with biopsies 
followed up at school age, figure 7.1. Only 8 children with ASM in their EB had 
asthma when followed up at school age. Secondly, not all children had 
complete data sets available for measurements of airway pathology at 
preschool age or measurements of airway inflammation and lung function at 
school age. Multiple comparisons were made in a small number of patients 
which could have generated spurious associations. In any case no second 
validation cohort was available so all findings must be considered hypotheses 
generating. 
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Figure 7.1: Follow up of preschool wheezers at school age related to airway 
pathology measurements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Wheezers at preschool age 
An important limitation was that the wheezers enrolled in the original study 
were of necessity very severe otherwise they would not have undergone 
bronchoscopy. Children with asthma at school age had many reported 
admissions with wheeze as the main symptom (median n=17). These children 
are not representative of preschool wheezers in the general population but 
rather a specific group with more severe disease and so the findings in this 
thesis may not be applicable to children with less severe wheeze. However, 
those early severe wheezers who go on to wheeze persistently have the 
largest early reduction in lung function, which is why this group is important in 
studying the factors driving the development of asthma(6). Although recruiting 
children at or shortly after birth as in the Tuscon(1) or COAST(59) cohorts is 
preferable to preschool age, the numbers needed to capture enough 
wheezers severe enough to warrant bronchoscopy at preschool age would be 
impractical. Even by recruiting children with increased risk of wheeze (i.e. 
infants of asthmatic mothers) such as in the COPSAC(48) cohort, the study 
numbers needed to capture those severe preschool wheezers who would 
warrant bronchoscopy is clinically not feasible. The number of children who 
have bronchoscopy for investigation of recurrent wheeze at preschool age is 
Children recruited 2002-2005 
Wheezers (n=47) 
Controls (n=21) 
 
 
Lost to follow up (n=17) 
 
Followed up by questionnaire (n=51) 
Children with preschool biopsy measurements of: 
Reticular basement membrane thickness (n=39) 
Airway smooth muscle (n=32) 
Subepithelial eosinophils (n=27) 
Mast cells within smooth muscle (n=15) 
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likely less than 1% of all children, suggesting a sample size of 100 undergoing 
bronchoscopy would require a total recruitment cohort of 10,000. 
 
 Absence of truly healthy controls 
A further limitation of this thesis is the absence of healthy, asymptomatic 
controls. Genuine, healthy asymptomatic controls could not be obtained in 
view of the invasive nature of the initial study. Unlike in adults, it is not 
ethically acceptable to perform bronchoscopy in infants or children solely for 
the purpose of research. Several of the control children had other pathology 
including congenital heart disease at preschool age and a diagnosis of 
ulcerative colitis at school age. This made it difficult to compare assessments 
of lung function at school age.  
 
 Absence of bronchoalveolar lavage at preschool age 
At the time of the original study at preschool age BAL was not included in the 
research protocol. The main reason for this was logistic; there was no core 
facility for quantitative cell counting and storage of fluid at the time. Although 
BAL samples from the wheezers were done for clinical reasons at preschool 
age there was variability in methods used to obtain the lavage. However, 
subsequent cohort studies since recruitment of the original preschool RBH 
group have highlighted the importance of bacterial (COPSAC)(48) and viral 
(COAST)(59) infection in early wheezers in wheeze persistence and the 
development of asthma, and the absence of data on infection is an 
acknowledged weakness of the study.  
 
 Misclassification of asthma at school age 
Defining asthma in young children is difficult(156). In the present study, several 
children without asthma reported a dry cough at night (n=7), wheeze (n=7) 
and use of ICS (n=4) but none of these children had ever had a doctor 
diagnosis of asthma and many had a history of upper airway noises or co-
morbid pathology. Of the children who did not have asthma at school age 4 
had congenital heart disease, 1 had a vascular ring causing some mild airway 
compression, 1 had ulcerative colitis, 1 had non cystic fibrosis bronchiectasis 
likely related to an initial, severe viral bronchiolitis and 1 child had a diagnosis 
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of scimitar syndrome. The children with asthma who attended for clinical 
assessment had higher IgE at preschool age, were more likely to be atopic, 
have allergic rhinitis and eczema at school age recruitment, suggesting that a 
group likely to have asthma was selected. However, it is possible some 
children may have been misclassified as non-asthmatic at school age. The 
effect of this would have been to reduce the chances of showing differences 
between the groups 
 
 Possible confounding effects of ICS/ oral corticosteroids 
The majority of preschool wheezers had been treated with either or both of 
ICS and oral glucocorticosteroids prior to bronchoscopy and EB. Despite this 
there was still a difference in RBM thickness and RBM TN-C expression and 
tissue eosinophilia seen between preschool wheezers and controls. No 
difference in ASM was shown between preschool wheezers and healthy 
controls when compared as groups. It is possible that treatment with ICS and 
/or oral steroids may have masked a difference between these 2 groups. 
However, in adult asthmatics ASM mitogenesis and growth are resistant to 
glucocorticoids(288). In vitro studies suggest absence of CCAAT / Enhancer 
binding protein α (which binds to the glucocorticoid receptor to inhibit cell 
proliferation) in adult asthmatics is responsible for the enhanced proliferation 
of ASM cells and the failure of glucocorticoids to inhibit proliferation(288). On 
the other hand RBM TN-C has been shown to decrease in adult asthmatics 
with ICS therapy(144;244). There have been contradictory reports on the effect of 
ICS on RBM thickness, with some studies showing a reduction with treatment 
with ICS in adult asthmatics over varying time periods from 6 weeks(289) to 1 
year(286) to no treatment effect with ICS(290). ICS are also known to reduce 
tissue eosinophils(287) and mast cells(147). It may be that the preschool children 
were not prescribed high enough amounts or a long enough duration of 
treatment with ICS, or more likely inadequate drug delivery or poor 
compliance in this young age group. A further weakness is that ICS 
compliance was not assessed prior to bronchoscopy and EB at preschool 
age.  
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 Age of endobronchial biopsy when compared with school age asthma 
status  
A major strength of the original study was that wheezers and controls were 
age matched(9). However, when followed up at school age unavoidably 
children with school age asthma (median age 8.2 years) were older at the 
time of EB (28 months versus 17 months) when compared to children without 
school age asthma (median age 7.3 years). This means that age difference of 
EB between those who developed asthma at school age and those who did 
not may have affected the interpretation of some of the results. 
 
The natural history of airway pathology in preschool wheeze has not been 
explored, but it is likely that other structural airway changes, like RBM 
thickness, will also evolve throughout childhood and adolescence. RBM TN-C 
developmental expression is unclear, it is known that there is a small amount 
present at birth but none in adulthood(141), but it remains unknown when RBM 
TN-C disappears. RBM TN-C may disappear when RBM reaches adult 
thickness(113). In this thesis, the age discrepancy at the time of biopsy may be 
a confounder, because those without asthma at school age were younger 
when biopsied, and may have had normal but increased RBM TN-C than the 
children who went on to develop asthma. In this regard, the failure of 
subsequent runs of TN-C staining meant that developmental changes in TN-C 
expression could not be explored.  
 
Data on normal ASM development are scant. A post-mortem study showed 
that ASM increased linearly from 22 weeks post conceptual age to 8 months, 
and then two to four fold to early adulthood(256). Although adults have more 
ASM in real terms when compared to children, the proportion of ASM in the 
airway wall remains similar(261). Although the children with asthma were older 
than those without asthma, no correlation was found between ASM and age in 
non-wheezing preschool and school age children. This is likely because ASM 
was quantified as a proportion of the EB rather than the actual mass of ASM.  
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 All data are from single time points 
This thesis reports essentially two cross-sectional datasets, relying on 
retrospective recall of disease severity. In this study data are available on 
clinical symptoms (age 2-3 years and age 7-8 years), airway pathology (age 
2-3 years) and lung function and non-invasive airway inflammation 
assessment (age 7-8 years) from single time points. It would have been very 
useful to repeat endobronchial biopsies at school age to compare preschool 
and school age airway pathology, but ethically impossible in clinically well 
children. An attempt was made to collect details of medication use between 
the two study time points; however, quite often parents were unable to recall 
their child’s prior medication history.  
 
Meaning of the study 
Early childhood may be an important time when disease modifying or preventative 
therapies could be applied before the persistent asthma phenotype becomes 
established. The purpose of this research was to try and understand what features of 
airway pathology changes might be related to wheeze persistence and the 
development of childhood asthma. The data suggests that a future focus on ASM 
may be key in helping understand what drives some children to develop school age 
asthma.  
 
Study numbers were too small to allow identification of a specific endotype 
associated with increased ASM. However, those children with asthma (and ASM on 
their EB) had more severe disease at school age. Almost all children (7/8) with 
asthma at school age were still attending tertiary services for asthma management, 
had persistent asthma symptoms despite treatment with high dose ICS (6/8) and 4 
children were classified as severe asthma at school age(195). The data suggests that 
increased ASM is associated with severe preschool wheeze, suggesting that intrinsic 
abnormalities in ASM may predispose children to developing asthma and particularly 
severe asthma at school age. Longitudinal studies have suggested that children with 
severe wheeze early in life are more likely to have severe asthma later in life(71).  
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Future work and unanswered questions 
As there is no remaining endobronchial tissue from the preschool wheezers recruited 
between 2002 and 2005, future studies will need to recruit a second cohort of 
preschool wheezers. Although it would be interesting to recruit preschool children 
with a wider spectrum of wheeze severity, bronchoscopy and EB will be only 
clinically indicated in those children with severe recurrent wheeze and these are the 
group of children most likely to have pathological abnormalities. A future study would 
recruit recurrent preschool wheezers with assessments of lung function (measured 
by MBW and specific airways resistance) and BDR measured at entrance to the 
study, followed by clinically indicated bronchoscopy, bronchoalveolar lavage and EB. 
MBW is currently the most sensitive indicator of airway abnormality in young children 
with wheeze(62;172) and bronchodilator reversibility has been successfully performed 
using both specific airways resistance and MBW in the preschool age group(62). 
FeNO50 was assessed in the present study but more distal inflammation was not 
assessed as children were too young to perform FeNO at multiple flows. Preschool 
RBM correlated with FeNO50 at age 4-5 years
(63) and a non-significant trend with 
FeNO50 at school age in those with preschool wheeze. It would be interesting to 
follow up the RBH cohort at age 10 years or older to measure fractional exhaled NO 
to calculate alveolar and bronchial flux NO and relate this to preschool RBM 
thickness(190). BAL should be assessed by bacterial culture and molecular studies 
(16s rRNA) and molecular techniques (including polymerase chain reaction) for 
common viruses. The BAL cytokine, microbiome and metabolome profile in 
preschool wheezers should also be measured. The airway microbiome is discussed 
in more detail in the ‘Novel areas for possible further exploration’ section which 
follows.  
 
Exploring airway smooth muscle further in preschool wheezers  
To date airway remodelling and airway inflammation has been quantified in 
preschool wheezers and compared to age matched controls, but no assessment has 
been made as to whether different structural components of the airway wall are 
inherently functionally different in preschool wheezers who develop asthma when 
compared to children who do not. In particular pilot data from this study suggests 
that a focus on ASM may yield some answers as to why some preschool children 
with wheeze develop asthma. 
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Although it was not possible to further characterise the mechanisms underlying ASM 
increase in this group of preschool wheezers as there was no remaining EB tissue, 
both smooth muscle hypertrophy and hyperplasia contribute to the increase in ASM 
in adults and school-age children with asthma(110;121;122;249). There is an increasing 
body of evidence that ASM is fundamentally different in asthmatics compared to 
healthy controls suggesting that abnormalities in ASM cells may play a critical role in 
the development of the abnormal physiology in asthma and may contribute to the 
persistent airway inflammation(291). Recent evidence suggests that ASM from adult 
asthmatics is intrinsically hyper-contractile and exhibits an increased oxidative stress 
burden when compared to healthy controls(291). Nicotinamide adenine dinucleotide 
phosphate oxidase (NOX)4 expression is increased in asthma and its inhibition or 
siRNA knockdown normalises this airway smooth muscle hyper-contractility(291). 
Cultured adult asthmatic (n=9) ASM cells in gel contraction assays have also shown 
an increased velocity of contraction in response to histamine when compared to 
adults without asthma(292). It is possible but unproven that the ASM cells in those 
children with preschool wheeze who develop asthma are functionally distinct 
compared with children who do not develop asthma. ASM in preschool wheezers 
may also be intrinsically hypercontractile before children develop persistent wheeze 
and asthma. Future work needs to be undertaken to characterise ASM from 
preschool wheezers further, and will likely include the isolation of primary ASM 
bundles from EBs and culture of ASM cells(293). ASM cell responses in preschool 
wheezers to allergen(70), virus(59) and bacterial exposure(23) may be a fruitful source 
of future work since all have been implicated in the evolution of preschool wheeze 
into persistent wheeze and asthma. 
 
ASM cells also express a wide variety of mediators, and in particular recent research 
highlights the innate cytokines thymic stromal lymphopoietin (TSLP) and IL-33 as 
mediators of AHR, with increased ASM expression of these mediators in severe 
adult asthmatics(294-296). It may be that these or other ASM derived mediators are 
important in the switch from severe preschool wheeze to school age asthma. The 
identification of key mediators regulating the contribution of ASM to asthma may 
provide new opportunities for therapeutic intervention(297).  
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However, the airway epithelium also plays a central role in the pathogenesis of 
asthma, and the role of the epithelium has not yet been explored in severe preschool 
wheezers who develop asthma at school age(126). There is evidence that 
dysregulated epithelial repair originates in childhood asthma and is a critical 
determinant of disease progression into adulthood(128). Bronchial epithelial cells from 
asthmatic children function abnormally even in the absence of inflammation with 
decreased production of TGF-β and the release of anti-inflammatory mediators(128). 
There is also some in vitro evidence that an injured airway epithelium stimulates 
ASM cell hyperplasia, through IL-6, IL-8, monocyte chemotactic protein-1, and MMP-
9 dependent mechanisms(298). It is therefore possible that severe recurrent preschool 
wheezers who develop asthma at school age have inherently functionally different 
epithelial cells which thus respond abnormally to viral, bacterial or environmental 
stimuli leading to ASM hyperplasia. To address this hypothesis, a co-culture model 
of epithelial cells and ASM cells isolated from EB from severe recurrent wheezers 
could be compared with age matched non-wheezing controls(298) to analyse epithelial 
production of chemokines, cytokines, and growth factors and identify what stimulates 
ASM hyperplasia(246).  
 
Serially monitoring preschool wheezers 
It is likely that airway remodelling changes in preschool wheezers who develop 
school age asthma evolve gradually between preschool and school age.  An 
important part of future studies will be to serially monitor airway remodelling, 
inflammation and ongoing symptoms. Most of the methods used to monitor 
remodelling require invasive procedures, use of a general anaesthetic in children or 
ionising radiation. High resolution CT has shown a positive correlation with RBM 
thickness in adult asthmatics, but overlap among the groups limits the diagnostic 
value in individual adult patients(112). In children with problematic severe asthma 
there are conflicting reports on whether HRCT correlates with RBM thickness in 
children(299;300). In any case, concerns regarding radiation exposure means this is 
unlikely to be a useful tool to monitor disease progression in wheezy preschool 
children through to school age(301). Endobronchial ultrasound is a radiation free new 
technique that enables the assessment of bronchial wall layers(302). In adults there 
was no significant difference in the measurements of total bronchial wall thickness 
between endobronchial ultrasound and high resolution CT scanning, suggesting it 
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may be a radiation free way of monitoring disease progression in adults. 
Furthermore, the thickness of the bronchial wall positively correlates with RBM 
thickness and negatively correlates with FEV1 in adults with asthma
(302). However, 
this technique in children while radiation free will still require a general anaesthetic 
and is unlikely to be an acceptable technique to use serially. Novel areas such as 
exhaled breath condensate analytes could be investigated further to see if they could 
provide a serial marker for airway remodelling. 
 
Asthmatic symptoms in young children are due to a heterogeneous group of 
diseases. Although symptoms are the primary endpoint in both research and clinical 
management, there is no standardised method of symptom assessment. 
Assessment of ongoing disease is also important and wheeze severity has shown to 
be a risk factor for future asthma(79). Daily diaries have been used to assess 
symptoms and endotype asthma(303). A symptom algorithm based on a predeﬁned 
number of days and episodes of troublesome lung symptoms rather than disease 
categorisation using qualitative characteristics or temporal patterns of wheeze 
showed a stronger relation to an underlying ORMDL3 genetic variant which is 
associated to asthma susceptibility in those of North European descent(303). In future 
cohorts a daily symptom diary which also records medication use and is submitted 
weekly either electronically or by telephone interview may help record disease 
persistence more accurately. 
 
Novel areas for possible further exploration 
There are several new areas of research which may be fruitful in exploring the 
development of asthma in preschool wheezers. Non-invasive methods of serially 
assessing airway inflammation and remodelling are an attractive way of improving 
our understanding of the progression of early wheezing to asthma. Exhaled 
biomarkers which could be used to serially monitor inflammation are volatile organic 
compounds (VOCs) and non-volatile organic compounds in exhaled breath 
condensate. Recent research has also suggested a focus on the airway microbiome 
may also be important.  
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Volatile organic compounds 
VOCs are groups of exhaled biomarkers which are gaining interest as a method to 
serially monitor airway inflammation in preschool wheezers. Breath testing dates 
back to the early history of medicine, when ancient physicians tried to use the 
specific smell on the human breath to recognise illness such as diabetes or liver 
disease. VOCs are carbon‐based chemicals that are volatile at room temperature 
and are formed during several pathophysiological processes, including airway 
inflammation(304). During inflammatory processes free radicals are produced leading 
to lipid peroxidation and formation of volatile products including hydrocarbons such 
as ethane, pentane, hexanal, octanal, nonanal, propanol and butanol. Once VOCs 
are formed they enter the bloodstream and are excreted in the breath and can be 
measured by collection of exhaled breath and analysed by gas chromatography and 
mass spectrometry or the electronic e-nose. Hundreds of different VOCs are present 
in human breath, and their relative concentrations may alter in the presence of the 
disease. VOCs in exhaled air can be used to distinguish children with cystic 
fibrosis(305) and asthma from healthy children(306). In children and adults with cystic 
fibrosis (aged 8-29 years), the VOC pentane was much higher than in healthy 
controls, and higher in those with more severe lung disease or those having 
concurrent pulmonary exacerbations(305). A total of 945 VOCs were screened to 
profile which hydrocarbons could differentiate between asthmatic and healthy 
children (aged 5-16 years)(306). Eight VOCs discriminated between asthmatic and 
healthy children with a 92% positive predictive index, achieving a sensitivity of 89% 
and a specificity of 95%(306).  
 
One hypothesis is that the exhaled VOC profile is different in those severe recurrent 
wheezing preschool children when compared to healthy controls, and in particular in 
those wheezers who will go on to develop school age asthma. The e-nose technique 
creates a ‘breath‐print’ of multiple different VOCs and is quick, easy to use and not 
very expensive, which suggests it could be used to serially monitor the exhaled VOC 
pattern in children over time. However, exhaled compounds can be affected by 
various factors including ambient VOCs, exhaled flow, and prior consumed food and 
before VOCs can be used in clinical practice standardisation and validation of VOC 
profiling is essential.  
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Exhaled breath condensate 
Exhaled breath condensate analysis has also been successfully used in infant and 
preschool wheezers to monitor inflammation(307). Exhaled breath condensate mainly 
consists of water droplets but also contains small amounts of non‐volatile molecules. 
Airway turbulence during breathing is thought to cause the release of small aerosols 
of the epithelial lining fluid and to serve as a proxy method of monitoring airway 
inflammation. A modified gas chromatography system with a closed-glass condenser 
which enables recirculation of exhaled breath, increases the condensate collection 2 
fold and enables collection in less than 10 minutes in young children(307).  
 
The exhaled breath condensate cytokine profile has been able to differentiate 
between recurrent wheezers and non-wheezing controls in the Asthma DEtection 
and monitoring (ADEM) study(307). The ADEM study started in 2006 in the 
Netherlands and recruited 258 preschool children (aged 1.9-4.5 years), who were 
divided into children who never wheezed (n=57), children with 1-3 wheezing 
episodes (n=78) and children who experienced more than 3 wheezing episodes 
during life (recurrent wheezers, n=123). Recurrent wheezers had elevated TH2 
cytokines (IL-4, IL-5, IL-13), a proinflammatory cytokine (IL-1a), a TH1 cytokine (IL-2), 
a chemokine (IL-8), an anti-inflammatory cytokine (IL-10), and an adhesion molecule 
(sICAM) when compared to controls(307). The elevated levels of different types of 
cytokines fit the concept that in wheezing preschool children, more than one immune 
mechanism is involved. Children were followed up until age 6 years and those 
children with persistent wheeze had raised IL-2, IL-4, IL-8 and IL-10 at preschool age 
when compared to children who never wheezed(308). However, exhaled breath 
condensate measurements at 2 and 3 years, did not differentiate between the 
transient and persistent wheezing phenotype(308). The cytokine content of exhaled 
breath condensate could in the future be used to serially monitor inflammation in 
preschool wheezers, but more validation work is needed.  
 
Several mediators of airway remodelling can be assessed in exhaled breath 
condensate including MMPs, TIMPs, cysteinyl leukotrienes and endothelins(309-311). 
Endothelins mediate increased proliferation of ASM cells and thickening of the 
RBM(311). Endothelin-1 was higher in exhaled breath condensate from adult 
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asthmatics, particularly in those with uncontrolled asthma, when compared with 
healthy controls(311). Cysteinyl leukotrienes also increase ASM cell proliferation and a 
pilot study showed a correlation between cysteinyl leukotrienes and RBM thickness 
in school aged children with asthma(310). However, ASM was not quantified in this 
study(310). MMPs, particularly MMP-9, are also key mediators in airway remodelling 
(particularly increased RBM thickness), and have been investigated for their role in 
the pathogenesis of asthma. MMP-9 levels have been recently shown to be elevated 
in exhaled breath condensate from children with asthma and inversely correlated 
with lung function and had a positive correlation with other inflammatory markers 
such as IL-4 and IL10 in exhaled breath condensate(309). Exhaled breath condensate 
could be used to measure mediators of airway remodelling, particularly of ASM 
hyperplasia and hypertrophy, including alpha-smooth muscle actin, endothelins, 
cysteinyl leukotrienes on the day of bronchoscopy and EB and relate this to 
quantified ASM. Serial measurements of exhaled breath analytes could then 
potentially be used as markers to monitor changes in ASM with wheeze persistence 
or remission. 
 
The Airway Microbiome  
Although the human airways were traditionally thought to be sterile, and there is now 
evidence that the respiratory tract harbors microbes including bacteria, yeasts, 
viruses and bacteriophages(50). The airway microbiome refers to all microbes, their 
genomes, and environmental interactions in the lower airways. The respiratory tract 
is likely to be repetitively inoculated with the normal flora of the pharynx and the 
bacterial load in the airways has been proposed to be in the order of 2000 bacterial 
genomes per cm2 of surface area(50).  
 
Dysregulation of interactions between the immune system and commensal bacteria 
is one factor that underpins the development of many inflammatory diseases(312). 
Several animal studies have investigated the respiratory microbiome and its 
relationship to the development of allergic diseases such as asthma. Pulmonary 
exposure of mice to Escherichia Coli results in protection against the development of 
allergic airways disease(54). Secondly, mice who were intratracheally infected or 
treated with killed Streptococcus pneumoniae before, during or after ovalbumin 
sensitisation and subsequent challenge had suppression of hallmark features of 
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allergic airways disease with increased Tregs which reduced T cell proliferation and 
cytokine release(53). Gastrointestinal Helicobacter pylori infection protected 
ovalbumin stimulated mice from AHR, tissue inflammation, and goblet cell 
hyperplasia and prevented bronchoalveolar infiltration with eosinophils, TH2 cells, 
and TH17 cells
(313). This was more pronounced in those neonatally infected mice 
than adult mice(313). In contrast germ free mice (that lack pathogenic and non-
pathogenic organisms) develop worse allergic airways disease than those with a 
normal host flora(52).  
 
Further evidence for the role of the microbiome in the development of allergic 
disease is that children who grow up in environments with a wide range of microbial 
exposures, such as traditional farms, are protected from childhood asthma and 
atopy(49). In two recent European cross-sectional studies, microbial diversity and the 
prevalence of asthma were compared in children living on farms and children who 
were not farm-dwellers. The PARSIFAL (Prevention of Allergy-Risk Factors for 
Sensitization in Children Related to Farming and Anthroposophic Lifestyle) study in 
Bavaria, Germany screened samples of the children’s mattress dust for bacterial 
DNA with the use of single-strand conformation polymorphism analyses to detect 
environmental bacteria that cannot be measured by means of culture techniques(49). 
The GABRIELA (Multidisciplinary Study to Identify the Genetic and Environmental 
Causes of Asthma in the European Community) based in five rural areas in southern 
Germany, Switzerland, Austria and Poland evaluated samples of settled dust from 
children's rooms for bacterial and fungal taxa with the use of culture techniques in 
five rural areas in southern Germany, Switzerland, Austria and Poland(49). In both 
studies, children who lived on farms had lower prevalence’s of asthma and atopy 
and were exposed to a greater variety of environmental microorganisms than the 
children who did not live full time on farms(49). Diversity of microbial exposure was 
inversely related to the risk of asthma in both the PARSIFAL and GABRIELA 
studies(49). 
 
School-aged asthmatic children have an abundant lower airway bacterial flora, which 
is different to that of controls(50). Futhermore, a pilot study in adults with uncontrolled 
asthma, showed AHR correlated strongly with airway microbiota composition and 
diversity(314). The influence of microbial exposures in infancy and their effects on 
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asthma development are now recognised(48;49;55).The COPSAC cohort study 
highlighted the importance of bacteria in the development of asthma(48). Neonates 
colonized in the hypopharyngeal region with Streptococcus pneumoniae, 
Haemophilus influenzae, or Moraxella. catarrhalis or with a combination of these 
organisms, are at increased risk for recurrent wheeze and asthma early in life(48). 
However, more recent developments have demonstrated that the composition of 
bacterial communities colonising mucosal surfaces, rather than simply the presence 
of individual species, is important in the pathogenesis of disease(49).  
 
The airway microbiota composition of preschool wheezers is unknown, but it is likely 
the microbial flora influences host innate immune responses to infection and 
allergens in preschool wheezers who develop future asthma. It is also possible that 
microbial flora will differ between those wheezers whose symptoms remit and those 
who go on to persistently wheeze. Conventional microbial cultures are inadequate to 
identify microbiota and only reveal part of the airway microbiome. However, 
bronchial epithelial brushings or BAL from children and adults with asthma have 
previously been used to profile the microbiome with high-density 16S ribosomal RNA 
microarray and parallel clone library-sequencing analysis(314). A trial of antibiotic 
therapy could then be initiated and microbial flora, inflammation and immune 
responses (TH2, TH1, TH17 and Tregs) and mediators of airway remodelling assessed 
before and after antibiotic therapy. Key of course would be long-term outcome. 
 
Conclusion 
In summary, the work of this thesis has showed for the first time that ASM is 
increased in those preschool children with severe wheeze who go on to develop 
asthma at school age. The numbers are small and represent children with 
particularly severe wheeze at preschool age, such that the findings cannot be 
assumed to be applicable to children with less severe wheeze. However, the data 
indicate that future studies exploring the mechanisms underlying the persistence of 
preschool wheeze and its progression to asthma might profitably focus on changes 
in airway smooth muscle.  
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ppendix 1- Letter of invitation 
 
Department of Respiratory Paediatrics 
Royal Brompton Hospital 
Sydney Street 
London, SW3 6NP 
Tel: 020 7352 8121 
Mr & Mrs NAME 
ADDRESS 
 
DATE 
 
Dear Mr & Mrs NAME 
I am writing to ask whether you would consider allowing NAME to take part in a research 
project at the Brompton Hospital. 
 
You will remember that NAME had a camera test called a bronchoscopy at the Brompton 
Hospital when he was a baby. At that time you very kindly agreed for us to use any samples 
that were taken, and were left over after his clinical tests, for a research project looking at 
asthma in young children. We have now completed that study, and have found that overall 
children that were wheezy when they had their bronchoscopy did have features in their 
airway samples that suggested asthma. But at that time, we could not say for certain which 
children would have asthma when they got older and which would no longer be wheezy.  
 
In order to see whether the samples that we took at that young age will help us to see whether 
a child will have asthma when they are older, we want to ask whether you would bring 
NAME back  to the Brompton Hospital to answer a few questions about his breathing and to 
do some very simple blowing tests (no bronchoscopy). Details of all of the tests, how long 
they take and the reasons for doing this study are given in the information sheet enclosed with 
this letter. 
 
We are very grateful to you for taking the time to read this information. 
 
The doctor doing the research will contact you in a week or so to ensure you have received 
this information, and at the same time will be very happy to explain the research to you 
further and answer any questions that you might have. Please bear in mind that you are under 
no obligation to take part, and you may refuse without giving any reason. 
 
Thank you again for your time and help in considering this information. 
 
Yours sincerely 
 
 
Dr Ruth O’ Reilly 
Clinical Research Fellow 
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WHEEZING AND ASTHMA IN CHILDREN 
Children’s Information Sheet 
 
 
THANK YOU for taking the time to read this leaflet. We are doing a research study looking at 
breathing problems in children.  
 
What is research?  
Research is done to try and find out answers to important questions.  
 
What is this research about? 
By doing this research we hope to find out more about why some very young toddlers that have 
noisy breathing get asthma when they get older. 
 
Why have I been asked to take part? 
When you were a young toddler you had a special camera test of your lungs called a 
bronchoscopy at the Brompton Hospital. As you’ve had this special test, we now want to 
ask whether you would take the time to read on and consider taking part in our study. 
 
What is wheezing? 
Wheezing is a type of noise that comes from the chest. It can cause difficulty in breathing. 
Wheezing is very common and can sometimes make children very ill. Luckily, most children grow 
out of the problem, but some continue to wheeze as they get older and they can develop a 
problem called asthma. At the moment we can’t tell which children will carry on wheezing and get 
asthma.  
 
Why is this research important? 
We want to know whether you have any noisy breathing or wheezing, and whether you might 
have asthma. 
We want to know whether we can recognize who will have asthma at your age by looking at 
the results of the special bronchoscopy test that you and other children had when you were 
toddlers. 
 
Appendix 2 
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What happens if I agree to take part? 
 We will ask you and your mum or dad to answer some questions about your breathing 
 We will ask you to do 2 blowing tests 
 We will do some special tests on your forearm to see if you have any allergies  
 We will ask you to breathe in some misted air that tastes a bit salty, and then see if you can 
cough up some phlegm, and ask you to do some blowing tests after you’ve breathed in the 
misted air. 
 We will ask you to sit still and breathe air mixed with a small amount of a harmless gas 
called a ‘tracer gas’ slowly from a mouth piece. This gas is not absorbed by your body at all. 
You may watch a DVD or read a book during this test so you don’t get bored. 
 We will explain all of the tests and the results to you 
 All of the tests can be done in one visit to the hospital. You will be at the hospital for 
about 3 hours. 
 
Do I have to take part? 
You do not have to take part in the project. You do not have to say why not, either. 
 
Will joining in with the research help me? 
We cannot promise that taking part will help you, but the information that we get will help us to 
treat other toddlers and children with wheezing and asthma early and stop them from getting 
very ill. 
 
What if I don’t have asthma? 
 We would still like you to take part so that we can tell the difference between children 
with and without asthma 
 
What if I already have asthma? 
 You may already know whether you have asthma, and if so, we will be happy to give you all 
of the results from the tests and answer any of your questions.  
 Taking part will not affect your asthma medicines, or the way your doctors treat you in 
any way 
 
What do I do next? 
If you would like to know more, or are interested in taking part in the study please tell your 
mum or dad and they will tell the doctors that are doing the study. 
 
What if I change my mind and don’t want to do the research anymore? 
If you agree to take part in the research, you can still change your mind and stop doing the 
research at anytime. This will not change your normal treatment in any way. You do not have to 
say why you have changed your mind. 
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EARLY AIRWAY PATHOLOGY PREDICTS LATER CHILDHOOD ASTHMA 
 Parent Information Sheet 
 
THANK YOU for taking the time to read this leaflet. We are doing a study looking at children 
that have previously had a bronchoscopy at the Brompton Hospital. By doing this, we hope to 
find out more about which infants and toddlers will develop asthma. As your child had a 
bronchoscopy when he/she was under 5 years old, we wonder whether you would take the 
time to read on and consider taking part in this study. 
 
What is wheezing? 
Wheezing is a type of noise associated with difficulty in breathing, which is very common and 
can sometimes make children very ill. Luckily, most children grow out of the problem, but some 
continue to wheeze and get asthma when they get older. At the moment we are unable to tell 
which children will carry on wheezing. Also, we don’t know which is the best treatment for this 
problem. A lot of children are given strong medicines that they may not need, and these can 
cause many side-effects. 
 
Why are we doing this study? 
You will remember that when your child was younger, you came to the Brompton Hospital for 
your child to have a camera test to look at their airways (this was called a bronchoscopy). At the 
time, you very kindly agreed for us to use any samples (biopsies) that were taken for a research 
project in which we were looking for changes that suggest asthma. We have completed that 
study and found that children that were wheezing at the time of the bronchoscopy had some 
features suggestive of asthma in their airways. We would now like to confirm whether or not 
the children that had features suggestive of asthma in their biopsies early on have developed 
asthma in school age. 
 
Why is this study important? 
Understanding which infants and toddlers will carry on wheezing and get asthma is very 
important because if we could predict early which children will get asthma, we might use 
treatments to stop asthma developing or to minimize its severity. 
 
No other studies have looked at biopsies in such young children to see if they help to identify 
children that will become asthmatic. 
 
By doing this study we aim to: 
1. See which children that were wheezing when they had a bronchoscopy now have asthma (at 
school age) 
2. See if any children that were not wheezing when they had a bronchoscopy have developed 
asthma (by school age) 
3. See whether changes in the biopsies that were taken during bronchoscopy were already 
present early in the children that now have asthma 
Appendix 3 
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What happens if you agree to take part in the study? 
 We ask you to answer some questions about any wheezing or related problems, like 
eczema and hay fever in your family 
 We ask you to answer some more specific questions about your child’s chest symptoms 
(if they have any) 
 We would like your child to perform a blowing test so that we can assess how well their 
lungs are working (test takes 5 minutes) 
 We would like your child to perform a second blowing test to see if they have inflamed 
airways (test takes 5 minutes) 
 We would like to test your child for allergies to things like cat, dog, house dust and 
pollen using skin prick tests (takes about 20 minutes).  
 We would like to see if your child has a tendency to be asthmatic by asking him/her to 
inhale a salty mist for 5 minutes and then doing the blowing test for lung function again. 
This would be repeated four times for a maximum of up to 20 minutes. During this test 
we would also see if your child can cough up a sample of sputum. This would then be used 
to look for inflammation in the airways. A small part of this sample would be frozen and 
stored for future tests to help identify asthma. (test takes about 40 minutes). 
 We would like to do another test to see how the smaller airways in your child’s lungs are 
working by asking him/her to breathe in air with a small amount of a harmless ‘tracer 
gas’ while breathing normally. This gas is not taken up by the body at all, it is just 
breathed out again unchanged, and is harmless. After a few minutes the gas will be 
disconnected and we will continue to measure breathing while they breathe normal room 
air again. This would be repeated 3 times.  This test is a measure of how well gases are 
mixed in the lungs and will tell us if there is any obstruction in the smaller airways that 
may not be picked up by the previous blowing tests. This test has been performed 
before in hundreds of babies, children and adults with no problems. (test takes about 45 
minutes). 
 We will be very happy to tell you the results once they are available. 
 All information relating to your child will be completely confidential. 
 
Where will the tests be done? 
All of the tests will be done at the Brompton Hospital. 
They can all be completed in one visit lasting approximately 3 hours. 
We will reimburse your reasonable travel fare to and from the hospital. 
 
What will happen once the tests have been done? 
 Once the tests have been completed, we will look at the results to see whether your 
child has asthma. 
 We will then go back to the biopsies that we took when they had a bronchoscopy. The 
biopsies will be looked at in detail under the microscope to see if they have features of 
asthma.  
 Results from the current tests and previous biopsies will then be put together to see 
whether or not the early biopsies correctly predicted asthma in school age. 
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Will we be told the results? 
We will be very happy to tell you the results of the study, once it has been completed.  
If the tests show your child has asthma, or there are any other findings that you did not know 
about, we will tell you and will advise on any appropriate treatment that is needed. Your GP 
will also be informed of the results. 
 
 
What happens next? 
 If you would like to know more, or are interested in taking part in the study, please 
contact: 
Dr Ruth O’Reilly, Clinical Research Fellow, by phoning 077 72056622 or 020 73528121 
Extension 2257 
email roreilly@imperial.ac.uk 
                                                                    
OR 
Dr Sejal Saglani, Clinical Senior Lecturer, by phoning 020 7594 3167 or email 
s.saglani@imperial.ac.uk 
 
 
What if we change our mind? 
If you and your child agree to take part in the study, but then either or both of you change your 
mind, you may withdraw at anytime. This will not change your child’s normal treatment in any 
way. You do not have to give any reason for withdrawing, or not taking part at all. 
 
What if we don’t take part in the study? 
It is fine to decline to take part. You do not have to give a reason. If you do not wish your child 
to take part in the study, this will not alter your child’s normal treatment in any way. 
          
Imperial College London holds insurance policies which apply to this study. If your child 
experiences harm or injury as a result of taking part in this study, you may be eligible to claim 
compensation without having to prove that Imperial College is at fault. This does not affect your 
legal rights to seek compensation 
 
If your child is harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of the 
way your child has been treated during the course of this study then you should immediately 
inform the Investigator (Dr Sejal Saglani, Tel: 0207 594 3167).  The normal National Health 
Service complaint complaints mechanisms are also available to you.  If you are still not satisfied 
with the response, you may contact the Imperial College Clinical Research  Governance Office.   
 
 
THANK YOU VERY MUCH FOR YOUR TIME AND PATIENCE IN READING 
THIS LEAFLET 
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Royal Brompton & Harefield NHS Trust & National Heart and Lung Institute 
 
STUDY INFORMATION & CONSENT FORM 
 
Title of project: Early airway pathology predicts later childhood asthma 
 
EXPLANATION OF PROJECT 
 
We would like to invite you and your child to take part in this clinical study which we hope 
will help us to understand more about which wheezy infants will go on to develop asthma. 
 
We know from previous research that although many children under 5 years old suffer from 
wheezing, only about one-third of wheezers develop asthma by school age. The aim of this 
study is to see if we can use information from tiny pieces of tissue (biopsies) taken from a 
child’s airways to predict which wheezy infants and preschool children will develop asthma. 
If we can find a predictor of future asthma, then we can look for treatments that can be used 
very early to either stop the development of asthma or minimise its severity. 
 
You will remember that when your child was very young, you came to the Brompton 
Hospital for them to have a camera test to look at their airways (this was called a 
bronchoscopy). At the time, you very kindly agreed for us to use any samples that were taken 
for a research project in which we were looking for changes that suggest asthma. We have 
completed that study and found that children that were wheezing at the time of the 
bronchoscopy had some features suggestive of asthma in their airways.  
We would now like to confirm whether the children that had features suggestive of asthma 
early on are still wheezing and whether they have developed asthma in school age. 
 
In order to do this, we would like to ask whether you would consider coming back to the 
Brompton Hospital with your child for the following tests: 
i) We would ask you and your child some questions about their breathing, and how 
they have been since the bronchoscopy. This takes about 40 minutes 
ii) We would like your child to perform a blowing test so that we can assess how well 
their lungs are working. This takes about 5 minutes 
iii) We would like to perform a second blowing test to see if your child has inflamed 
airways. This also takes about 5 minutes 
iv) We would like to test your child for allergies using skin prick tests. This takes 
approximately 20 minutes 
v) We would like to see if your child has a tendency to be asthmatic by asking him/her 
to inhale a salty mist for 5 minutes and then doing the blowing tests for lung 
function again. This would be repeated four times for a maximum of up to 20 
minutes. During this test we would also see if your child can cough up a sample of 
sputum. This would then be used to look for inflammation in the airways. A small 
part of this sample would be frozen and stored for future tests to help identify 
asthma. 
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vi) We would like to do another test to look at how well your child’s airways are 
working by asking him/her to inhale air containing a small amount of a harmless 
‘tracer gas’ while breathing normally. We will then see how quickly the ‘tracer gas’ 
is removed from the lungs during continued normal breathing. This will be repeated 
3 times and will take approximately 45 minutes.   
 
 
All of this would be done on one day and would take approximately 3 hours. 
The tests will all be done by a children’s doctor. If any of the tests make your child feel 
uncomfortable, then they will be stopped. 
 
The information obtained from the answers to the questions and the tests will allow us to 
work out whether or not your child now has asthma. We will then relate this back to the 
biopsies that we took from your child when they had their bronchoscopy to see if early 
information from the biopsies tallies with whether your child now has asthma or not. 
 
Although taking part in this study will not benefit your child directly, it will allow us to help 
other children in the future. We will know whether information from airway biopsies taken 
early from wheezy preschool children can be used to identify which children will develop 
asthma.  
 
Please take the chance to discuss this study fully, asking any questions that you need to, 
before deciding whether or not to take part. If you do not wish your child to take part, 
this will not affect his or her current or future treatment at the Brompton Hospital. If 
you and your child do agree to take part, but later decide you would like to withdraw 
from the study, you may do so at any time, and you do not have to give a reason and this 
will not affect your child’s treatment in any way. Thank you very much for your time. 
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12/01/2009  Study number: __________________ 
 
CONSENT FORM FOR PARENTS & CHILDREN 
 
Title of project: Early airway pathology predicts later childhood asthma 
 
Name of researcher:  
 
1. I confirm that I / my child have read and understand the information sheet dated 12th 
Jan 2009 v3 for the above study. I have had the opportunity to ask questions and have 
had these answered satisfactorily.   
 
2. I understand that my child’s participation is voluntary and that we as parents or he/she 
is free to withdraw at any time without giving any reason and without their medical 
care or legal rights being affected.   
 
3. I understand that sections of my child’s medical notes may be looked at by 
responsible individuals from the Brompton Hospital where it is relevant to my child 
taking part in this research. I give permission for these individuals to access my 
child’s records that are relevant to this research.   
 
4. I understand that samples from the study will be stored and may be used in future for 
similar tests.  
 
5. The compensation arrangements have been discussed with me.  
 
 
6. I agree to the child named below taking part in this study, and I am their parent / legal 
guardian.   
 
 
___________________________  _______________________  _________
  
Name of child     Signature    Date 
 
 
 
___________________________  _______________________ 
 __________ 
 
Name of parent/legal guardian  Signature    Date 
 
 
 
___________________________  ________________________
 __________ 
 
Name of person taking consent  Signature    Date 
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Royal Brompton & Harefield NHS Trust & National Heart and Lung Institute 
 
Study Information Leaflet 
 
Project title: Early airway pathology predicts later childhood asthma 
 
Dear Doctor 
 
This is to inform you that your patient __________________________, DOB:____________ 
is taking part in the above research project being carried out at the Royal Brompton Hospital, 
London. 
 
This study is following up children that have previously had a bronchoscopy at the Brompton 
hospital, aged 3 months to 5 years, between October 2002 and May 2005. We are looking at 
the current asthma status of the previously bronchoscoped children, and will relate this to 
pathological findings in airway biopsies that were taken during the bronchoscopy to see 
whether early airway pathology in the infant and preschool years predicts the development of 
asthma by school-age. 
 
The children will undergo the following: 
1. An interview / questionnaire with parents to assess current asthma symptoms 
2. Skin prick tests to 5 common aero-allergens and 3 common food allergens 
3. Spirometry  
4. Measurment of exhaled nitric oxide 
5. Combined sputum induction and assessment of airway hyperresponsiveness using 4.5% 
nebulised saline 
6. Measurement of Lung Clearance Index  (lung function test that gives a measure of 
small airways function) 
 
All tests will be performed at the Brompton Hospital. Parents and children will be told the 
results. If any previously unknown results are found, we will write to you and let you know 
these, with our recommendations for future management and follow-up. 
There are no implications for the treatment of the child or long term follow-up. 
 
If you have any questions relating to this study, please do not hesitate to contact the Principle 
Investigator:  
Dr Sejal Saglani 
Clinical Senior Lecturer & Honorary Consultant in Respiratory Paediatrics 
Imperial College London & The Royal Brompton Hospital 
374 Sir Alexander Fleming Building 
Exhibition Road, London SW7 2AZ 
Tel: 020 7594 3167 
s.saglani@imperial.ac.uk 
 
Thank you 
Yours sincerely 
 
Dr Sejal Saglani BSc, MBChB, MRCPCH, MD 
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Appendix 6 
 
Date: 
 
 
 
Birth History:  
Gest  _________    Wgt_________     Scubu/NICU  Yes/ No   Vent Days_______  
Cpap Days_______ 
 
Smoking                                                                                     
Smoking during pregnancy (mother)      
Smoking during pregnancy father (lived in house) 
Does anyone in the house smoke now? 
Father 
Mother 
Other adult                                     
 
Day Care 
Did your child attend nursery? 
What age_______months       Length of time________ months 
 
Animals                                                                    
Do you live on a farm?                                
Do you have pets at home? 
 
If so which      cat       dog        other 
 
 
Medications in First 2 years of life 
Inhaled Corticosteriods  ____________________         Spacer    Yes/  No 
Inhaled Salbutamol     ______________________         Spacer     Yes/ No 
No of courses of Oral Steroids    _____________ 
Monteleukast            Yes /No 
 
Medications Aged 2-5 years 
Inhaled Corticosteriods  ____________________         Spacer    Yes/  No 
Inhaled Salbutamol     ______________________         Spacer     Yes/ No 
Monteleukast            Yes /No 
Number of courses of Oral steroid/year     Age 3_________ 
                                                                        Age 4_________ 
                                                                        Age 5_________ 
 
 
Medications Age 5 to date 
Inhaled Corticosteriods  ____________________         Spacer    Yes/  No 
Inhaled Salbutamol     ______________________         Spacer     Yes/ No 
Monteleukast            Yes /No 
Name  
Hospital No  
DOB  
Address  
 
 
Telephone  
Y N 
Y N 
Y N 
Y N 
Y N 
Y N 
Y N 
Y N 
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Number of courses of Oral steroid/year     Age 5-7_________ 
                                                                        Age 7+ _________ 
                                                                         
ISAAC Core questionnaire wheezing module for 6–7 year olds 
1. Has your child ever had wheezing or whistling in the chest at any time in the past?    
Y/ N 
IF YOU ANSWERED "NO" PLEASE SKIP TO QUESTION 6 
When was the first time? ______________ Age months 
 
2. Has your child had wheezing or whistling in the chest in the last 12 months?               
Y/N 
IF YOU ANSWERED "NO"  
When was the last time your child had wheeze  __________ Age months 
Continue to question  6 
 
3. How many attacks of wheezing has your child had in the last 12 months? 
None [ ] 1 to 3 [ ] 4 to 12 [ ] More than 12 [ ] 
On average how many attacks does your child have per year? 
None [ ] 1 to 3 [ ] 4 to 12 [ ] More than 12 [ ] 
 
4. In the last 12 months, how often, on average, has your child's sleep been 
disturbed due to wheezing?  
Never woken with wheezing [ ] Less than one night per week [ ]  
One or more nights per week [ ] 
 
5. In the last 12 months, has wheezing ever been severe enough to limit your child's 
speech to only one or two words at a time between breaths?    Y/N                                      
 
6. Has your child ever had asthma?  Y/ N 
Please Circle       Doctor diagnosed       Parent diagnosed  
 
7. In the last 12 months, has your child's chest sounded wheezy during or after 
exercise?  Y/N 
 
8. In the last 12 months, has your child had a dry cough at night, apart from a cough 
associated with a cold or a chest infection?    Y/N    
 
9. Does your child wheeze  
only with colds               multi trigger           Atopic  
                                                            
10. Any hospital visits with wheeze?__________________Number 
If yes Age of last admission:_________ years 
 
Family History of Asthma    yes/ No                             Who? 
 
 
Isaac Core questionnaire rhinitis module for 6–7 year olds 
11. Has you child ever had a problem with sneezing, or a runny, or a blocked nose 
when he/she DID NOT have a cold or the flu?    Y/N                                                           
IF YOU ANSWERED "NO" PLEASE SKIP TO QUESTION 16 
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12. In the past 12 months, has your child had a problem with sneezing, or a runny, or 
a blocked nose when he/she DID NOT have a cold or the flu?                                     
Y/N 
IF YOU ANSWERED "NO" PLEASE SKIP TO QUESTION 16 
 
13. In the past 12 months, has this nose problem been accompanied by itchy-watery 
eyes?                                                                                                                                    
Y/N 
 
14. In which of the past 12 months did this nose problem occur? (please tick any 
which apply) 
January [ ] February [ ] March [ ] April [ ] May [ ] June [ ]July [ ] August [ ] September [ 
] October [ ] November [ ] December [ ] 
 
15. In the past 12 months, how much did this nose problem interfere with your child's 
daily activities? 
Not at all [ ]  A little [ ]  A moderate amount [ ]  A lot [ ] 
 
16. Has your child ever had hay fever?           Y/N                                                                    
 
Core questionnaire eczema module for 6–7 year olds 
17. Has your child ever had an itchy rash which was coming and going for at least 6 
months?   Y/N 
IF YOU ANSWERED "NO" PLEASE SKIP TO QUESTION 22 
 
18. Has your child had this itchy rash at any time in the last 12 mths?                                    
Y/N 
IF YOU ANSWERED "NO" PLEASE SKIP TO QUESTION 22 
 
19. Has this itchy rash at any time affected any of the following places: the folds of 
the elbows, behind the knees, in front of the ankles, under the buttocks, or around 
the neck, ears or eyes?       Y/N 
 
20. At what age did this itchy rash first occur?  
Under 2 years [ ]  Age 2–4 [ ]  Age 5 or more [ ] 
 
21. Has this rash cleared completely at any time during the last 12 months?                           
Y/N 
 
22. In the last 12 months, how often, on average, has your child been kept awake at 
night by this itchy rash? 
 Never in the last 12 months [ ] Less than one night per week [ ]  
One or more nights per week [ ] 
 
22. Has your child ever had eczema?  Y/N 
  
 
